



British Journal of Rheumatology

VOL. XXX 1991

Official Journal of
The British Society
for Rheumatology
published by
Baillière  Tindall · London



GENERAL INDEX

(A1 and A2 = Abstracts Supplements 1 and 2, S1 and S2 = Supplements 1 and 2, E = Editorial,
L = Letter to the Editor, CC = Clinical Conundrum)

- ABBOT SE, KAUL A, BLAKE DR, STEVENS CR. Increased expression of endothelial cell adhesion molecules *in vitro* by rheumatoid arthritic synovial microvasculature, (A1) 13
- ABEDI-VALUGERDI M, RIDDERSTAD A, STROM H, MOLLER E, MOLLER G. Partial biochemical characterization of new cytokine activity (Ig2b inducing factor) from synovial fluid of patients with rheumatoid arthritis, (S2) 86
- ABNEY E *see* Chu CQ
- Abnormal fibrinolytic response in patients with rheumatoid arthritis complicated by vasculitis, (A2) 34
- ABRAHAM DJ *see* Beauchamp JR, Vancheeswaran R
- Absence of a class I MHC-restricted pathogen-specific T cell response in the synovial fluid of patients with reactive arthritis, (A2) 67
- Absence of microalbuminuria in SLE patients without renal disease, (A2) 90
- Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis, (A2) 2
- ACKRILL P *see* Hay EM, MacDiarmid-Gordon AR
- Acquired hypofibrinogenemia and lupus anticoagulant: response to steroid therapy, 308
- Acromegaly, MRI in evaluation, (A1) 37
- Activated, cytotoxic non-T lymphocytes in vasculitis, (A1) 16
- Acute reactive arthritis, reversal of peripheral blood T cell anergy to bacterial antigens on recovery, (A1) 15
- ADAMS L *see* Swanepoel M
- ADEBAJO AO *see* Vecchio PC
- ADEBAJO W *see* Holligan S
- Adherent properties of blood leucocytes in Wegener's granulomatosis, (A2) 87
- Adhesive interactions between lymphocytes and skeletal muscle cells in tissue culture, (A2) 137
- Adjuvant arthritis
induction of an inhibitory splenic macrophage during progression in a susceptible rat strain, (A2) 115
serum levels of hyaluronic acid correlate with disease activity, (A2) 143
- Adjuvant induced arthritis, hypothalamo-pituitary mRNA responses during development in the adrenalectomized rat, (A2) 141
- Adoptive transfer of severe collagen-induced arthritis into immunodeficient mice, (A2) 114
- ADORINI L. Peptide interactions with MHC class II molecules, (S2) 10
- ADU D *see* Luqmani RA
- Adult respiratory distress syndrome: an unrecognized premortem event in systemic lupus erythematosus, 346
- Adult Still's disease, low-dose methotrexate in, (A2) 101
- Agalactosyl-IgG, in healthy individuals increased level is found in males and those with HLA DR2 and 7 gene expression, (A2) 34
- AGARWAL AK *see* Poppelman WC
- AHMED T *see* Hill TA
- Air cast ankle support brace for subtalar joint instability in patients with rheumatoid arthritis. Analysis using a gait and balance laboratory, (A1) 27
- AL-ARJAF H *see* El-Hazmi MA
- AL-BALLAA SR *see* El-Hazmi MA
- AL-DALAAN AN *see* El-Hazmi MA
- AL-SUGHAIR S *see* El-Hazmi MA
- ALAM C, THOMPSON PW, JAMES IT. Urinary excretion of deoxyypyridoline as a marker of bone resorption in an animal model of inflammation associated osteoporosis, (A1) 35
- ALARCON-SEGOWIA D *see* Kraus A
- ALAVI A *see* Hunt K
- Alcoholism, effect of abstinence on bone mass, (A2) 94
- ALFAYATE R *see* Carto A
- Algodystrophy
elevated neuropeptide levels, (A2) 64
post-traumatic, use of nasal calcitonin in the treatment, 291
- ALLARD SA *see* Collins DA
- ALLISON AC, EUGUI EM. Immunosuppressive and long-acting anti-inflammatory activity of mycophenolic acid and derivative, RS-61443, (S2) 57
- ALLOWAY JA *see* Clauw DJ
- ALONSO JL *see* Ramos A
- ALONSO-RUIZ A, CALABOZO RALUY M, PÉREZ RUIZ F, MANCEBO ARA-GONES L. Results of long-term follow-up of the toxic oil syndrome, (A2) 29
- ALVAREZ R *see* Muñoz S
- ALVAREZ-DARDET C *see* Ruiz MT
- AMIGO MC *see* Khamashta MA
- AMLOT P *see* Kirkham B
- AMLOT PL *see* Kirkham BW
- AMORIM R *see* Herrero-Beaumont G
- AMOS N *see* Teh LS
- AMOS RS, BAX DE, BOURNE JT, WINFIELD J, SHEEHAN NJ. Arthritis artefacta: factitious disease in rheumatology, 455
- Anaerobic metabolism: elucidation of its role in rheumatoid and osteoarthritis by high field nuclear magnetic resonance imaging spectroscopy: evidence for hypoxic metabolism in rheumatoid arthritis, (A1) 32
- Analogue pain scores, (L) 390
- Analysis of
antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases, (A2) 134
antibody isotype in patients with autoimmune rheumatic disease, (A2) 14
cysteine/sulphate metabolism confirms defective sulphoxidation in patients with rheumatoid arthritis, (A2) 113
fibroblast cell surface markers in systemic sclerosis, (A2) 119
the immunohistological features of the synovial membrane in psoriatic arthritis and comparison with rheumatoid arthritis, (A1) 8
- ANCA specificity
and concentration relationship to disease activity in patients with systemic vasculitis, (A2) 84
in systemic vasculitis, (A2) 83
- ANDARY M *see* Wendling D
- ANDONOPOULOS AP. Adult respiratory distress syndrome: an unrecognized premortem event in systemic lupus erythematosus, 346
- ANDREU JL, MORENO I, MARCOS MAR, KROEMER G, MARTÍNEZ-A C. IL-2 promotes autoimmunity in neonatally thymectomized mice, (A2) 11
- ANDREW EM, PLATER-ZYBERK C, BROWN CMS, WILLIAMS DG, MAINI RN. Potential role of B-lymphocytes in the pathogenesis of rheumatoid arthritis, (S1) 47
- ANDREWS HJ, PLUMPTON TA, HARPER GP, CAWSTON TE. Low molecular weight metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage *in vitro*, (A2) 144
- Angiogenesis and cartilage breakdown, (A2) 143
- Angiotensin converting activity in paired serum and synovial fluid, (A1) 31
- Angiotensin converting enzyme activity
early morning stiffness and diurnal variation, (A2) 47
is lower in rheumatoid arthritis patients than age and sex matched controls, (A2) 117
- Angiotensin converting enzyme- and dipeptidyl peptidase IV-like immunoreactivity in human synovium, (A2) 124
- Animal models: insights into osteoarthritis provided by the cruciate-deficient dog, (S1) 5
- Ankylosing spondylitis, 50
aspects of, 1
bone mineral density and vertebral compression fracture rates, (A2) 56
cardiac abnormalities. Early detection of aortic incompetence with Doppler echocardiography, (A2) 60
clinical assessment: a study of observer variation in spinal measurements, 29
enthesitis as a measure of disease activity, (A2) 81
immunocorrection in, (S2) 98
late onset—a distinct disorder, (L) 69
methods of assessment used in clinical trials: a review, 326
and osteoporosis, (L) 318
osteoporosis in, (L) 160
outcome assessment in clinical trials, (E) 321
patients show individual patterns of variation in disease activity, 336
quantitation of HLA class, I (A1) 10
raised levels of von Willebrand factor antigen, (A2) 36
relationship of clinical and laboratory measurements to radiological change, 330
and secretor status—a reappraisal, (A2) 4
spinal trabecular bone density by lateral dual energy X-ray absorptiometry, (A1) 29
subclinical valvular and myocardial disease: a Doppler echocardiographic study, (A2) 60
total hip arthroplasty in, (A1) 29
- ANSELL BM *see* Davies UM
- Anti endothelial cell antibody characterization in systemic lupus erythematosus and rheumatoid arthritis complicated by vasculitis, (A2) 134
- Anti-CD4 treatment with chimeric monoclonal antibody results in prolonged CD4+ cell depression, (S2) 87
- Anti-centromere antibodies in multiple family members, (A2) 26
- Anti-DNA antibody binding to ROS-DNA in spouses and relatives of patients with systemic lupus erythematosus, (A2) 15

- Anti-inflammatory drug effects on human osteoblast metabolism, (A2) 47
- Anti-La ELISA but not anti-Ro correlates with total serum IgG1 and degree of salivary gland infiltration in primary Sjögren's syndrome, (A2) 24
- Anti-neutrophil cytoplasmic antibodies (ANCA)
spectrum of disease associated with, (A1) 16
stimulate neutrophils by activating protein kinase C, (A2) 84
- Anti-Proteus antibodies in rheumatoid arthritis: a longitudinal and clinical study, (A1) 17
- Anti-T CD4+ monoclonal antibodies, immunological follow up of 13 patients with rheumatoid arthritis, (S2) 88
- Anti-thymocyte globulin in the treatment of systemic sclerosis, (A1) 21, (S2) 91
- Antibodies
to CD44 and to a hyaluronan-binding protein from rat chondrosarcoma co-distribute in normal human tissues, (A1) 12
to HSP65 in twin pairs with rheumatoid arthritis, (A2) 69
to phospholipids in chronic fatigue syndrome: implications for a viral aetiology, (A2) 11
to *Proteus* in rheumatoid arthritis, (L) 390
- Antibody to the 65kDa mycobacterial heat shock protein contaminates antibody raised to lactoferrin and possibly many other antibody preparations, (A2) 111
- Anticardiolipin antibodies
insidious loss of renal function in patients and absence of overt nephritis, 422
in patients with small vessel vasculitis, (A2) 20
their relationship with HLA-DR antigens in systemic lupus erythematosus, (L) 156
- Antiendothelial cell antibodies in patients with SLE and urticarial vasculitis, (A2) 19
- Antigen presentation in joints in the pathogenesis of arthritis, (S1) 53
- Antineutrophil cytoplasmic antibodies (ANCA): their role in diagnosis and pathogenesis of vasculitis, 229
- Antinuclear antibodies in first degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes, 429
- Antinuclear cytoplasmic antibody (ANCA) in pursuing cause of vasculitis, (CC) 254
- Antioxidant enzymes, identification and localisation in synovium and synovial fibroblasts, (A2) 39
- Antiperinuclear factor, diagnostic value, (A2) 112
- Antiphospholipid antibody, human monoclonal, idiopathic and genetic studies, (A2) 21
- Antiphospholipid syndrome
effect of immunoglobulin G from patients with systemic lupus erythematosus and the antiphospholipid syndrome on the release of von Willebrand factor antigen from human umbilical vein endothelium, (A2) 19
high prevalence of heart valve disease, (A2) 21
primary, non-infective verrucous endocarditis in a patient, 305
- Antirheumatic drugs
disease modifying, variation in dose and monitoring schedules for amongst UK and Irish rheumatologists, (A1) 19
uncoupling the toxicological morass in the development of new drugs—is there any hope, (E) 161
- Antiribosomal P protein antibodies
in different populations of patients with systemic lupus erythematosus, (A2) 18
and neuropsychiatric disease in patients with systemic lupus erythematosus, (A2) 18
- alpha1-Antitrypsin in synovial fluid is inactivated by exercise in rheumatoid arthritis, (A2) 50
- ANTI-POIKA I see Kontinen YT
- Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism, 301
- APPLEBY P see Bowen JG
- Archer CW see Pitsillides AA
- Are retroviruses involved in the aetiology of rheumatic disease, (S1) 63
- AREND WP, MALYAK M, BIGLER CF, SMITH MF, JANSON RW. Biological role of naturally-occurring cytokine inhibitors, (S2) 49
- ARMAS J see Will R
- ARMAS JB see Herrero-Beaumont G
- AROMAA A see Kontinen Y
- ARÓSTEGUI A see Pascual E
- Arrhythmia after pulse methylprednisolone therapy, (L) 392
- Arribas Castrillo JM see Torre Alonso JC
- Arthritis
adoptive transfer of severe collagen-induced arthritis into immunodeficient mice, (A2) 114
antigen presentation in joints, (S1) 53
antigen-induced, quantitative NMR-microscopy of progression in the rabbit knee, (A1) 35
artefact: factitious disease in rheumatology, 455
characteristic patterns of cellular activation in chronic inflammation: immune-mediated activity and non-specific cellular infiltration distinguished by interleukin-1 beta distribution, (S2) 84
cytokines and their interrelationships in the joints and plasma, (A2) 126
and driving, 361
driving for the disabled, 54
mianserin as cause, (L) 74
in one knee enhances the vascular response to bradykinin in the opposite knee, (A2) 142
pristane induced, use of bacterial antigens and stress proteins in modulation, (S2) 95
selective suppression of IgM antibody production protects type II collagen-immunized rats, (S2) 92
severe, provision of medical and community services: an audit, 356
synovial fluid and serum levels of the complex immunoglobulin A alpha-1-antitrypsin in inflammatory and non-inflammatory arthritis, (A2) 114
- Arthropathy of haemochromatosis, bilateral septic arthritis of the hips complicating, (L) 395
- ARTHUR V see Gough A
- Articular disease severity in rheumatoid subjects with and without Felty's syndrome, 217
- ASHERSON RA see D'Cruz DP; Khamashta MA
- ASPAR DG, KRZESICKI RF, CHIN JE, STAIT ND. Effect of cytokines on proliferation and PGE₂ production by synoviocytes derived from mBSA/IL-1 arthritic mice, (S2) 83
- Aspirin effect of administration on erythrocyte ATP, (A2) 38
- Assessing activity of rheumatoid arthritis with radiolabelled leucocytes, (A1) 25
- Assessment
by microdensitometry of regional distribution of hyaluronan in normal and inflamed synovium, (A2) 123
of disability in male and female rheumatoid patients, (L) 477
- ASSMANN KJM see Kerstens PJSM
- Association
of psoriatic arthritis and psoriasis with HLA-Cw6 detected by polymerase chain reaction, (A1) 10
of a T-cell receptor β -chain variable region restriction fragment length polymorphism with outcome in rheumatoid arthritis, (A2) 31
- ASTBURY C, HILL J, BIRD HA. Phthalylsulphathiazole in rheumatoid arthritis, (A1) 20
- ASUZU M see Holligan S
- ATHANASIOU PL see Papazoglou SN
- Athletes and osteoarthritis—is there any relationship, (L) 67, (L) 68
- ATKINS RM see Majkowski RS
- Audit of new patient referrals to paediatric rheumatology clinics, (A2) 104
- Auranofin
rashes in rheumatoid arthritis, (A1) 20
severe thrombocytopenia associated with: evidence for immunological mechanism with peripheral destruction in the spleen, (L) 75
- Autoantibodies and thyroid disease in a family study of primary Sjögren's syndrome, (A1) 17
- Autoimmune disease
genes beneficial to, (S1) 38
and HTLV-1 infection, 141
immune response to cross-reactive GAG sequences, (A2) 24
prevalence of gammadelta T cells and usage of TCR-V gene families, (S2) 97
- Autoimmune rheumatic disease, analysis of antibody isotype in patients, (A2) 14
- AXFORD JS, HAY FC. Oligosaccharides, just the icing on the protein or are they of functional relevance, 196
- AXFORD JS, see also Hunt K
- AXON JMC, HAWLEY PR, HUSKISSON EC. Ileal pouch arthritis, (A2) 74
- AXON JMC, JACOBS RA, PERRETT D, SCOTT DL, HERBERT KE. Phenotypic transformation of synovial cells in culture, (A2) 123
- AXON JMC, see also Jacobs RA
- AYDINTUG AO, D'Cruz D, CERVERA R, KHAMASHTA MA, HUGHES GRV. Low-dose methotrexate in adult Still's disease, (A2) 101
- Azathioprine and methotrexate influence on the radiologic progression in rheumatoid arthritis, (A2) 2
- AZQUETA M see Font J
- B cell chimerism reduction as a major mechanism for the self-limitation of the lupus-like syndrome developed in mice neonatally tolerized to alloantigens, (A2) 12
- Back pain and sciatica cause may be a venous matter too, (L) 70
- BACON P see Gado K; Hay EM
- BACON PA see Farr M; Gado K; Gaston JSH; Hassell AB; Luqmani RA; Rousseau E; Tucker SC; Viner NJ

- BADDERLY H *see* Shawe DJ
- BADGER AM, OLIVERA DL, KING A. Induction of non-specific suppressor cells and myeloregulatory effects of an anti-arthritis azapirane, SK&F 105685, (S2) 82
- BADGER AM, SWIFT BA, BUGELSKI PJ, HIGH WB, DIMARTINO MJ, GREIG R. Effect of SK&F 105685, a novel suppressor cell-inducing compound, in the adjuvant arthritis rat, (S2) 66
- BADGER AM, SWIFT BA, BUGELSKI PJ, HIGH WB, DIMARTINO MJ, GREIG R. Effect of SK&F 105685, a novel suppressor cell-inducing compound, on disease parameters in the adjuvant arthritis rat, (S2) 82
- BADLEY EM, TENNANT A. Which rheumatic disorders have the greater impact on the population? Estimates of severity and prevalence from the Calderdale rheumatic disablement survey, (A2) 102
- BAGGIOLINI M *see* Seitz M
- BAILLIE K *see* Scott DL
- BAKKER NPM, VAN ERCK MGM, JONKER M, T'HART LA, BONTROP RE. Resistance to collagen-induced arthritis in rhesus monkeys: MHC antigens, CD8+ cells and IL2 determine T cell low responsiveness, (S2) 99
- BAKKER NPM, *see also* T'Hart BA
- BALLINA GARCIA J *see* Torre Alonso JC
- BALSA A *see* Muñoz S
- BAMBER M *see* Hicklin JA
- BARAK V, MAHAJNA N, OKON E, PERITT D, FLECHNER I, YANAI P, HALPERIN
- T, TREVES AJ. Reduction or elimination of rheumatoid arthritis by an IL-1 inhibitor, (S2) 84
- BARBATH C *see* Corkill MM; Kirkham BW
- BARDHAN KD *see* Scott DL
- BARDIN T, GOUTALLIER D, BERNAGEAU J. Magnetic resonance imaging study of dialysis shoulder, (A2) 87
- BARDIN T, *see also* Leblat-Darné JL
- BARDSLEY M *see* Swinden DC
- BARKER M *see* Helliwell P
- BARLOW R *see* Botto M
- BARNES L *see* Veale D
- BAROJAS E *see* Kraus A
- BARRACLOUGH DRE *see* Pun YLW
- BARRY C *see* Foley-Nolan D
- BASSIOUNY MR *see* Hafez M
- BATE AS *see* Hillarby MC
- BATLLE E *see* Carro A
- BAX DE *see* Amos RS; Peel NFA
- BAYLISS MT *see* Hardingham TE; Pitsillides AA; Worrall JG
- BEAMAN M *see* Hay EM; MacDiarmid-Gordon AR
- BEAUCHAMP JR, PARKRIDGE T, ABRAHAM DJ, BOU-GHARIOS G, OLSEN I. Adhesive interactions between lymphocytes and skeletal muscle cells in tissue culture, (A2) 137
- BECKER W *see* Emmrich F
- BEGENT RH *see* Davies KA
- Behçet's syndrome
diffuse proliferative glomerulonephritis in, 63
inefficacy of topical alpha interferon in the treatment of oral ulcers: a randomized, double blind trial, (L) 395
use of high dose intravenous immunoglobulin, (S2) 91
- BELCH JFF *see* Lau CS
- BELL AL *see* Boyd HK
- BELL JI *see* Loveridge JA; Pile KD; Wordsworth BP; Wordsworth BP
- BELLAMY N. Prior score availability: observations using the WOMAC Osteoarthritis Index, (L) 150
- BELLAMY N, THOMPSON RT, DRIEDGER AA, ROTH JH, PEEMOELLER H, CAMPBELL J. Preliminary study of magnetic resonance relaxation times (T_1 and T_2) in inflammatory and degenerative synovial fluids, 464
- BELLAMY N, *see also* Laurent MR
- BEN-BASSAT M *see* Shoenfeld Y
- BENDIX G, BJELLE A. Outcome of parenteral gold therapy by RA patients: a comparison between two periods using life-table analysis, 407
- Benefit in social and physical function produced by early treatment of rheumatoid arthritis (A2) 99
- BENOIT J *see* Leblat-Darné JL
- BERMAN P *see* Jones AC
- BERNAGEAU J *see* Bardin T
- BERNHAGEN J *see* McCarthy DA
- BERNSTEIN R *see* Davies E; Kay R
- BERNSTEIN RM *see* Hay E; Hay EM; Majeer AH
- BEST MJ *see* Pile KD
- BESWICK EJ *see* Taylor HG; Zukovskis K
- BEYNON HLC, GASKIN G, BRADSHAW AE, KELLY SM, WALPORT MJ. Extrinsic pathway inhibitor levels in patients with small vessel vasculitis, (A2) 35
- BEYNON HLC, GASKIN G, LOIZOU S, COFINER C, PUSEY CD, REES AJ, WALPORT MJ. Anticardiolipin antibodies in patients with small vessel vasculitis, (A2) 20
- BEYNON HLC, HASKARD DO, HAROTOJUNIAN R, WALPORT MJ. Synergy between low concentrations of cytokines and acute agonists causes increased endothelial permeability, (A2) 51
- BEYNON HLC, MASON J, MARGUERIE C, REES AJ, WALPORT MJ. Intravenous pulsed cyclophosphamide as a treatment for bone marrow hypocellularity in SLE, (A2) 140
- BEYNON HLC, ROSS CN, COHEN J, PUSEY CD, REES AJ. Gancyclovir treatment for cytomegalovirus infection in immunocompromised patients with renal disease, (A2) 89
- BHALLA A *see* Hertero-Beaumont G
- BHALLA AK *see* Knight SM
- BHAMBHANI MB, SKINGLE SJ, WATTS RA, POUNTAIN G, CRISP AJ. Effect of a single infusion of pamidronate on Paget's disease of bone, (A2) 95
- BHAVNANI M *see* Sivakumaran M
- BHOOLA KD *see* Bond AP
- Bicentric open study of the treatment of rheumatoid arthritis with monoclonal CD4 antibody, clinical and immunological results, (S2) 87
- BICKERSTAFF DR, KANIS JA. Use of nasal calcitonin in the treatment of post-traumatic algodystrophy, 291
- BIGG H *see* Curry VA
- BIGLER CF *see* Arend WP
- BIJLSMA JWI *see* Kruize AA; Lafeber F; Nietfeld JJ; van den Brink HR; Wilbrink B
- BILAG index
has good inter-observer agreement when used in a routine outpatient clinic, (A1) 23
is a valid instrument for measuring clinical disease activity in systemic lupus erythematosus, (A2) 16
- Bilateral iliopsoas bursitis in rheumatoid arthritis, (L) 68
- Bilateral septic arthritis of the hips complicating the arthropathy of haemochromatosis, (L) 395
- BILLINGHAM MEJ, HICKS C, CARNEY SL. Serum levels of hyaluronic acid correlate with disease activity during adjuvant arthritis, (A2) 143
- BILLINGHAM MEJ, *see also* Kingston AE
- Binding
of anti-DNA antibodies to ROS-DNA in spouses and relatives of patients with systemic lupus erythematosus, (A2) 15
of rheumatoid mononuclear cells to high endothelial cells of mucosal origin, (A2) 106
- BINT AJ *see* Deighton CM
- Biochemical markers, overinterpreting data, a new epidemic in rheumatology, (L) 237
- Biological role of naturally-occurring cytokine inhibitors, (S2) 49
- BIRD AR *see* Hift RJ
- BIRD HA *see* Astbury C; Hill H; Hill J; Hordon LD
- BIRRELL F *see* Holligan S
- BISWAS S *see* Rees RG
- BJARNASSON I *see* Scott DL
- BJELLE A. Rheumatology curriculum for medical students, 123
- BJELLE A, *see also* Bendix G
- BLACK C *see* David J; Vancheswaran R; Wells AU
- BLACK CM *see* Darton K; McWhirter A; Stephens CO; Tanner SB; Wells AU; Whyte J
- BLACK D *see* Teh LS
- BLACKWELL CC *see* Smith G
- BLAIR GS *see* Kelly CA
- BLAKE DR *see* Abbot SE; Chidwick K; Cruwys SC; Dowling EJ; Fairburn K; Farrell AJ; Herz H; Mapp PJ; Merry P; Naughton D; Nazhat NB; Singh D; Walsh DA; Williams RB; Winrow VR; Winyard PG; Zhang Z
- BLANCO F, KALSI J, ISENBERG D. Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases, (A2) 134
- BLANCO F, KALSI J, SPEIGHT P, ISENBERG DA. Analysis of antibody isotype in patients with autoimmune rheumatic disease, (A2) 14
- BLANK M *see* Shoenfeld Y
- BLANN AD, MORRIS CJ, CLAGUE RB. Synovial fluid enzymes are cytotoxic to endothelial cells and fibroblasts, (A1) 30
- BLANN AD, SCOTT DGI. Activated, cytotoxic non-T lymphocytes in vasculitis, (A1) 16
- BLANN AD, WAINWRIGHT AC, SHEERAN TP, EMERY P. Venostasis, sub-clinical vasculitis and von Willebrand factor antigen, 373
- BLANN AD, *see also* Jones PB
- BLOUNT S, LUNEC J, GRIFFITHS H, EMERY P, JACKSON J, COCHRANE C. 8-Hydroxydeoxyguanosine: a marker of oxygen radical damage to DNA in systemic lupus erythematosus, (A2) 50
- BLOUNT S, LUNEC J, GRIFFITHS H, ISENBERG D. Binding of anti-DNA antibodies to ROS-DNA in spouses and relatives of patients with systemic lupus erythematosus, (A2) 15

- BODEUTSCH C *see* Kruize AA
 BOERBOOMS AM *see* Jeurissen ME
 BOERBOOMS AMT *see* van den Hoogen FHJ
 BOERBOOMS AMTH *see* Kerstens PJSM
 BOERS M, DIJKMANS BAC, BREEDVELD FC, CAMPS JAJ, CHANG PC, VAN BRUMMELEN P, PAUWELS EKJ, CATS A. No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac, 56
 BOKI K, VAUGHAN RW, DROSSOS A, MOUTSOPOULOS H, PANAYI GS, LANCHBURY JSS. DNA analysis of HLA class II polymorphisms in Greek RA patients, (S2) 97
 BOLLINGER P *see* Mackenzie AR
 BOND A *see* Hunt K
 BOND AP, BREIPOHL G, WORTHY K, CAMPION G, DIEPPE PA, BHOOLA KD. Metabolism of bradykinin, kallidin and HOE 140 in synovial fluid, (A2) 45
 Bone
 cell development and function control, (A2) 66
 cells from osteoporotic patients are able to respond normally to 1,25-dihydroxyvitamin D₃, (A2) 54
 density of the hip and spine in post menopausal rheumatoid arthritis and the effect of low dose steroids, (A2) 53
 mass in primary generalised osteoarthritis, (A2) 54
 mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy, 86
 mineral density in rheumatoid arthritis: influence of functional capacity and disease activity, (A2) 52
 mineral density and vertebral compression fracture rates in ankylosing spondylitis, (A2) 56
 scintigraphy following intravenous pamidronate for Paget's disease, (A2) 63
 BONTROP RE *see* Bakker NPM
 BOTTO M, SO AK, FONG KY, BARLOW R, ROUTIER R, MORLEY BJ, WALPORT MJ. Homozygous inherited C3 deficiency due to a partial gene deletion, (A2) 135
 BOU-CHARIOS G *see* Beauchamp JR
 BOULTON-JONES JM *see* Murphy EA
 BOURKE B *see* Scott DL
 BOURKE BE *see* Collins DA
 BOURNE JT *see* Amos RS
 BOWEN JG, TELFORD G, NAYLOR G, DYKES SG, APPLEBY P. Treatment of murine SLE with the novel immunomodulator BTS 63 155, (A2) 12
 BOWMAN S. Death from unsuspected diverticular disease in patients taking corticosteroids for polymyalgia rheumatica or giant cell arteritis, (L) 159
 BOWMAN S, *see also* Smith CR
 BOWNESS P, DAVIES KAA, TOSSWILL J, BUNN CC, MACALPINE L, WEBER JN, WALPORT MJ. Autoimmune disease and HTLV-1 infection, 141
 BOWNESS P, SHOTLIFF K, MIDDLEMISS A, MYLES AB. Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis, 349
 BOWNESS P, *see also* Lunardi C
 BOYD HK, LAPPIN TRJ, BELL AL. Evidence for impaired erythropoietin response to anaemia in rheumatoid disease, 255
 BOYLE IT *see* Patel U
 BRADFORD DS *see* Oegama TR
 BRADLEY H, GOUGH A, SOKHI RS, WARING R, EMERY P. Analysis of cysteine/sulphate metabolism confirms defective sulphoxidation in patients with rheumatoid arthritis, (A2) 113
 BRADLEY H, *see also* Emery P
 BRADSHAW AE *see* Beynon HLC
 Bradykinin
 arthritis in one knee enhances the vascular response to bradykinin in the opposite knee, (A2) 142
 kallidin and HOE 140 metabolism in synovial fluid, (A2) 45
 BRANCÓS MA *see* Peris P
 BRAND SR *see* Hay E
 BRANDT KD. Animal models: insights into osteoarthritis provided by the cruciate-deficient dog, (S1) 5
 BRAUN J. Severe lupus crisis with agranulocytosis and anuric renal failure due to a mesangial lesion (WHO IIB)—successful treatment with cyclophosphamide pulse followed by plasmapheresis, (L) 312
 BREEDVELD FC *see* Boers M; Eggemeijer F; Landewé RBM; Miltenburg AMM; van der Zee JM; van Laar JM
 BREIPOHL G *see* Bond AP
 BREMER ME *see* Iyengar S
 BRENNAN FM, FIELD M, CHU CQ, FELDMANN M, MAINI RN. Cytokine expression in rheumatoid arthritis, (S1) 76
 BRENNAN P, SILMAN A. Comparison of three methods for clinical assessment of Raynaud's phenomenon, (A1) 28
 Brequinar sodium effects on experimental allergic encephalomyelitis, (S2) 83
 BRESNIHAN B *see* Callaghan M; O'Neill T; O'Neill TW; Veale D; Yanni G
 BREWERTON DA *see* Rees RG
 BRICKNELL S *see* Roffe C
 BRIDGES AB *see* Lau CS
 BRIGGS DC *see* Stephens CO; Whyte J
 British Paediatric Rheumatology Group national diagnostic index: development and implementation, (A2) 103
 British rheumatologists' perception of fibromyalgia, (A2) 80
 BROCHIER J *see* Wendling D
 BRÖKER BM, PIRNER K, ROSSMANN C, POTOCNIK A, BURMESTER G, HEPPT P, WESELOH G, EMMRICH F. Prevalence of gammadelta T cells and usage of TCR-V gene families in autoimmune disease, (S2) 97
 Bronchoalveolar lavage cell profiles and high resolution computed tomography in systemic sclerosis: a correlation, (A2) 28
 BROOKES SM, FANDOLFINO YA, SHATTLES WG, VENABLES PJW, MAINI RN. Immune response to cross-reactive GAG sequences in autoimmune disease, (A2) 24
 BROOKES SM, *see also* Lawrance RA
 BROOKS P. Combination therapy in rheumatoid arthritis, (L) 311
 BROOKS P. Rheumatology manpower in Australia, (L) 316
 BROOKS PM *see* Buchanan HM
 BROWN CMS, WILLIAMS DG, FITZGERALD KJ, MAINI RN. Immunoglobulin heavy chain variable region gene sequences of hybridomas derived from a rheumatoid synovium, (A2) 113
 BROWN CMS, *see also* Andrew EM
 BROWN GMM *see* Kalla AA
 BROWN KA, MAZURE G, PERRY JD, DUMONDE DC. Rheumatoid monocytes exhibit abnormal adherence characteristics to cultures of cytokine-treated and untreated vascular endothelium, (A2) 106
 BROWN KA, *see also* Hill TA
 BROWN R *see* Turner N
 BROWN RA *see* Ejim OS
 BRUCE A *see* Dowling EJ
 BRUCE D *see* Winyard PG
 BRZESKI M, MADHOK R, CAPELL HA. Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs, 370
 BUCHANAN HM, PRESTON SJ, BROOKS PM, WATSON BUCHANAN W. Is diet important in rheumatoid arthritis, 125
 BUCHANAN WW. Reclassifying adult rheumatoid arthritis, (L) 153
 BUCHANAN WW, *see also* Laurent MR
 BUCKLAND-WRIGHT JC, MACFARLANE DG, JASANI MK, LYNCH JA. Joint space loss in osteoarthritic knees using high definition macroradiography: comparison of weight bearing standing & tunnel views, (A2) 74
 BUCKNALL R, *see* Phelan M
 BUCKNALL RC *see* Watson F
 BUGELSKI PJ *see* Badger AM
 BUJIS WCAM *see* Laan RFJM
 BUNN CC *see* Bowness P
 BURGER MC *see* Kalla AA
 BURMEST G *see* Emmerich F
 BURMESTER G *see* Bröker BM
 BUTLER MG *see* Waller HA; Woodward L
 BUTLER RC, DAVIE MWJ, WORSFOLD M, SHARP CA. Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy, 86
 BYRNE J *see* Phelan M
 C3 deficiency, homozygous inherited, due to a partial gene deletion, (A2) 135
 C3D estimation in patients with vasculitis: evidence for in vivo complement activation and correlation with disease activity, (A1) 18
 C4 null alleles as a marker of drug toxicity to D-penicillamine and gold in rheumatoid arthritis, (A2) 32
 CABALLERIA J *see* Peris P
 CAHILL MR *see* Roffe C
 CALABOZO RALUY M *see* Alonso-Ruiz A
 CALIN A. Late onset ankylosing spondylitis—a distinct disorder, (L) 69
 CALIN A. Osteoporosis and ankylosing spondylitis, (L) 318
 CALIN A. What do patients and rheumatologists regard as an acceptable risk in the treatment of rheumatic disease, (L) 318
 CALIN A, *see also* Kennedy LG
 CALLAGHAN M, MULHERIN D, O'MAHONEY S, WHELAN A, FEIGHERY C, FITZGERALD MX, BRESNIHAN B. In vitro rheumatoid factor production and circulating CD5+ B lymphocytes during bacterial infections, (A2) 5
 CAMERON JS *see* Chan TM; Perry GJ
 CAMILLERI JP, DOUGLAS-JONES AG, PRITCHARD MH. Rapidly progressive aortic valve incompetence in a patient with rheumatoid arthritis, 379
 CAMPBELL A *see* Phelan M
 CAMPBELL AK *see* Davies EV
 CAMPBELL GA *see* Patel U
 CAMPBELL J *see* Bellamy N
 CAMPION G *see* Bond AP

- CAMPS JAJ *see* Boers M; Eggemeijer F
 Can exercise prevent osteoporosis, (L) 313
 Can genetic factors predict erosions in rheumatoid arthritis patients, (A2) 31
 Can we alter junior doctors' awareness of locomotor problems, (A2) 1
 CANDELA M *see* Danieli MG; Gabrielli A
 CAPELL H *see* Taha AS
 CAPELL HA, PORTER DR, HUNTER JA. Combined studies of second line therapy in rheumatoid arthritis from a single centre: an analysis of 1344 patients, (A2) 100
 CAPELL HA, *see also* Brzeski M; Marshall DAS; Murphy EA; Porter DR
 CAPPER SJ *see* Eastgate JA
 Cardiac abnormalities in ankylosing spondylitis. Early detection of aortic incompetence with Doppler echocardiography, (A2) 60
 CARNEY SL Billingham MEJ
 Carpal tunnel syndrome
 complicated by reflex sympathetic dystrophy syndrome, 468
 magnetic resonance imaging of the carpal tunnel before and after treatment, (A2) 61
 CARPENTER TA, EVERETT JR, HALL LD, HARPER GP, HODGSON R, JAMES MF, WATSON P. Magnetic resonance imaging of the rat knee, (A2) 64
 CARR A *see* Cox NL; Williams RB
 CARRELL RW *see* Winyard PG
 CARRO A, ALFAYATE R, BATLLE E, CASTELLANO JA, ROMÁN J, VELA P, ROSAS J, RIVERA F, PASCUAL E. Absence of microalbuminuria in SLE patients without renal disease, (A2) 90
 CARSON DA, CHEN PP, SILVERMAN GJ, KIPPS TJ. Immunoglobulin gene expression in systemic rheumatic diseases, (S1) 43
 CARSON DICK W *see* Goodacre JA
 CARTER SD. Relationship between rheumatological diseases of man, pet dogs and their viruses, (L) 393
 CARTHY D *see* MacGregor AJ
 Cartilage
 breakdown and angiogenesis, (A2) 143
 collagens and joint degeneration, (S1) 10
 damage, effects of sex steroids, (A1) 37
 damage, sex differences in using an *in vivo* model, (A2) 127
 degradation detection with sodium NMR, (L) 318
 stiffness mapping in the apophyseal joint, (A2) 70
 CASE JP *see* Wilder RL
 CASTELLANO JA *see* Carro A
 CASTRO A *see* Lima J
 CATOGGIO LJ. Treatment of polymyalgia rheumatica: lower initial dose, (L) 393
 CATS A *see* Boers M
 Cause of back pain and sciatica may be a venous matter too, (L) 70
 CAWLEY MID *see* Gaywood IC; Howell CJ; Jenkins EA
 CAWSTON T. Metalloproteinase inhibitors—crystal gazing for a future therapy, (E) 242
 CAWSTON TE *see* Andrews HJ; Clark IM; Curry VA; Pountain G; Riley G; Riley GP
 CD4 monoclonal antibody, bicentric open study of rheumatoid arthritis treatment, (S2) 87
 CD23 expression in patients with rheumatoid arthritis, (A2) 110
 CD44
 antibodies and hyaluronan-binding protein antibodies from rat chondrosarcoma co-distribute in normal human tissues, (A1) 12
 relationship to hyaluronan in rheumatoid nodule, (A1) 12
 Cell adhesion molecule distribution in peripheral muscle from patients with SLE, (A2) 23
 CERVERA R *see* Aydinoglu AO; Font J; Khamashta MA
 Cervical spine surgery in rheumatoid arthritis: improvement of neurological deficit following cervical spine fusion, (A2) 96
 CHACON P *see* Lima J
 Challenge of osteoporosis: coordinating a service to the community, (A1) 4
 CHALTON D *see* Kalla AA
 CHAMBERLAIN MA, TENNANT A. Health service reforms and access to specialist services, (E) 322
 CHAN TM, FRAMPTON G, JAYNE DRW, PERRY GJ, LOCKWOOD CM, CAMERON JS. Clinical importance of anti-endothelial cell antibody (AECA) in systemic vasculitis, (A2) 86
 CHAN TM, FRAMPTON G, JAYNE DRW, PERRY GJ, LOCKWOOD CM, CAMERON JS. Vasculitis sera stimulate von Willebrand factor secretion by endothelial cells in culture. This activity correlates with AECA but not ANCA, (A2) 85
 CHAN TM, *see also* Perry GJ
 CHANDER C *see* Da Silva JAP
 CHANG JY, SEHGAL SN. Pharmacology of Rapamycin: a new immunosuppressive agent, (S2) 62
 CHANG PC *see* Boers M
 Changes in
 frequency of natural killer cells in SLE patients with disease activity and renal involvement, (A2) 16
 glycosaminoglycan composition of adult human supraspinatus tendon, (A2) 79
 serum interleukin-6 following intramuscular gold treatment in rheumatoid arthritis, (S2) 99
 Characteristic patterns of cellular activation in chronic inflammation: immune-mediated activity and non-specific cellular infiltration distinguished by interleukin-1 beta distribution in arthritis, (S2) 84
 Characterization of anti endothelial cell antibodies in systemic lupus erythematosus and rheumatoid arthritis complicated by vasculitis, (A2) 134
 CHARD M *see* Riley G
 CHARD MD *see* Riley GP; Vecchio PC
 CHARLES P *see* Foster H; Kelly CA
 CHARLES PJ *see* Lawrance RA; Teh LS
 CHASSAGNE PH. Neurosensory adverse effects after combined phenylbutazone and misoprostol, (L) 392
 CHATTOPADHYAY C *see* Hillarby MC
 CHECKLEY D *see* Waterton JC
 Chemical, structural and morphological analyses of mineral deposits in synovial fluid, (A2) 129
 Chemonucleolysis (chymopapain injection) in lumbar disc protrusion, (CC) 118
 CHEN PP *see* Carson DA
 CHEN ST *see* Hukkanen M
 CHERUBINI G *see* Gabrielli A
 CHIDWICK K, FARRELL AJ, ZHANG Z, BLAKE DR, WINYARD PG. Loss of functional activity of synovial fluid α -1-antitrypsin in rheumatoid arthritis correlates with disease activity as measured by serum C-reactive protein, (A2) 130
 CHIDWICK K, *see also* Winyard PG; Zhang Z
 CHIECO-BIANCHI F *see* Verwilghen J
 CHIKANZA I *see* Choy EHS
 CHIKANZA IC. Arrhythmia after pulse methylprednisolone therapy, (L) 392
 CHIKANZA IC, PANAYI GS. Hypothalamic-pituitary mediated modulation of immune function: prolactin as a neuroimmune peptide, 203
 CHIKANZA IC, PANAYI GS. Neuroendocrine-immune interactions in the pathogenesis of rheumatoid arthritis: therapeutic implications, (S2) 96
 CHIKANZA IC, *see also* Kirkham BW
 CHILAS GI *see* Papazoglou SN
 Chimaeric (human/mouse) CD7 monoclonal antibody treatment in rheumatoid arthritis, (S2) 88
 CHIN JE *see* Aspar DG
 Chondrocyte responses in cartilage and in experimental osteoarthritis, (S1) 32
 Chondroitin sulphate species distribution in inflammatory muscle disease, (A2) 22
 CHOU YK *see* Vandembark AA
 CHOY EHS, CHIKANZA I, KINGSLEY GH, PANAYI GS. Treatment of relapsing polychondritis with chimaeric monoclonal antibodies, (A2) 10
 CHOY EHS, CORKILL MM, GIBSON T, HICKS BH. Isolated ACTH deficiency presenting with bilateral frozen shoulder, 226
 Chronic fatigue syndrome, antibodies to phospholipids: implications for a viral aetiology, (A2) 11
 CHU C *see* Deleuran B
 CHU CQ, FIELD M, ABNEY E, FELDMANN M, MAINI RN. Immunolocalisation of GM-CSF in the RA synovial tissue, (A2) 7
 CHU CQ, *see also* Brennan FM
 CHU S *see* Vancheeswaran R
 Circadian variations in the superoxide production, enzyme release and neutrophil aggregation in patients with rheumatoid arthritis and controls, 138
 CLACKSON TP. Genetically engineered monoclonal antibodies, (S2) 36
 CLAGUE RB *see* Blann AD; Jones STM
 CLARK IM, WRIGHT JK, CAWSTON TE. Measurement of collagenase by enzyme assay, (A2) 129
 CLARK IM, *see also* Curry VA
 CLARKE AM. Does the weather affect the osteoarthritic patient, (L) 477
 CLARKE R *see* Sheeran T
 CLARKE S *see* Davis MJ
 CLARKSON R *see* Hillarby MC
 CLARKSON RWE, SANDERS P, GRENNAN DM. C4 null alleles as a marker of drug toxicity to D-penicillamine and gold in rheumatoid arthritis, (A2) 32
 Class II heterozygote status contributes to RA susceptibility, (A2) 57
 CLAUW DJ, ALLOWAY JA, REED C, KATZ P. Use of cyclosporin A in the eosinophilia myalgia syndrome, (A2) 30
 CLAXSON AW *see* Dowling EJ
 CLAXSON AWD *see* Herz H
 Clearance of intraarticular albumin in RA, AS and OA patients: what is the effect of IA corticosteroid, (A1) 33
 Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements, 29

- Clinical importance of anti-endothelial cell antibody (AECA) in systemic vasculitis, (A2) 86
- Clinical profile of acute vertebral compression fractures in osteoporosis, 418
- Clinical T cell vaccination, (S2) 17
- Clinics, comparative study of a traditional medical and a nurse practitioner clinic, (A1) 2
- CLOSE DR, NIXON N, TAYLOR HG, DAWES PT, STANWORTH DR, MATTEY DL. Inhibition of natural killer cell cytotoxicity in rheumatoid arthritis by the non-immune complex IgA-alpha-1-antitrypsin, (A2) 107
- CLOSKEY EV *see* Rolfe I
- CLOT J B *see* Wendling D
- Co-localisation of tumour necrosis factor α and its receptor in rheumatoid arthritis synovial membrane, (A2) 7
- COATES ARM *see* Winrow VR
- CORBE SM *see* Marshall DAS
- CORBOLD SP *see* Waldmann H
- COCHRANE C *see* Blount S
- CODINA M *see* Escudero D
- COFINER C *see* Beynon HLC; Loizou S
- COGON D *see* Croft P; Silman A
- COHEN IR. Unresolved questions in clinical T cell vaccination, (S2) 17
- COHEN IR, *see also* Danicli MG
- COHEN J *see* Beynon HLC
- COLL J *see* Escudero D
- Collagen arthritis and oral tolerance, (S2) 40
- Collagen-induced arthritis in rhesus monkeys, resistance to: MHC antigens, CD8+ cells and IL2 determine T cell low responsiveness, (S2) 99
- Collagenase
measurement by enzyme assay, (A2) 129
reserves in synovial fluid neutrophils in RA, (A2) 128
- COLLINS DA, ALLARD SA, HERON C, BOURKE BE. MRI scanning can detect cerebral abnormalities in lupus patients without clinical neurological disease, (A2) 61
- COLLINS DA, GOGGIN PM, MARRERO JM, NORTHFIELD TC, BOURKE BE. *Helicobacter pylori* status does not modify the acute gastric toxicity of non-steroidal anti-inflammatory drugs, (A2) 138
- Collins Grimley Sokoloff synovial giant cell: mononuclear phagocyte polykaryon, fibroblast polykaryon, osteoclast or all three, (A2) 44
- COLOMBO B *see* Sakkas LI
- COLSTON MJ *see* Gaston JSH
- COLTON MJ *see* Winrow VR
- COLVILLE-NASH P *see* Da Silva JAP
- COLVILLE-NASH PR, SCOTT DL, WILLOUGHBY DA. Angiogenesis and cartilage breakdown, (A2) 143
- COMBE B *see* Wendling D
- Combination therapy in rheumatoid arthritis, (L) 311
- Combined studies of second line therapy in rheumatoid arthritis from a single centre: an analysis of 1344 patients, (A2) 100
- Comparative study of a traditional medical and a nurse practitioner clinic, (A1) 2
- Comparison of
disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients, 298
the efficacy of hydrotherapy and seated immersion in rheumatoid arthritis, (A2) 76
manual and automated cell counts in synovial fluid. Storage has little influence in the result of the cell counts, (A2) 130
three methods for clinical assessment of Raynaud's phenomenon, (A1) 28
- Compliance with hormonal replacement therapy after screening for post menopausal osteoporosis, (A2) 94
- Computerized measurement of radiological changes in the rat knee, (A2) 127
- Connective tissue disease
efficacy of plasmapheresis in treatment, (S2) 92
long-term follow-up of iloprost infusion of patients using infra-red thermography, (A2) 76
urinary C3D/neopterin ratio in assessment—a measure of humoral/cellular immunity, (A2) 110
- Contracting for rheumatology services, 200
- CONTRERAS PC *see* Iyengar S
- Control of bone cell development and function, (A2) 66
- COOK N *see* Howell CJ; Jenkins EA
- COOPER C. Can exercise prevent osteoporosis, (L) 313
- COOPER C. Osteoporosis, 135
- COOPER C, *see also* Croft P; David J; McAlindon TE
- COOPER EH *see* Hordon LD
- COOPER J *see* Leak AM
- COOPER PH *see* Mackenzie AR
- COOPER R *see* Freemont AJ
- COOPER RG *see* Davies E; Herrick AL; Holt I
- CORKILL M *see* Dasgupta B
- CORKILL MM. Interpretation of therapeutic trials, (L) 66
- CORKILL MM, KIRKHAM BW, HASKARD DO, BARBATIS C, GIBSON T, PANAYI GS. Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1, (S2) 81
- CORKILL MM, *see also* Choy EHS; Kirkham B
- CORLESS W *see* Rolfe I
- CORNELIS C *see* van den Brink HR
- Correlation of serum IgG1 with biopsy findings in primary Sjögren's syndrome, (A1) 18
- CORRIGALL V *see* Jobanputra P
- CORRIN B *see* Wells AU
- CORSTENS FHM *see* Laan RFJM
- Corticosteroid secretion, age-related increase in rats, and postmenopausal predisposition in women to develop osteoporosis, (CC) 90
- CORVETTA A, DELLA BITTA R, LUCHETTI MM, POMONIO G. 5-Methylcytosine content of DNA in blood and synovial mononuclear cells from patients affected by rheumatic disease, (S2) 98
- Cost-benefit analysis of three different recruitment techniques in a regional osteoporosis screening study: report of a pilot study, (A2) 93
- COUGHLAN RJ *see* Foley-Nolan D
- COX NL, CARR A. Relationship between range of movement of joints and disability, (A1) 4
- COX NL, *see also* Gaywood IC; Williams RB
- COZZI L *see* Fiocco U
- Cranial MRI in patients with Sjögren's syndrome, (A2) 25
- CREAMER P, EDMONDS JP, SULLIVAN J, MATTHEWS S. Quantitation of HLA class I in ankylosing spondylitis, (A1) 10
- CREED F *see* Teh LS
- CRISP AJ *see* Bhambhani MB; Patel U
- CROFT P. Natural history of shoulder problems in primary care, (A2) 78
- CROFT P, COOPER C, WICKHAM C, COGON D. Physical activity and osteoarthritis of the hip in men, (A2) 73
- CROFT PR, RIGBY AS, PAPAGEORGIOU AC, WILLIAMS GH. Socioeconomic influences on the occurrence of common musculoskeletal problems, (A2) 102
- CRONIN CC. Bilateral septic arthritis of the hips complicating the arthropathy of haemochromatosis, (L) 395
- CROSSMAN MV *see* Worrall JG
- CRUWYS SC, KIDD BL, MAPP PI, WALSH DA, BLAKE DR. Arthritis in one knee enhances the vascular response to bradykinin in the opposite knee, (A2) 142
- CRUWYS SC, KIDD BL, MAPP PI, WALSH DA, BLAKE DR. Substance P—a specific vascular receptor in rat synovium, (A2) 44
- CRUWYS SC, *see also* Mapp PI; Walsh DA
- CSUKA ME *see* Darton K
- CUESTA M *see* Muñoz S
- CULLINAN P *see* Wells AU
- CURRY VA, CLARK IM, BIGG H, CAWSTON TE. Large inhibitor of metalloproteinase consists of TIMP-2 bound to 72000 Mr-progelatinase, (A2) 128
- CUSHNAGHAN J *see* Dacre JE; Dieppe P
- Cutaneous gold toxicity, keeping patients on treatment, (A2) 100
- Cyclophosphamide as a treatment for bone marrow hypocellularity in SLE, (A2) 140
- Cysteine/sulphate metabolism analysis confirms defective sulfoxidation in patients with rheumatoid arthritis, (A2) 113
- Cytidine deaminase serum changes in rheumatoid arthritis correlate with clinical assessments of joint inflammation, (A1) 33
- Cytochrome oxidase activity of guinea pig cartilage and its relationship to the onset of osteoarthritis, (A2) 126
- Cytokine
effects on proliferation and PGE₂ production by synoviocytes derived from mBSA/IL-1 arthritic mice, (S2) 83
expression in rheumatoid arthritis, (S1) 76
inhibitors, biological role of naturally-occurring, (S2) 49
levels in rheumatoid synovial fluid do not reflect levels in synovial membrane cultures, (A1) 31
network in rheumatoid arthritis, (S2) 44
- Cytokines
and the acute phase response in rheumatoid arthritis, (A2) 6
synergy between low concentrations of cytokines and acute agonists causes increased endothelial permeability, (A2) 51
in synovial fluid and plasma of patients with inflammatory arthritis: relationships to local and systemic parameters of disease activity, (A2) 124
and their interrelationships in the joints and plasma of arthritis patients, (A2) 126
- DA SILVA JAP, CHANDER C, SCOTT DL, WILLOUGHBY DA. Effects of sex steroids on cartilage damage, (A1) 37

- DA SILVA JAP, COLVILLE-NASH P, SPECTOR TD, SCOTT DL, WILLOUGHBY DA. Sex differences in cartilage damage using an *in vivo* model, (A2) 127
- DA SILVA JAP, MATSON M, PERRY LA, HERBERT KA, SPECTOR TD. Examination of the cause of low testosterone levels in male rheumatoid patients, (A2) 36
- DA SILVA JAP, *see also* Dacre JE
- DABBAGH A *see* Winrow VR
- DACRE JE, CUSHNAGHAN J, JACK MJ, KIRWAN JR, DIEPPE PA. Knee X-rays: should we take them lying down, (A1) 3
- DACRE JE, SCOTT DL, DA SILVA JAP, WELSH G, HUSKISSON EC. Joint space in radiologically normal knees, 426
- DACRE JE, *see also* Spector TD
- DADDONA PE *see* Jonker M
- DAHA MR *see* Landewé RBM; Miltenburg AMM; van der Zee JM; van Laar JM
- DANIELI G *see* Danieli MG; Gabrielli A
- DANIELI MG, CANDELA M, RICCIATTI AM, REGINELLI R, GABRIELLI A, DANIELI G, COHEN IR. Humoral reactivity to mycobacterial 65 heat shock protein in systemic sclerosis, (S2) 94
- DANIELI MG, MARKOVITZ D, GABRIELLI A, DANIELI G, COHEN IR. Immune response to mycobacterial heat shock protein 65 kD in juvenile and adult rheumatoid arthritis, (S2) 94
- DANIELI MG, *see also* Gabrielli A
- DANPURE HJ *see* Jones AKP
- DARLINGTON LG. Is diet important in rheumatoid arthritis, (L) 315
- DARTON K. Use of infra-red thermography in a Rheumatology Unit, (L) 72
- DARTON K, BLACK CM. Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon, 190
- DARTON K, TANNER SB, WATSON HR, CSUKA ME, BLACK CM. Long-term follow-up of illoprost infusion of patients with connective tissue disease using infra-red thermography, (A2) 76
- DASGUPTA B, CORKILL M, PANAYI GS. Changes in serum interleukin-6 following intramuscular gold treatment in rheumatoid arthritis, (S2) 99
- DASH A *see de* Oliveira J
- DAUNT SO'N *see* Gaywood IC
- DAVID J, BLACK C, Woo P. Scleroderma in childhood, (A2) 75
- DAVID J, LLOYD J, COOPER C, HICKEY L, DORÉ C, MEHTA R, ROSSOUW D, MCCULLOUGH C, Woo P. Juvenile chronic arthritis in early adult life, (A2) 98
- DAVIDSON JE, WILSON J, SANDILANDS GP. Glycoprotein 60 on peripheral blood lymphocytes in rheumatoid arthritis, (A2) 109
- DAVIE MWJ *see* Butler RC
- DAVIES E, HILLARY MC, COOPER RG, HAYES E, HOLT L, BERNSTEIN R. MHC class II variants in SLE, (A2) 33
- DAVIES EV, CAMPBELL AK, WILLIAMS BD, HALLETT MB. Single cell imaging reveals abnormal intracellular calcium signals within rheumatoid synovial neutrophils, 443
- DAVIES GR, PERRY JD, GARVIE NW, RAMPTON DS. Assessing activity of rheumatoid arthritis with radiolabelled leucocytes, (A1) 25
- DAVIES GR, PERRY JD, RAMPTON DS. Influence of misoprostol on non-steroidal anti-inflammatory drug-influenced intestinal damage and disease activity in rheumatoid arthritis, (A2) 91
- DAVIES GR, *see also* Wilkie ME
- DAVIES J *see* Stuart RA
- DAVIES KA, BEGENT RH, WALPORT MJ. Hepatic clearance of immune complexes formed *in vivo* results in loss of CR1 from erythrocytes, (A2) 86
- DAVIES KA, ERLÉNDSÖN K, PATERS AM, BEYON H, STEINSSON K, VALDIMARSSON H, WALPORT MJ. Splenic localisation of immune complexes is complement dependent, (A2) 136
- DAVIES KAA *see* Bowness P
- DAVIES UM, ANSELL BM, Woo P. Measurement of growth hormone in children with juvenile chronic arthritis and growth retardation on alternate day corticosteroid therapy, (A2) 75
- DAVIS J *see* Situnayake RD
- DAVIS M *see* Hillaby MC; Situnayake RD
- DAVIS MJ, CLARKE S, FISHER J, DAWES PT. Disease course and outcome in rheumatoid arthritis, (A2) 98
- DAVIS MJ, DAWES PT, EVANS L, LEWIN I, STANWORTH DR. Synovial fluid and serum levels of the complex immunoglobulin A alpha-1- antitrypsin in inflammatory and non-inflammatory arthritis, (A2) 114
- DAVIS MJ, DAWES PT, FOWLER PD, CLARKE S, FISHER J, SHADFORTH MF. Should disease-modifying agents be used in mild rheumatoid arthritis, 451
- DAVIS MJ, *see also* Wilkinson SM
- DAVIS P. Rheumatology manpower in the 1990s, in Canada, (L) 234
- DAVISON AN, LEVINE S, JAFFEE BD. Effect of Brequinar sodium on experimental allergic encephalomyelitis, (S2) 83
- DAVYAN VG, YU GARIB F. Immunocorrection in the ankylosing spondylitis, (S2) 98
- DAWES PT. Visiting other departments, (E) 403
- DAWES PT, *see also* Close DR; Davis MJ; Taylor HG; Wilkinson SM; Zukovskis K
- DAWSON R *see* Lindsey NJ
- D'CRUZ D *see* Aydtug AO; Hill TA; Jedryka-Goral A
- D'CRUZ DP, ASHERSON RA, TRIPATHI P, WISNIESKI J, McKEE P, HUGHES GRV. Antiendothelial cell antibodies in patients with SLE and urticarial vasculitis, (A2) 19
- DE KUIPER R *see* Miltenburg AMM
- DE LA HERA M *see* Ramos A
- DE LANGE G *see* Sidebottom D
- DE SILVA L *see* Thompson PW
- DE VRIES N, PRINSEN CFM, VAN 'T HOF MA, VAN RIEL PCLM, VAN DE PUTTE LBA. Association of a T-cell receptor β -chain variable region restriction fragment length polymorphism with outcome in rheumatoid arthritis, (A2) 31
- DE VRIES RRP *see* van Laar JM
- DE WILDE PCM *see* Kruize AA
- DEAN MF *see* Martin H
- Death from unsuspected diverticular disease in patients taking corticosteroids for polymyalgia rheumatica or giant cell arteritis, (L) 159
- DECKERS G *see* Verheul HAM
- Defective corticosteroid induction of lipocortin-1 in rheumatoid leukocytes, (A2) 116
- Defects of the retinal pigment epithelium in scleroderma, 112
- Degenerative disc disease and facet joint disease osteoarthritis interrelationship, (S1) 16
- Degenerative disease of the spine, link between vascular damage and fibrosis, (A2) 49
- DEIGHTON CM. Reclassifying adult rheumatoid arthritis, (L) 152
- DEIGHTON CM, FAY A, WALKER DJ. Rheumatoid arthritis, in same-sexed sibships with and without evidence of thyroid abnormalities, (A1) 11
- DEIGHTON CM, GRAY J, ROBERTS DF, WALKER DJ. P blood group phenotype anti-*Proteus* antibody titres and rheumatoid arthritis, (A2) 3
- DEIGHTON CM, GRAY JW, BINT AJ, WALKER DJ. Anti-*Proteus* antibodies in rheumatoid arthritis: a longitudinal and clinical study, (A1) 17
- DEIGHTON CM, *see also* McDonagh J; Swinden DC; Sykes HR
- DEL POZO E *see* Mackenzie AR
- Delayed diagnosis of systemic lupus erythematosus associated pulmonary hypertension, (L) 391
- DELEURAN B, CHU C, FELDMANN M, FIELD M, MAINI RN. Co-localisation of tumour necrosis factor α and its receptor in rheumatoid arthritis synovial membrane, (A2) 7
- DELLA BITTA R *see* Corvetta A
- DELL'ISOLA B. Recovery of anterior spinal artery syndrome in a patient with systemic lupus erythematosus and antiphospholipid antibodies, (L) 314
- Demonstration of diphosphoglucose dehydrogenase activity in normal and rheumatoid synovial lining cells, (A1) 6
- IL-2 mRNA and protein in different arthropathies using biotinylated oligonucleotide probes for mRNA detection, (A2) 68
- initial lymphatics in human synovial tissue, (A1) 7
- DEN OTTER W *see* Niefeld JJ; Wilbrink B
- DENMAN M *see* Kirkham B
- DENNIS MJ *see* Hicklin JA
- DENOTTER W *see* Wilbrink B
- DENTON A *see* Rolfe I
- DENTON J *see* Holt I
- DE'OLIVEIRA J, GASKIN G, DASH A, REES AJ, PUSEY CD. Relationship of ANCA specificity and concentration to disease activity in patients with systemic vasculitis, (A2) 84
- Deoxyypyridinoline excretion as a marker of bone resorption in an animal model of inflammation associated osteoporosis, (A1) 35
- DEQUEKER J *see* Jacobs JWG
- Designer antibodies, *in vivo* model for testing, (S2) 89
- Detection of cartilage degradation with sodium NMR, (L) 318
- IL-6 receptors in cultured explants of human articular cartilage, (A2) 125
- Determinants of osteoporotic thoracic spine vertebral fractures, (A2) 55
- DEUTSCH J *see* Luqmani RA
- DEUXBOUTS N *see* Jacobs JWG
- Development and use of a patient knowledge questionnaire in rheumatoid arthritis, 45
- DEWALD B *see* Seitz M
- Dexamethasone injection, intrathecal, effects on plasma cortisol level, (L) 238
- Diagnostic value of antiperinuclear factor, (A2) 112
- Dialysis arthropathy and kidney transplantation, (A2) 89
- shoulder, magnetic resonance imaging study, (A2) 87
- DICK WC *see* Kelly CA

- Diclofenac, no effect of misoprostol on renal function of rheumatoid patients treated with diclofenac, 56
- DIDRY C *see* Wendling D
- DIEPPE P. Osteoarthritis, clinical and research perspective, (S1) 1
- DIEPPE P. Regenerative joint disease, (E) 322
- DIEPPE P, McALINDON T, CUSHNAGHAN J. Symmetry and compartmental involvement of established osteoarthritis of the knee joint, (A2) 65
- DIEPPE PA. Osteoarthritis joint, intra-articular steroid injections for treatment, (CC) 199
- DIEPPE PA. Overinterpreting data on biochemical markers, a new epidemic in rheumatology, (L) 237
- DIEPPE PA, *see also* Bond AP; Dacre JE; Heywood BR; McAlindon TE; McGill NW
- Diffuse proliferative glomerulonephritis in Behçet's syndrome, 63
- DIJKMANS BAC *see* Boers M; Eggelmeijer F; Janssen M; Landewé RBM
- DILORETO C *see* Gabrielli A
- DIMARTINO MJ *see* Badger AM
- Diphosphoglucose dehydrogenase activity in normal and rheumatoid synovial lining cells, (A1) 6
- Directed gold therapy using myocrisin coupled to fibronectin, (A1) 19
- Disability
- assessment in male and female rheumatoid patients, (L) 477
 - measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients, 298
 - relationship between range of movement of joints and, (A1) 4
- Disease course and outcome in rheumatoid arthritis, (A2) 98
- Distribution of
- cell adhesion molecules in peripheral muscle from patients with SLE, (A2) 23
 - vitronectin in tissue biopsies of synovitis, (A2) 122
- Diuretic induced gout in chronic cardiac failure, (CC) 225
- Diurnal variation in the symptoms and signs of the fibrositis/fibromyalgia syndrome, (A2) 96
- DIXEY J *see* Doherty M
- DNA analysis of HLA class II polymorphisms in Greek RA patients, (S2) 97
- DOCHERTY AJP *see* Murphy G
- DOODS RA *see* Wilkinson LS
- Does deposition of debris from TiAlV alloy lead to prosthetic joint failure, (A2) 116
- Does gold therapy reduce non-steroidal peptic damage in rheumatoid arthritis, (A2) 139
- Does misoprostol have a reno-protective effect in co-administration with indomethacin, (A2) 90
- Does the weather affect the osteoarthritic patient, (L) 477
- DOESBURG W *see* Jeurissen ME
- DOHERTY M, HAMILTON E, HENDERSON J, MISRA H, DIXEY J. Familial chondrocalcinosis due to calcium pyrophosphate dihydrate crystal deposition in English families, 10
- DOHERTY M, *see also* Hamilton E; Hopkinson N; Jones AC; Ledingham J; Priestley L
- DOHERTY S *see* Ledingham J
- DOHERTY SM, PURDIE DW. North Humberside osteoporosis screening project—preliminary observations, (A1) 5
- DONALDSON C *see* Garton MJ
- DORÉ C *see* David J
- Double blind controlled trial of the addition of hydroxychloroquine or placebo to patients with a suboptimal response after 6 months of IM gold, (A2) 138
- DOUGLAS-JONES AG *see* Camilleri JP
- DOWD GSE *see* Waller HA
- DOWLING EJ, CLAXSON AW, MAPP PI, BRUCE A, GRIFFITHS H, LUNEC J, LILLIE C, BLAKE DR. Study of human recombinant manganese superoxide dismutase in experimental inflammation, (A2) 142
- DOYLE DV *see* Hall GM; Hart DJ; Rolfe I; Spector TD; Woodward L
- DRAAD MP *see* Laan RFJM
- DRIEDGER AA *see* Bellamy N
- Driving
- and arthritis, 361
 - for the disabled by arthritis, 54
- DROSSOS A *see* Boki K
- DU BOIS RM *see* Wells AU
- DUFF G *see* Yanni G
- DUFF GW *see* Eastgate JA
- DUMONDE DC *see* Brown KA
- DURRANT STS *see* Roffe C
- DYER P *see* Kay R
- DYKES SG *see* Bowen JG
- Early arthritis clinics, (E) 241
- Early morning stiffness and diurnal variation in angiotensin converting enzyme activity (ACE), (A2) 47
- EASTELL R *see* Peel NFA
- EASTGATE JA, SYMONS JA, WOODS NC, CAPPER SJ, DUFF GW. Plasma levels of interleukin-1-alpha in rheumatoid arthritis, 295
- EBERHARDT K, MALCUS JOHNSON P, RYDGREN L. Occurrence and significance of hand deformities in early rheumatoid arthritis, 211
- EDMONDS JP *see* Creamer P
- EDWARDS AC *see* Thompson PW
- EDWARDS JCW, MOORE AR, WILKINSON LS, WORRALL JG, WILLOUGHBY DA. Subcutaneous air pouch lacks a specialised cell population found in synovial lining, (A2) 121
- EDWARDS JCW, *see also* Pitsillides AA; Wilkinson LS; Worrall JG
- EDWARDS S *see* Phelan M
- EDWARDS SW *see* Watson F
- Effect of
- abstinence on bone mass in chronic alcoholism, (A2) 94
 - aspirin administration on erythrocyte ATP, (A2) 38
 - biological crystals and human serum on the rate of formation of crystals of monosodium urate monohydrate *in vitro*, 107
 - Brequinar sodium on experimental allergic encephalomyelitis, (S2) 83
 - cytokines on proliferation and PGE₂ production by synoviocytes derived from mBSA/IL-1 arthritic mice, (S2) 83
 - effusion volume and type on exercise induced intra-articular pressure changes in human knee joints, (A1) 38
 - food on the pharmacokinetics of methotrexate in the treatment of rheumatoid arthritis, (A2) 37
 - immunoglobulin G from patients with systemic lupus erythematosus and the antiphospholipid syndrome on the release of von Willebrand factor antigen from human umbilical vein endothelium, (A2) 19
 - intrathecal dexamethasone injection on plasma cortisol level, (L) 238
 - prednisolone on fibrinolytic activity and disease activity in rheumatoid arthritis, (A2) 35
 - a single infusion of pamidronate on Paget's disease of bone, (A2) 95
 - SK&F 105685, a novel suppressor cell-inducing compound, in the adjuvant arthritic rat, (S2) 66
 - SK&F 105685, a novel suppressor cell-inducing compound, on disease parameters in the adjuvant arthritis rat, (S2) 82
 - sulphasalazine on reactive oxidant generation by neutrophils, (A2) 41
 - sulphasalazine on in vivo antibody response to orally administered antigen—evidence for an effect on the mucosal immune system, (A2) 4
- Effects of
- anti-inflammatory drugs on human osteoblast metabolism, (A2) 47
 - Maxepa on non-steroidal anti-inflammatory drug usage in patients with mild rheumatoid arthritis, (A2) 137
 - methotrexate on glycosaminoglycan production of cultured fibroblasts from scleroderma patients and healthy controls: preliminary results, (A2) 133
 - sex steroids on cartilage damage, (A1) 37
- Efficacy of plasmapheresis in the treatment of recalcitrant undifferentiated connective tissue disease, a case report, (S2) 92
- EGGELMEIJER F, CAMPS JAJ, VALKEMA R, PAPADOPOULOS SE, PAUWELS EKJ, DIJKMANS BAC, BREEDVELD FC. Lumbar bone mineral density in rheumatoid arthritis: normal values in ambulant, non-steroid treated patients, (A2) 53
- Ehlers-Danlos syndrome type II
- molecular analysis, (E) 163
 - segregation analysis of the structural genes of the major fibrillar collagens provides further evidence of molecular heterogeneity, 173
- EISENBEIS JR CH *see* Peppelman WC
- EJIM OS, WELLS T, HARVEY MJ, MORE J, BROWN RA. Directed gold therapy using myocrisin coupled to fibronectin, (A1) 19
- EL-BATTOUTY MF *see* Hafez M
- EL-HAZMI MA, AL-BALLAA SR, WARSY AS, AL-ARJAF H, AL-SUGHAIR S, AL-DALAAAN AN. Transferrin C subtypes in patients with rheumatoid arthritis, 21
- EL-ZINY M *see* Hafez M
- ELDRIDGE J *see* Jones STM
- Electron microscopic study of muscle capillary wall thickening in SLE and MCTD, (A2) 22
- Elevated neuropeptide levels in patients with algodystrophy, (A2) 64
- Elevated serum IL6 levels associated with active disease in systemic connective tissue disorders, (A2) 135
- ELFORD P *see* Mackenzie AR
- ELISA of anti-La but not anti-Ro correlates with total serum IgG1 and degree of salivary gland infiltration in primary Sjögren's syndrome, (A2) 24
- ELL PJ *see* Hall GM
- ELLIS RE *see* Moore EA

- ELSON CJ *see* Thompson SJ
- EMERY P, GOUGH A. Why early arthritis clinics. (E) 241
- EMERY P, SALMON M, BRADLEY H, GOUGH A, FAINT J, TUNN E, WARING R. Can genetic factors predict erosions in rheumatoid arthritis patients. (A2) 31
- EMERY P, *see also* Blann AD; Blount S; Bradley H; Gado K; Gough A; Loveridge JA; Luqmani RA; Rousseau E; Sheeran T
- EMMRICH F, HORNEFF G, GUSE A, KINNE R, BURMEST G, BECKER W. Unspecific accumulation of anti-CD4 antibodies and negative signalling but not modulation of the CD4-molecule may contribute to the efficacy of anti-CD4 treatment in rheumatoid arthritis. (S2) 100
- EMMRICH F, *see also* Bröker BM
- Endocrine properties of androgen-derived steroids are not correlated with favourable effects on lupus and sialoadenitis in NZB/W mice. (S2) 96
- Endopeptidase, localisation of neutral to the human synovium. (A2) 121
- Enhanced 99mTcDTPA clearance in systemic sclerosis correlates with extent of lung involvement on high resolution computed tomography and is a predictor of decline in gas transfer. (A1) 23
- ENNIS J *see* Foley-Nolan D
- Enthesitis as a measure of disease activity in ankylosing spondylitis. (A2) 81
- Eosinophilia myalgia syndrome, use of cyclosporin A. (A2) 30
- Epidemiology of vertebral fractures in the general population: the Chingford Study. (A2) 91
- Epitopes within the CB-11 peptide of type II collagen recognised by sera from patients with rheumatoid arthritis. (A2) 112
- ERKELLER-YUKSEL F *see* Sinclair HD
- ERKELLER-YUKSEL FM, ISENBERG DA, HANNET I, STRAUSS K, LYDYARD PM. Changes in frequency of natural killer cells in SLE patients with disease activity and renal involvement. (A2) 16
- ERLENDSSON K *see* Davies KA
- Erysipelas polyarthritis, immunomodulating properties of a monoclonal antibody protecting rats. (S2) 90
- Erythrocyte glutathione reductase activity and riboflavin status in rheumatoid arthritis. (A2) 39
- Erythropoietin response to anaemia, impaired in rheumatoid disease. 255
- ESCUERO D, LATORRE P, CODINA M, OLIVÉ A, COLL J. Cranial MRI in patients with Sjögren's syndrome. (A2) 25
- ESDAILE JM *see* Fitzcharles M-A
- ESPIÑOZA G *see* Kraus A
- ESR
- CRP, IL1beta and IL6 in polymyalgia rheumatica and giant cell arteritis. (A1) 24
 - spectroscopy of RA synovial fluid using the spin trap DBNBS demonstrates a reactive oxygen species which progressively increases after exercise. (A2) 132
- EUGUI EM *see* Allison AC
- EULAR study of immunosuppressive drugs: mortality and malignancy experience of the first 461 patients to complete 10 years follow-up. (A2) 141
- European audit of rheumatology practice. (A2) 103
- EUSTACE S *see* O'Neill T
- Evaluation of
- hand bone mineral measurement by dual-energy X-ray absorptiometry in rheumatoid arthritis. (A2) 62
 - a method for clinically assessing osteoarthritis of the knee. (A1) 3
 - the Thompson articular score. (A2) 97
- EVANS L *see* Davis MJ
- Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs. 370
- EVERETT JR *see* Carpenter TA
- Evidence
- of complete activation in both limited and progressive systemic sclerosis. (A2) 27
 - for impaired erythropoietin response to anaemia in rheumatoid disease. 255
 - for the non-accumulation of ketoprofen in plasma on long-term therapy. (A2) 37
- EVISON G *see* Woolf AD
- Examination of
- the cause of low testosterone levels in male rheumatoid patients. (A2) 36
 - synovial vascular endothelium in untreated and advanced rheumatoid arthritis. (A1) 7
- Extracellular lipocortin-1 binding to leucocyte membranes is decreased in rheumatoid arthritis. (A2) 51
- Extrinsic pathway inhibitor levels in patients with small vessel vasculitis. (A2) 35
- EYRE DR, WU JJ, WOODS PE, WEIS MA. Cartilage collagens and joint degeneration. (S1) 10
- Facet joint disease osteoarthritis and degenerative disc disease inter-relationship. (S1) 16
- Factor VIII von Willebrand factor antigen levels correlate with symptoms severity in patients with Raynaud's phenomenon. 433
- FAGIOLO E *see* Fiocco U
- Failed surgical back—a therapeutic disaster. (A2) 95
- Failure to isolate *Proteus* in the urine of rheumatoid arthritis patients more frequently than controls. (A2) 3
- FAINT J *see* Emery P
- FAIRBURN K, WILLIAMS R, WINYARD P, GROOTVELD M, WARD R, BLAKE DR. Levels of α -tocopherol in rheumatoid serum and synovial fluid. (A2) 41
- Familial chondrocalcinosis due to calcium pyrophosphate dihydrate crystal deposition in English families. 10
- FARAHAT MNMR, YANNI G, POSTON R, PANAYI GS. Gold treatment in rheumatoid arthritis diminishes synovial membrane cytokine expression. (A2) 6
- FARR M, KITAS GD, TUNN EJ, BACON PA. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. 413
- FARR M, *see also* Rousseau E; Tucker SC
- FARRELL AJ, JUPP RA, BLAKE DR. Angiotensin converting activity in paired serum and synovial fluid. (A1) 31
- FARRELL AJ, JUPP RA, BLAKE DR. Kininase II activity in synovial fluid before and after joint exercise. (A2) 45
- FARRELL AJ, JUPP RA, BLAKE DR. Serum angiotensin converting enzyme activity is lower in rheumatoid arthritis patients than age and sex matched controls. (A2) 117
- FARRELL AJ, MCCARTHY DA, JUPP RA, PERRY JD, BLAKE DR. Early morning stiffness and diurnal variation in angiotensin converting enzyme activity (ACE). (A2) 47
- FARRELL AJ, *see also* Chidwick K; Nazhat NB; Zhang Z
- FARRELL M *see* Veale D
- FARZATI B *see* Valentini G
- FAST JH *see* Kerstens PJSM
- FAY A *see* Deighton CM
- Features of early OA identified with MRI at two resolutions. (A1) 36
- FEELHALL J *see* Samanta A
- FEIGHERY C *see* Callaghan M; Yanni G
- FELDMANN M *see* Brennan FM; Chu CQ; Deleuran B
- FELTCAMP TEW *see* Kruize AA
- Felty's syndrome
- articular disease severity in rheumatoid subjects. 217
 - primary selection for particular DR4 subtypes accounts for the HLA-DQw7 association. (A2) 56
- Female rheumatoid arthritis patients have an older age of menarche than their non-RA sisters. (A2) 32
- Femoral bone mineral density is increased in osteoarthritis of the hip. (A2) 73
- FENN GC *see* Scott DL
- FERGUSON C *see* Priestley L
- FERNÁNDEZ-CORTIJO J *see* Lima J
- Ferritin and adult Still's disease. (L) 158
- FERRONE S *see* Fiocco U
- FESTEN J *see* Jeurissen ME
- FEWINS HE, MCGOWAN I, WHITEHOUSE GH, WILLIAMS J, MALLYA R. High definition computed tomography in rheumatoid arthritis associated pulmonary disease. 214
- Fibroblast cell surface marker analysis in systemic sclerosis. (A2) 119
- Fibromyalgia. (L) 235
- British rheumatologists' perception. (A2) 80
 - primary, and the irritable bowel syndrome: different expressions of a common pathogenetic process. 220
- Fibrositis/fibromyalgia syndrome, diurnal variation in the symptoms and signs. (A2) 96
- FIELD M. Antineutrophil cytoplasmic antibodies (ANCA): their role in diagnosis and pathogenesis of vasculitis. 229
- FIELD M, *see also* Brennan FM; Chu CQ; Deleuran B
- FIELDING JF *see* Veale D
- FINN JD *see* Symmons DPM
- FIOCO U, COZZI L, FAGIOLO E, FERRONE S. Treatment of rheumatoid arthritis by murine antidiotypic monoclonal antibodies to a syngeneic anti-HLA class II monoclonal antibody. (S2) 90
- FISHER J *see* Davis MJ
- FITZCHARLES M-A, ESDAILE JM. Carpal tunnel syndrome complicated by reflex sympathetic dystrophy syndrome. 468
- FITZGERALD KJ *see* Brown CMS
- FITZGERALD MX *see* Callaghan M
- FITZGERALD O *see* Veale D; Yanni G
- FLECHNER I *see* Barak V
- FOGELMAN I. Oestrogen, the prevention of bone loss and osteoporosis. 276
- FOGELMAN I, *see also* Ryan PJ
- FOLEY-NOLAN D, STACK JP, RYAN M, REDMOND U, BARRY C, ENNIS J, COUGHLAN RJ. Magnetic resonance imaging in the assessment of rheumatoid arthritis—a comparison with plain film radiographs. 101

- FONG KY *see* Botto M
 FONOLLOSA V *see* Lima J
 FONT J, CERVERA R, PARÉ C, LÓPEZ-SOTO A, PALLARÉS L, AZQUETA M, KHAMASHTA MA. Non-infective verrucous endocarditis in a patient with primary antiphospholipid syndrome, 305
 FONT J, *see also* Khamashta MA
 FONTAN G *see* Muñoz S
 FOSTER H, KELLY C, CHARLES P, WALKER D, GRIFFITHS I. Autoantibodies and thyroid disease in a family study of primary Sjögren's syndrome, (A1) 17
 FOSTER HE, PYLE C, WALKER DJ. Provision of medical and community services to people with severe arthritis: an audit, 356
 FOSTER H, *see also* Kelly CA
 FOWLER PD *see* Davis MJ
 FOX H *see* MacGregor AJ
 FOX J *see* Lawrance RA
 FOX JG *see* Murphy EA
 FRAMPTON G *see* Chan TM; Perry GJ
 FRANZ B *see* Ziesenis A
 FREEMAN MAR *see* Singh D
 FREEMONT AJ, HOYLAND J, HADIDY K, COOPER R, JAYSON MIV. Link between vascular damage and fibrosis in degenerative disease of the spine, (A2) 49
 FREEMONT AJ, *see also* Hay E; Hay EM; Yucel AE
 FRIMAN C *see* Jalkanen H
 Frozen shoulder
 isolated ACTH deficiency presenting with, 226
 thermographic imaging, (A2) 79
 FRY ME *see* Moore EA
 FUJIMOTO T *see* Rifkin IR
 Functional differentiation of the synovial surface fibroblastic cell, (A2) 120
 Further evidence
 of a polymorphonuclear cell activation in patients with Raynaud's phenomenon, (A2) 115
 that endocrine properties of androgen-derived steroids are not correlated with favourable effects on lupus and sialoadenitis in NZB/W mice, (S2) 96
 GABRIELLI A, DILORETO C, TABORRO R, CHERUBINI G, CANDELA M, DANIELI MG, RICCIATTI AM, DANIELI G. Immunohistochemical localization of TGF β in the skin of patients with systemic sclerosis (scleroderma), (S2) 85
 GABRIELLI A, *see also* Danieli MG
 GADO K, EMERY P. Suprascapular nerve block with marcain alone effectively controls chronic shoulder pain in patients with rheumatoid arthritis, (A2) 77
 GADO K, ROBINSON M, LUQMANI R, BACON PA, EMERY P. C3D estimation in patients with vasculitis: evidence for in vivo complement activation and correlation with disease activity, (A1) 18
 GADO K, ROBINSON M, SHEERAN T, BACON PA, EMERY P. Evidence of complete activation in both limited and progressive systemic sclerosis, (A2) 27
 GADO K, SHEERAN T, LUQMANI RA, RICHARDSON K, GORDON C, WINKLES J, BACON P, EMERY P. Urinary C3D/neopterin ratio in assessment of connective tissue diseases—a measure of humoral/cellular immunity, (A2) 110
 GAIROLA A. Laryngeal and ear involvement in rheumatoid arthritis in North India, (L) 65
 GALBRAITH I *see* Murphy EA
 Gancyclovir treatment for cytomegalovirus infection in immunocompromised patients with renal disease, (A2) 89
 GARDINER P *see* Kelly CA
 GARTON MJ, TORGESON D, DONALDSON C, RUSSELL IT, REID DM. Cost-benefit analysis of three different recruitment techniques in a regional osteoporosis screening study: report of a pilot study, (A2) 93
 GARVIE NW *see* Davies GR
 GASKIN G, RYAN JJ, REES AJ, PUSEY CD. ANCA specificity in systemic vasculitis, (A2) 83
 GASKIN G, TURNER AN, PUSEY CD. Purification of proteinase 3 and its reactivity with sera from patients with Wegener's granulomatosis and microscopic polyarteritis, (A2) 83
 GASKIN G, *see also* Beynon HLC; deOliveira J
 GASTON JSH, LIFE PF, JENNER PJ, TONKS S, COLSTON MJ, BACON PA. How important are responses to mycobacterial HSP65 in rheumatoid arthritis, (A2) 68
 GASTON JSH, *see also* Hassell AB; Viner NJ
 GAYWOOD IC, DAUNT SO'N, CAWLEY MID, COX NL. Sex differences in rheumatoid-like psoriatic arthritis, (A1) 28
 GEBOREK P *see* Östenson A
 Genes beneficial to autoimmune disease, (S1) 38
 Genetically engineered monoclonal antibodies, (S2) 36
 Genetics of
 RA: the HLA shared epitope hypothesis and its implications, (S2) 6
 rheumatoid arthritis, (L) 319, (L) 476
 Geographical distribution of SLE/MCTD in Nottingham, (A2) 17
 GERBER N *see* Seitz M
 GERBER NJ, REY B. Can exercise prevent osteoporosis, (E) 2
 Giant cell arteritis
 death from unsuspected diverticular disease in patients taking corticosteroids, (L) 159
 ESR, CRP, IL1 β and IL6 in, (A1) 24
 prevalence of hypothyroidism in patients, 349
 GIBSON SJ *see* Hukkanen M
 GIBSON T *see* Choy EHS; Corkill MM; Kirkham BW; Price R; Ryan PJ
 GUÓN J *see* Muñoz S
 GINER V *see* Pascual E
 GIRARD A *see* Racadot E
 GIUNTA G *see* Piazza I
 Glycoprotein 60 on peripheral blood lymphocytes in rheumatoid arthritis, (A2) 109
 Glycosaminoglycan composition changes of adult human supraspinatus tendon, (A2) 79
 GM-CSF immunolocalisation in the RA synovial tissue, (A2) 7
 GOGGIN PM *see* Collins DA
 Gold
 (III) but not gold (I) induces lymphocyte proliferation in patients with gold induced dermatitis, (S2) 81
 cutaneous toxicity, keeping patients on treatment, (A2) 100
 double blind controlled trial of the addition of hydroxychloroquine or placebo to patients with a suboptimal response after 6 months of IM gold, (A2) 138
 responsive T cells in patients with gold induced dermatitis: gold (III) rather than gold (I) induces lymphocyte proliferation, (A2) 66
 rheumatoid arthritis patients on intramuscular gold have a decreased prevalence of *Helicobacter pylori* infections, (A2) 139
 therapy reduction of non-steroidal peptic damage in rheumatoid arthritis, (A2) 139
 therapy using mycristin coupled to fibronectin, (A1) 19
 treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1, (S2) 81
 treatment in rheumatoid arthritis diminishes synovial membrane cytokine expression, (A2) 6
 GOODACRE JA, MANDER M, CARSON DICK W. Patients with ankylosing spondylitis show individual patterns of variation in disease activity, 336
 Goodpasture antigen, primary sequence and an amino acid sequence polymorphism, (A2) 82
 GORDON C *see* Gado K; Hay EM
 GORDON J *see* Rousseau E
 GORDON M *see* Luqmani RA
 GOUGH A, ARTHUR V, PANAYI G, EMERY P. Steroids in early rheumatoid disease: no long term impact when given with sulphasalazine, (A2) 140
 GOUGH A, *see also* Bradley H; Emery P; Loveridge JA
 GOUGH SCL, GRANT PJ, PULLAR T. Effect of prednisolone on fibrinolytic activity and disease activity in rheumatoid arthritis, (A2) 35
 GOUGH SCL, GRANT PJ, RICE PJ, ZEBOUNI L, PULLAR T. Relationship of fibrinolytic activity to disease activity in rheumatoid arthritis, (A1) 25
 GOULDING NJ *see* Jefferiss CM; Morand EF; Woolf AD
 GOUTALLIER D *see* Bardin T
 GOWEN M. Control of bone cell development and function, (A2) 66
 GOWEN M, *see also* Knight SM
 GOWER PE *see* Hawkins PN
 GRAEBER M *see* Mackenzie AR
 GRAHAM IM *see* O'Neill TW
 GRAHAME R. British rheumatologists' perception of fibromyalgia, (A2) 80
 GRAHAME R, PYERITZ R. Study of joints and skin in the Marfan syndrome, (A2) 82
 GRAHAME R, WOOLF AJ. European audit of rheumatology practice, (A2) 103
 GRAHAME R, *see also* Kirkham BW
 GRANT PJ *see* Gough SCL
 GRAY J *see* Deighton CM; McDonagh J
 GRAY JW *see* Deighton CM
 Greater monocyte/macrophage numbers in rheumatoid synovial membrane predict a worse radiological outcome, (A1) 8
 GREAVES I *see* Luqmani RA
 GREAVES M *see* Lindsey NJ
 GREEN JR *see* Sidebottom D
 GREEN L *see* Kay R
 GREENSTONE MA. Delayed diagnosis of systemic lupus erythematosus associated pulmonary hypertension, (L) 391

- GREGORY J *see* Joshi AB
 GREGSON N *see* Perry GJ
 GREIG R *see* Badger AM
 GRENNAN DM. Genetics of rheumatoid arthritis, (L) 476
 GRENNAN DM, *see also* Clarkson RWE; Hillarby MC; McMahon MJ; Sidebottom D
 GRIFFIN WM *see* Scott DL
 GRIFFITHS H *see* Blount S; Dowling EJ
 GRIFFITHS I *see* Foster H
 GRIFFITHS ID *see* Kelly CA; Swinden DC
 GRIFFITHS M *see* Leaker B
 GROOTVELD M *see* Fairburn K; Herz H; Naughton D
 GROSCH C *see* O'Neill T
 GUAÑABENS N *see* Peris P
 GUBLER H-U *see* Mackenzie AR
 GUERRA-BAUTISTA G *see* Kraus A
 GUERRERO A. Joint manifestations of Lyme disease in Spain, (L) 71
 GULAIID AA *see* Hicklin JA
 GUMPEL JM *see* Shawe DJ
 GUSE A *see* Emmrich F
 GUTKNECHT J. Renal microaneurysms in rheumatoid arthritis, (L) 235
 WILLIAM M *see* Jones AKP
- HADIDY K *see* Freemont AJ
 Haemarthrosis associated with thrombolytic therapy, (L) 236
 HAFEZ M, EL-BATTOUTY MF, HAWAS S, EL-ZINY M, SHEASHAA A, SETTIN A, BASSIOUNY MR, HAWAS SA. Susceptibility to and severity of rheumatoid arthritis in multicase families, 181
 Hair cell leukaemia and rheumatoid arthritis, (L) 391
 Hair-cell leukaemia-associated polyarthritis: a report of two cases, (L) 157
 HAJEER AH, BERNSTEIN RM. Antibody to the 65kDa mycobacterial heat shock protein contaminates antibody raised to lactoferrin and possibly many other antibody preparations, (A2) 111
 HAJEER AH, WORTHINGTON J, MORGAN K, BERNSTEIN RM. Identification of binding sites of monoclonal antibodies to the 65 kDa heat shock protein of mycobacteria, (A2) 111
 HALL G *see* Woodward L
 HALL GM, HALL ML, ELL PJ, DOYLE DV, SPECTOR TD. Bone density of the hip and spine in post menopausal rheumatoid arthritis and the effect of low dose steroids, (A2) 53
 HALL GM, HALL ML, ELL PJ, PERRY LA, SPECTOR TD. Sex hormone levels in post menopausal rheumatoid arthritis and relationship with bone density, (A2) 93
 HALL GM, *see also* Woodward L
 HALL J, MADDISON P, SKEVINGTON S, O'HARE P. Comparison of the efficacy of hydrotherapy and seated immersion in rheumatoid arthritis, (A2) 76
 HALL LD *see* Carpenter TA
 HALL M *see* Lanchbury J
 HALL MA *see* Stephens CO
 HALL ML *see* Hall GM
 HALL ND *see* Stuart RA; Woolf AD
 HALLETT MB *see* Davies EV
 HALPERIN T *see* Barak V
 HALSEY JP, PEEBLES ACI. Rheumatology referrals to a district general hospital, (A2) 104
 HAMBLIN AS *see* Hill TA; McCarthy DA
 HAMILTON E, PATRICK M, DOHERTY M. Inorganic pyrophosphate, nucleoside triphosphate pyrophosphatase, and cartilage fragments in normal human synovial fluid, 260
 HAMILTON E, *see also* Doherty M
 HAMMOND A *see* Woodward L
 HAMURYUDAN V. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial, (L) 395
 HAMURYUDAN V, YURDAKUL S, KURAL AR, INCE U, YAZICI H. Diffuse proliferative glomerulonephritis in Behçet's syndrome, 63
 Hand bone mineral measurement by dual-energy X-ray absorptiometry in rheumatoid arthritis, (A2) 62
 HANNET I *see* Erkeller-Yaksel FM
 HANSELL DM *see* Wells AU
 HANSLIP J *see* Lau CS
 HARBUS MS, REES RG, LIGHTMAN SL. Hypothalamo-pituitary mRNA responses during the development of adjuvant-induced arthritis in the adrenalectomized rat, (A2) 141
 HARDINGE K *see* Joshi AB
 HARDINGHAM TE, VENN G, BAYLISS MT. Chondrocyte responses in cartilage and in experimental osteoarthritis, (S1) 32
 HARMER IJ, LOIZOU S, SO AKL, WALPORT MJ, MACKWORTH-YOUNG CG. Idiopathic and genetic studies of a human monoclonal antiphospholipid antibody, (A2) 21
 HARMER R *see* Hill J
- HAROTOUNIAN R *see* Beynon HLC
 HARPER GP *see* Andrews HJ; Carpenter TA; James MF; Muxlow NJ
 HARRALL RL *see* Riley GP
 HARRIS PA *see* Spector TD
 HARRISON K *see* Wells AU
 HARRISON NK *see* Wells AU
 HARRISON R *see* Ryan PJ
 HART DJ, LEEDHAM-GREEN M, SPECTOR TD. Prevalence of knee osteoarthritis in the general population using different criteria: the Chingford Study, (A2) 72
 HART DJ, SPECTOR TD, LAW M, DOYLE DV. Relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study, (A2) 55
 HARVEY A *see* Kendall R
 HARVEY GR *see* Whyte J
 HARVEY MJ *see* Ejim OS
 HASHIM G *see* Vandenberg AA
 HASKARD DO *see* Beynon HLC; Corkill MM; Pallis M
 HASLAM PL *see* Wells AU
 HASLOCK I *see* Scott DL
 HASSELBACHER P. Letter from America, 368
 HASSELL AB, LIFE PF, VINER NJ, BACON PA, GASTON JSH. Reversal of peripheral blood T cell anergy to bacterial antigens on recovery from acute reactive arthritis, (A1) 15
 HASSELL AB, PILLING D, REYNOLDS D, LIFE PF, GASTON JSH. Absence of a class I MHC-restricted pathogen-specific T cell response in the synovial fluid of patients with reactive arthritis, (A2) 67
 HAWAS S *see* Hafez M
 HAWAS SA *see* Hafez M
 HAWKINS PN, NELSON SR, RICHARDSON S, LAVENDER JP, SETHI D, GOWER PE, PUGH CW, WINEARLS CG, OLIVER DO, PEPYS MB. Imaging dialysis arthropathy with ¹²⁵I-serum amyloid P component, (A2) 63
 HAWLEY PR *see* Axon JMC
 HAY E, BRAND SR, FREEMONT AJ, WORTHINGTON J, HOLT PJJ, BERNSTEIN RM. ELISA of anti-La but not anti-Ro correlates with total serum IgG1 and degree of salivary gland infiltration in primary Sjögren's syndrome, (A2) 24
 HAY E, SYMMONS DPM. BILAG index has good inter-observer agreement when used in a routine out-patient clinic, (A1) 23
 HAY E, *see also* Kay R
 HAY EM. Rheumatoid diseases, 474
 HAY EM, BEAMAN M, RALSTON AJ, ACKRILL P, BERNSTEIN RM, HOLT PJJ. Wegener's granulomatosis occurring in siblings, 144
 HAY EM, FREEMONT AJ, BERNSTEIN RM, HOLT PJJ. Correlation of serum IgG1 with biopsy findings in primary Sjögren's syndrome, (A1) 18
 HAY EM, GORDON C, VINER N, BACON P, ISENBERG D, MADDISON P, SYMMONS DPM, SNAITH M, ZOMA A. BILAG index is a valid instrument for measuring clinical disease activity in systemic lupus erythematosus, (A2) 16
 HAY EM, *see also* Sanders PA; Teh LS
 HAY FC *see* Axford JS; Hunt K
 HAYES E *see* Davies E
 HAZLEMAN B. Polymyalgia rheumatica, policy for weaning patients from corticosteroids, (CC) 34
 HAZLEMAN BL *see* Kyle V; Pountain G; Riley G; Riley GP; Vecchio PC
 HEALD G *see* James MF; Muxlow NJ
- Health
 assessment questionnaire and the Nottingham health profile in chronic inflammatory arthritis, (A2) 105
 service reforms and access to specialist services, (E) 322
 65 kDa Heat shock protein of mycobacteria, identification of binding sites of monoclonal antibodies to, (A1) 111
 65kD Heat-shock protein
 can activate rheumatoid synovial fluid mononuclear cells to inhibit cartilage proteoglycan synthesis, (A2) 8
 expression in human chondrocytes, (A2) 9
 HEATH S *see* Kalla AA
 HEINIGÄRD D, SAXNE T. Molecular markers of processes in cartilage in joint disease, (S1) 21
 HEINIGÄRD D, *see also* Saxne T
 HEINRICH I *see* Price R
Helicobacter pylori
 rheumatoid arthritis patients on intramuscular gold have a decreased prevalence of infections, (A2) 139
 serological evidence of infection may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis, 16
 status does not modify the acute gastric toxicity of non-steroidal anti-inflammatory drugs, (A2) 138
 HELIÖVAARA M *see* Kontinen Y
 HELLIWELL P, MARCHESONI A, PETERS M, BARKER M, WRIGHT V. Re-evaluation of the osteoarticular manifestations of psoriasis, 339

- HELLIWELL PS, WRIGHT V. Low back pain, indications for use of a lumbar corset, (CC) 62
- HEMBRY RM *see* Murphy G
- HENDERSON FI *see* Lindsey NJ
- HENDERSON J *see* Doherty M
- HENÉ RJ *see* Kruize AA
- Hepatic clearance of immune complexes formed *in vivo* results in loss of CR1 from erythrocytes, (A2) 86
- HEPPT P *see* Bröcker BM
- HERBERT KA *see* Da Silva JAP
- HERBERT KE, HERBERT LL, PERRETT D, SCOTT DL. Synovial fluid leucocytes and ATP catabolism, (A2) 131
- HERBERT KE, *see also* Axon JMC; Herbert LL; Jacobs RA
- HERBERT LL, HERBERT KE, PERRETT D, SCOTT DL. Effect of aspirin administration on erythrocyte ATP, (A2) 38
- HERBERT LL, *see also* Herbert KE
- HERNÁNDEZ ME *see* Peris P
- HERON C *see* Collins DA
- HERON CW *see* Smith CR
- HERRANZ R *see* Peris P
- HERRERO-BEAUMONT G, ARMAS JB, AMORIM R, SHENSTONE B, BHALLA A, MADDISON PJ. Limited forms of Wegener's granulomatosis presenting as polymyalgia rheumatica, 382
- HERRICK AL, COOPER RG, JAYSON MIV. Failed surgical back—a therapeutic disaster, (A2) 95
- HERRICK AL, JAYSON MIV. Primary Raynaud's phenomenon in early childhood, 223
- HERZ H, GROOTVELD M, CLAXSON AWD, BLAKE DR. Oxygen radical-mediated oxidative damage to lactate in rheumatoid synovial fluid, (A2) 40
- Heterogeneity of T cell receptor gene rearrangement in patients with granular lymphocyte proliferation, neutropenia and polyarthropathy, (A1) 15
- repertoires in human autoimmune disease, (S2) 24
- HEURKENS AHM *see* van der Zee JM
- HEYWOOD BR, SWANN A, DIEPPE PA. Chemical, structural and morphological analyses of mineral deposits in synovial fluid, (A2) 129
- HICKEY L *see* David J
- HICKLIN JA, SCANE TMN, BAMBER M, GULAIID AA, DENNIS MJ. Evidence for the non-accumulation of ketoprofen in plasma on long-term therapy, (A2) 37
- HICKS BH. Corticosteroid secretion, age-related increase in rats, and postmenopausal predisposition in women to develop osteoporosis, (CC) 90
- HICKS BH, *see also* Choy EHS
- HICKS C *see* Billingham MEJ
- HICKS CA *see* Kingston AE
- HIFT RJ, BIRD AR, SAREMBOCK BD. Acquired hypofibrinogenemia and lupus anticoagulant: response to steroid therapy, 308
- High definition computed tomography in rheumatoid arthritis associated pulmonary disease, 214
- High prevalence of heart valve disease in patients with the primary antiphospholipid syndrome, (A2) 21
- High resolution computed tomography assessment of disease activity in the fibrosing alveolitis of systemic sclerosis: a histological correlation, (A2) 27
- HIGH WB *see* Badger AM
- Higher incidence of carpal tunnel syndrome in oophorectomized women, 60
- HIGLEY HR *see* Vancheeswaran R
- HILL J, BIRD HA, HARMER R, WRIGHT V. Comparative study of a traditional medical and a nurse practitioner clinic, (A1) 2
- HILL J, BIRD HA, HOPKINS R, LAWTON C, WRIGHT V. Development and use of a patient knowledge questionnaire in rheumatoid arthritis, 45
- HILL J, *see also* Astbury C; Kendall R
- HILL TA, D'Cruz D, BROWN KA, AHMED T, HAMBLIN AS, HUGHES GRV. Adherent properties of blood leucocytes in Wegener's granulomatosis, (A2) 87
- HILLARBY MC, CLARKSON R, GRENNAN DM, BATE AS, OLLIER W, SANDERS PA, CHATTOPADHYAY C, DAVIS M, O'SULLIVAN MM, WILLIAMS B. Immunogenetic heterogeneity in rheumatoid disease as illustrated by different MHC associations (DQ, Dw and C4) in articular and extra-articular subsets, 5
- HILLARBY MC, *see also* Davies E
- HINKES W *see* Hukkanen M
- HINNIE J. Athletes and osteoarthritis—is there any relationship, (L) 68
- Histopathological assessment of factor XIIIa and HLADR positive cells in scleroderma skin biopsies, (A2) 46
- HLA
- class II antigens in susceptibility to rheumatoid arthritis, (L) 151
- class II association of rheumatoid arthritis, (A1) 11
- haplotype sharing in rheumatoid arthritis sibships, (A2) 59
- influence on Vβ6.7 T cell receptor gene expression, (A2) 136
- HLA-B27 subtypes in the spondyloarthropathies, (A2) 33
- HODGSON R *see* Carpenter TA
- HOE 140, bradykinin and kallidin metabolism in synovial fluid, (A2) 45
- HOLEWIJN M *see* Wilbrink B
- HOLLIGAN S, BIRRELL F, ADEBAJO W, ASUZU M, THOMSON W, OLLIER WER, SILMAN AJ. Low prevalence of rheumatoid arthritis in a rural Nigerian population, (A2) 1
- HOLLIGAN S, *see also* MacGregor AJ
- HOLLIS S *see* McMahon MJ
- HOLT I, COOPER RG, DENTON J, MEAGER A, HOPKINS SJ. Cytokines in synovial fluid and plasma of patients with inflammatory arthritis: relationships to local and systemic parameters of disease activity, (A2) 124
- HOLT I, COOPER RG, MEAGER A, HOPKINS SJ. Cytokines and their interrelationships in the joints and plasma of arthritis patients, (A2) 126
- HOLT L *see* Davies E
- HOLT PIL *see* Hay E; Hay EM; Teh LS
- HOLT PL *see* Kay R
- Homozygous inherited C3 deficiency due to a partial gene deletion, (A2) 135
- HONKANEN V, KONTTINEN YT, HUKKANEN M, KEMPPINEN P, WESTERMARK T, SEGERBERG M. Serum zinc and copper in rheumatoid arthritis, (A2) 117
- HONKANEN V, *see also* Konttinen Y
- HOPKINS R *see* Hill H
- HOPKINS SJ *see* Holt I
- HOPKINSON N, DOHERTY M. Diuretic induced gout in chronic cardiac failure, (CC) 225
- HOPKINSON N, DOHERTY M, POWELL R. Incidence and prevalence of systemic lupus erythematosus in Nottingham, UK 1989-1990, (A2) 17
- HOPKINSON N, HUNT C, LOWE J, POWELL R. Inclusion body myositis: experience with 11 cases in Nottingham, (A2) 77
- HOPKINSON N, POWELL R, DOHERTY M. Increased frequency of IgG rheumatoid factor in nodal generalised osteoarthritis—further support for an auto-immune aetiology, (A2) 70
- HOPKINSON N, POWELL R, DOHERTY M, MUIR K, TURNBALL N. Geographical distribution of SLE/MCTD in Nottingham, (A2) 17
- HOPKINSON N, *see also* Markus H
- HOPKINSON ND *see* Parris M
- HOPKINSON NH *see* Jones AC
- HORDON LD, BIRD HA, COOPER EH. Renal tubular dysfunction in rheumatic diseases, 115
- HORDON LD, STEWART SP, TROUGHTON PR, HORSMAN A, WRIGHT V, SMITH MA. Bone mass in primary generalised osteoarthritis, (A2) 54
- HORNEFF G *see* Emmrich F
- HORSFALL AC *see* Venables PJW
- HORSMAN A *see* Hordon LD
- HOTHERSALL TE *see* Symmons DPM
- How important are responses to mycobacterial HSP65 in rheumatoid arthritis, (A2) 68
- HOWE J *see* Kelly CA
- HOWELL WM, WARREN CJ, COOK N, CAWLEY MID, SMITH JL. Demonstration of IL-2 mRNA and protein in different arthropathies using biotinylated oligonucleotide probes for mRNA detection, (A2) 68
- HOVLAND J *see* Freemont AJ
- HTLV-1 infection and autoimmune disease, 141
- HUBER-BRUNING O *see* Lafeber F; Nietfeld JJ; Wilbrink B
- HUDDY A *see* Teh LS
- HUGHES GRV *see* Aydinoglu AO; D'Cruz DP; Hill TA; Khamashta MA
- HUGHES P *see* Lindsey NJ
- HUGHES R *see* MacLean L
- HUGHES RA, ROWE IF, SHANSON D, KEAT ACS. Septic bone, joint and muscle lesions associated with human immunodeficiency virus infection, (A1) 38
- HUKKANEN M, KONTTINEN YT, SEGERBERG M, REES RG, KEMPPINEN P, SORSA T, SAARI H, POLAK JM. Neuropeptides and inflammatory cells in synovium: possible involvement of free radicals in neuropeptide degradation, (A1) 5
- HUKKANEN M, KONTTINEN YT, SPRINGALL DR, HINKES W, MOSCOSO G, CHEN ST, GIBSON SJ, POLAK JM. Laser scanning confocal microscopy and its application to the study of neuromuscular junctions and muscle spindles, (A2) 43
- HUKKANEN M, KONTTINEN YT, TERENGHI G, POLAK JM. Innervation and peptide-containing nerves in femoral lymphatic vessel walls in rat, (A2) 43
- HUKKANEN M, *see also* Honkanen V; Konttinen Y; Konttinen YT
- HULL RG *see* Jenkins EA
- Human
- α₁antitrypsin is cleaved and inactivated by stromelysin, (A1) 30
- immunodeficiency virus infection, septic bone, joint and muscle lesions associated with, (A1) 38
- recombinant manganese superoxide dismutase in experimental inflammation, (A2) 142

- Humanized monoclonal antibody treatment in rheumatoid arthritis, (S2) 89
- Humoral reactivity to mycobacterial 65 heat shock protein in systemic sclerosis, (S2) 94
- HUNT C *see* Hopkinson N
- HUNT K, BOND A, ALAVI A, MRAZEK I, SHARROCK C, HAY FC, AXFORD JS. In healthy individuals increased agalactosyl-IgG is found in males and those with HLA DR2 and 7 gene expression, (A2) 34
- HUNTER JA *see* Capell HA; Marshall DAS; Porter DR
- HUNTRIJS JD, LATCHMAN DS, WILLIAMS DG. Lupus sera bind to a tissue-specific variant of the Sm antigen, (A2) 133
- HUSKISSON EC *see* Axon JMC; Dacre JE; Spector TD
- HUTTON C. Osteoarthritis, looking for directions, 232
- HUTTON CW *see* Moore EA
- Hyaluronan
 assessment by microdensitometry of regional distribution in normal and inflamed synovium, (A2) 123
 concentration in normal and rheumatoid synovium assessed by ELISA, (A2) 122
- Hyaluronic acid serum levels correlate with disease activity during adjuvant arthritis, (A2) 143
- 8-Hydroxydeoxyguanosine: a marker of oxygen radical damage to DNA in systemic lupus erythematosus, (A2) 50
- Hypothalamic-pituitary mediated modulation of immune function: prolactin as a neuroimmune peptide, 203
- Hypothalamo-pituitary mRNA responses during the development of adjuvant-induced arthritis in the adrenalectomized rat, (A2) 141
- Hypoxic-reperfusion injury in inflamed and non-inflamed synovial tissue using electric spin resonance, (A2) 40
- Identification
 of binding sites of monoclonal antibodies to the 65 kDa heat shock protein of mycobacteria, (A2) 111
 and localisation of antioxidant enzymes in synovium and synovial fibroblasts, (A2) 39
- Idiotypic and genetic studies of a human monoclonal antiphospholipid antibody, (A2) 21
- Ig2b inducing factor, partial biochemical characterization of new cytokine activity from synovial fluid of patients with rheumatoid arthritis, (S2) 86
- Ig CH and D14S1 variants in rheumatoid arthritis—linkage and association studies, 167
- IgA anticardiolipin antibodies are usually present in conjunction with the IgG and/or IgM isotypes, (A2) 20
- IgM antibody production suppression protects type II collagen-immunized rats to arthritis, (S2) 92
- IL6 elevated serum levels associated with active disease in systemic connective tissue disorders, (A2) 135
- IL-2
 mRNA and protein demonstration in different arthropathies using biotinylated oligonucleotide probes for mRNA detection, (A2) 68
 promotes autoimmunity in neonatally thymectomized mice, (A2) 11
- IL-6 role in the interaction of IL-1 and human articular cartilage, (A2) 125
- IL-6-receptor detection in cultured explants of human articular cartilage, (A2) 125
- Ileal pouch arthritis, (A2) 74
- ILIOPOULOS AG *see* Papazoglou SN
- Iloprost infusion, long-term follow-up of patients with connective tissue disease using infra-red thermography, (A2) 76
- Imaging dialysis arthropathy with ¹²⁵I-serum amyloid P component, (A2) 63
- Immune complex hepatic clearance results in loss of CR1 from erythrocytes, (A2) 86
- Immune complexes, splenic localisation is complement dependent, (A2) 136
- Immune modifying effects of misoprostol and natural prostaglandins, (S2) 71
- Immune response to
 autoantigens and viruses in rheumatic disease, (S1) 70
 cross-reactive GAC sequences in autoimmune disease, (A2) 24
 mycobacterial heat shock protein 65 kD in juvenile and adult rheumatoid arthritis, (S2) 94
- Immunization
 of rheumatoid arthritis patients with mycobacterium vaccae: an open study of a novel therapeutic approach, (S2) 95
 with T cell receptor peptides, (S2) 20
- Immunocorrection in the ankylosing spondylitis, (S2) 98
- Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis, 413
- Immunogenetic heterogeneity in rheumatoid disease as illustrated by different MHC associations (DQ, Dw and C4) in articular and extra-articular subsets, 5
- Immunoglobulin
 gene expression in systemic rheumatic diseases, (S1) 43
 heavy chain gene polymorphisms in Italian patients with psoriasis and psoriatic arthritis, 449
 heavy chain variable region gene sequences of hybridomas derived from a rheumatoid synovium, (A2) 113
- Immunohistochemical features of the synovial membrane in psoriatic arthritis compared to rheumatoid arthritis, (A2) 67
- Immunohistochemical localization of TGFβ in the skin of patients with systemic sclerosis (scleroderma), (S2) 85
- Immunohistochemical markers for arthritis in psoriasis, (A2) 10
- Immunolocalisation of GM-CSF in the RA synovial tissue, (A2) 7
- Immunological follow up of 13 patients with rheumatoid arthritis treated by anti-T CD4+ monoclonal antibodies, (S2) 88
- Immunology of tolerance and autoimmunity, (S2) 1
- Immunomodulating properties of a monoclonal antibody protecting rats from chronic erysipelas polyarthritis, (S2) 90
- Immunopathogenesis of rheumatoid arthritis, (S2) 3
- Immunosuppressive drugs, EULAR study: mortality and malignancy experience of the first 461 patients to complete 10 years follow-up, (A2) 141
- Immunosuppressive and long-acting anti-inflammatory activity of mycophenolic acid and derivative, RS-61443, (S2) 57
- Immunotherapy of acute rheumatoid arthritis with antibodies neutralizing aberrant interferon-alpha, (S2) 86
- IMPROTA RDG *see* Valentini G
- In healthy individuals increased agalactosyl-IgG is found in males and those with HLA DR2 and 7 gene expression, (A2) 34
- In vitro*
 assessment of hypoxic-reperfusion injury in inflamed and non-inflamed synovial tissue using electric spin resonance, (A2) 40
 rheumatoid factor production and circulating CD5+ B lymphocytes during bacterial infections, (A2) 5
- In vivo* model for testing designer antibodies, (S2) 89
- INCE U *see* Hamuryudan V
- Incidence and prevalence of systemic lupus erythematosus in Nottingham, UK 1989-1990, (A2) 17
- Incidence of rheumatological problems in general medical outpatients, (A1) 1
- Inclusion body myositis: experience with 11 cases in Nottingham, (A2) 77
- Increased
 expression of endothelial cell adhesion molecules *in vitro* by rheumatoid arthritic synovial microvasculature, (A1) 13
 frequency of IgG rheumatoid factor in nodal generalised osteoarthritis—further support for an auto-immune aetiology, (A2) 70
 metacarpal bone mass following 18 months of slow-acting antirheumatic drugs for rheumatoid arthritis, 91
 release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis, (A2) 48
- Induction of
 an inhibitory splenic macrophage during progression of adjuvant arthritis in a susceptible rat strain, (A2) 115
 non-specific suppressor cells and myeloregulatory effects of an anti-arthritis azaspirane, SK&F 105685, (S2) 82
- Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial, (L) 395
- Inflammation of the subacromial bursa in chronic shoulder pain, (A2) 42
- Inflammatory arthritis
 cytokines in synovial fluid and plasma: relationships to local and systemic parameters of disease activity, (A2) 124
 with pitting oedema of ankles, indications for venography, (CC) 355
 preferential activation of memory T cells by synovial antigen presenting cells, (A2) 8
- Inflammatory muscle disease is associated with differential alteration in the distribution of chondroitin sulphate species, (A2) 22
- Influence of
 HLA and primary Sjögren's syndrome on Vβ6.7 T cell receptor gene expression, (A2) 136
 methotrexate and azathioprine on the radiologic progression in rheumatoid arthritis, (A2) 2
 misoprostol on non-steroidal anti-inflammatory drug-influenced intestinal damage and disease activity in rheumatoid arthritis, (A2) 91
 steroidhormones on proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis, (A2) 108
- Infra-red thermography use in a Rheumatology Unit, (L) 71, (L) 72
- INGELMO M *see* Khamashta MA
- Inhibition of
 human endothelial cell proliferation by tiopronine, (A2) 107
 natural killer cell cytotoxicity in rheumatoid arthritis by the non-immune complex IgA-alpha-1-antitrypsin, (A2) 107
- Innervation and peptide-containing nerves in femoral lymphatic vessel walls in rat, (A2) 43

- Inorganic pyrophosphate, nucleoside triphosphate pyrophosphatase, and cartilage fragments in normal human synovial fluid, 260
- Insidious loss of renal function in patients with anticardiolipin antibodies and absence of overt nephritis, 422
- Inter-relationship of facet joint disease osteoarthritis and degenerative disc disease, (S1) 16
- Interferon-gamma and interleukin-2 production by activated T-cell clones is synergistically inhibited by cyclosporine and chloroquine, (A2) 109
- Interleukin-1-alpha plasma levels in rheumatoid arthritis, 295
- Interleukin-2 and interferon-gamma production by activated T-cell clones is synergistically inhibited by cyclosporine and chloroquine, (A2) 109
- Interleukin-6
activity in paired samples of synovial fluid, correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation, 186
serum changes following intramuscular gold treatment in rheumatoid arthritis, (S2) 99
- Interleukin-8, preferential production in rheumatoid arthritis, relationship to rheumatoid factors in vivo and inhibition by gold sodium thiomalate and methotrexate in vitro, (S2) 85
- Interpretation of
therapeutic trials, (L) 66
trials—the other side, (L) 237
- Intraarticular corticosteroids
and cartilage: what is the effect, (A1) 32
effects in clearance of intraarticular albumin in RA, AS and OA patients, (A1) 33
- Intravenous pulsed cyclophosphamide as a treatment for bone marrow hypocellularity in SLE, (A2) 140
- IQBALL S see MacLean L
- Is diet important in rheumatoid arthritis, 125, (L) 315
- Is tolerance therapy a plausible possibility, (S1) 75
- ISAACS JD, WALDMANN H. *In vivo* model for testing designer antibodies, (S2) 89
- ISDALE A. Athletes and osteoarthritis—is there any relationship, (L) 67
- ISENBERG D see Blanco F; Blount S; Hay EM; Leaker B; Longhurst C; Ravirajan C
- ISENBERG DA. Systemic lupus erythematosus, does plasma exchange have any role in treatment, (CC) 335
- ISENBERG DA, see also Blanco F; Erkeller-Yuksel FM; Sinclair HD; Worral JG
- Isolated ACTH deficiency presenting with bilateral frozen shoulder, 226
- ISSACS B see Sheeran T
- ITESCU S see Kontinen YT
- IULIUCI JD see Jonker M
- IVARSSON M see McWhirter A
- IVORRA J see Salinas M
- IWAMURA H see Moore AR
- IX 207-887, pharmacological effects, (S2) 75
- IYENGAR S, CONTRERAS PC, MICK SJ, BREMER ME, MCKEARN JP. Immune modifying effects of misoprostol and natural prostaglandins, (S2) 71
- JACK MJ see Dacre JE
- JACKSON J see Blount S
- JACOBS HJM, VAN DEN HOEK AEM, VAN DEN BROEK MF, VAN DEN BERG WB. Lack of tolerance induction by cationic antigens, (S2) 93
- JACOBS JWG, OOSTERVELD FGJ, RASKER JJ, DEUXBOUTS N, DEQUEKER J. Opinion of patients with rheumatoid arthritis about their functional capacity, (A2) 97
- JACOBS RA, HERBERT KE, AXON JMC, PERRETT D, SCOTT DL. Rheumatoid synovocyte proliferation and fibronectin secretion, (A2) 120
- JACOBS RA, see also Axon JMC
- JACOBY RK see Moore EA
- JAEGER E see Lanchbury J
- JAFFEE BD see Davison AN
- JAGIELLO P see Jedryka-Goral A
- JAMES IT see Alam C; Thompson PW
- JAMES MF, HEALD G, SHORTER J, TURNER RA, HARPER GP. Joint space measurement in hand radiographs using image analysis, (A2) 62
- JAMES MF, see also Carpenter TA; Muxlow NJ
- JAMES V see Smith G
- JANSON RW see Arend WP
- JANSEN M, DIJKMANS BAC, VANDENBROUCKE JP, VAN DUYN W, PEÑA AS, LAMERS CBHW. Rheumatoid arthritis patients on intramuscular gold have a decreased prevalence of *Helicobacter pylori* infections, (A2) 139
- JASANI MK see Buckland-Wright JC
- JAYNE DRW see Chan TM
- JAYSON MIV see Freemont AJ; Herrick AL; Yucel AE
- JEDRYKA-GORAL A, D'CRUZ D, JAGIELLO P, MALDKOWA H/1 LUFT S. Von Willebrand factor antigen in Sjögren's syndrome, (A2) 23
- JEFFERISS CM, GOULDING NJ. Extracellular lipocortin-1 binding to leucocyte membranes is decreased in rheumatoid arthritis, (A2) 51
- JEFFERISS CM see Morand EF
- JENKINS EA, COOK N, HULL RG, CAWLEY MID. Audit of new patient referrals to paediatric rheumatology clinics, (A2) 104
- JENNER PJ see Gaston JSH
- JEURISSEN ME, BOERBOOMS AM, FESTEN J, VAN DE PUTTE LB. Pulmonary function tests in rheumatoid arthritis: a double blind study of azathioprine and methotrexate, (A2) 99
- JEURISSEN ME, BOERBOOMS AM, VAN DE PUTTE LB, DOESBURG W. Influence of methotrexate and azathioprine on the radiologic progression in rheumatoid arthritis, (A2) 2
- JEURISSEN MEC see Kerstens PJSM
- JOBANPUTRA P. Lyme disease, 228
- JOBANPUTRA P, CORRIGALL V, KINGSLEY GH, KLAESKOG L, PANAYI GS. 65kD Heat-shock protein, expression in human chondrocytes, (A2) 9
- JOHNSTONE D see Waterton JC
- Joint
cavitation site of embryo, uridine diphosphoglucose dehydrogenase activity and hyaluronan localisation at, (A2) 48
degeneration and cartilage collagens, (S1) 10
disease, molecular markers of processes in cartilage, (S1) 21
manifestations of Lyme disease in Spain, (L) 71
replacement in the 1990s, (E) 401
space loss in osteoarthritic knees using high definition macroradiography: comparison of weight bearing standing & tunnel views, (A2) 74
space measurement in hand radiographs using image analysis, (A2) 62
space in radiologically normal knees, 426
- JONES AC, HOPKINSON NH, PATRICK M, BERMAN P, DOHERTY M. Evaluation of a method for clinically assessing osteoarthritis of the knee, (A1) 3
- JONES AC, REGAN M, LEDINGHAM J, DOHERTY M. Can we alter junior doctors' awareness of locomotor problems, (A2) 1
- JONES AC, see also Ledingham J
- JONES AKP, OSMAN S, SILVA S, GWILLIAM M, DANPURE HJ, MYERS MJ. Quantitation of granulocyte migration with rheumatoid arthritis in response to intra-articular steroid injection using pure ¹¹¹In-labelled granulocytes, (A1) 26
- JONES DM see Jones STM
- JONES JG, McCANN J, LASSERE MN. Driving and arthritis, 361
- JONES P see Zukovskis K
- JONES PB, BLANN AD. Raised levels of von Willebrand factor antigen in ankylosing spondylitis, (A2) 36
- JONES S see Silman A; Symmons DPM
- JONES STM, CLAGUE RB, ELDRIDGE J, JONES DM. Serological evidence of infection with *Helicobacter pylori* may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis, 16
- JONKER M, SLINGERLAND W, TREACY G, PAK KY, WILSON E, TAM S, DADDONA PE, LOBUGLIO AF, RIETHMULLER G, IULIUCI JD. Anti-CD4 treatment with chimeric monoclonal antibody results in prolonged CD4+ cell depression, (S2) 87
- JONKER M, see also Bakker NPM
- JOSHI AB, GREGORY J, MURPHY JC, HARDINGE K. Total hip arthroplasty in ankylosing spondylitis, (A1) 29
- JOHIKAINEN T see Julkunan H
- JUBB R see Sheeran T
- JULKUNEN H, KAAJA R, JOHIKAINEN T, TEPPA A-M, FRIMAN C. Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives, 471
- JUPP RA see Farrell AJ
- Juvenile chronic arthritis in early adult life, (A2) 98
- Juvenile chronic arthritis, measurement of growth hormone in children and growth retardation on alternate day corticosteroid therapy, (A2) 75
- Juvenile rheumatoid arthritis, immune response to mycobacterial heat shock protein 65 kD, (S2) 94
- KAAJA R see Julkunan H
- KADIOGLU A, SHELDON P. Binding of rheumatoid monuclear cells to high endothelial cells of mucosal origin, (A2) 106
- KALDEN JR, WINKLER T, KRAFF F. Ate retroviruses involved in the aetiology of rheumatic disease, (S1) 63
- KALLA AA, MEYERS OL, CHALTON D, HEATH S, BROWN GMM, SMITH PR, BURGER MC. Increased metacarpal bone mass following 18 months of slow-acting antirheumatic drugs for rheumatoid arthritis, 91
- Kallidin, bradykinin and HOE 140 metabolism in synovial fluid, (A2) 45
- KALSI J see Blanco F; Longhurst C
- KANIS JA see Bickerstaff DR; Spector TD

- KANTHARIA B *see* Woolf AD
 KATER L *see* Kruize AA
 KATZ P *see* Clauw DJ
 KAUL A *see* Abbot SE
 KAVANAGH G *see* Veale D
 KAY A *see* Symmons DPM
 KAY E, PULLAR T. Variation in dose and monitoring schedules for disease modifying antirheumatic drugs amongst UK and Irish rheumatologists, (A1) 19
 KAY R, THOMSON W, HAY E, GREEN L, DYER P, HOLT PL, BERNSTEIN R, OLLIER W. Influence of HLA and primary Sjögren's syndrome on Vβ6.7 T cell receptor gene expression, (A2) 136
 KEAT A *see* MacLean L
 KEAT ACS. Reactive arthritis after episode of salmonella enteritis, associated sterile urethritis, (CC) 140
 KEAT ACS, *see also* Hughes RA
 KELLY C *see* Foster H
 KELLY CA. Incidence of rheumatological problems in general medical outpatients, (A1) 1
 KELLY CA, FOSTER H, PAL B, GARDINER P, MALCOLM AJ, CHARLES P, BLAIR GS, HOWE J, DICK WC, GRIFFITHS ID. Primary Sjögren's syndrome in north east England—a longitudinal study, 437
 KELLY SM *see* Beynon HLC
 KEMPPINEN P *see* Honkanen V; Hukkanen M; Kontinen Y; Kontinen YT
 KENDALL R, HILL J, NORFOLK D, PULLAR T. Serum erythropoietin response to anaemia in rheumatoid arthritis, (A1) 26
 KENDALL R, WATSI A, HARVEY A, NORFOLK DR, PULLAR T. Prednisolone has a paradoxical effect on haemoglobin and erythropoietin concentrations in anaemic rheumatoid patients, (A2) 77
 KENNEDY LG, WILL R, CALIN A. Sex ratio in spondylarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset, (A1) 28
 Keratan sulphate
 and the acute phase response, (A2) 118
 and disease activity in rheumatoid arthritis, (A1) 34
 as a marker of progression of knee OA, (A2) 118
 KERR L-A *see* Sakkas LI
 KERR LP *see* Kirkham B
 KERSTENS PJSM, BOERBOOMS AMTH, JEURISSEN MEC, FAST JH, ASSMANN KJM, VAN DE PUTTE LBA. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis, (A2) 2
 Ketoprofen, evidence for the non-accumulation in plasma on long-term therapy, (A2) 37
 KHAMASHTA M, CERVERA R, VIANNA JL, FONT J, REYES PA, ASHERSON RA, LOPEZ-SOTO A, AMIGO MC, PARE C, VARGAS J, ROMERO A, INGELMO M, HUGHES GRV. High prevalence of heart valve disease in patients with the primary antiphospholipid syndrome, (A2) 21
 KHAMASHTA MA, *see also* Aydtung AO; Font J
 KHOKHER MA *see* Singarayer C
 KIDD BL *see* Cruwys SC; Mapp PI; Walsh DA
 KING A *see* Badger AM
 KING G *see* O'Neill TW
 KINGSLEY G. Monoclonal antibody treatment of rheumatoid arthritis, (S2) 33
 KINGSLEY G, PANAYI G. Immunopathogenesis of rheumatoid arthritis, (S2) 3
 KINGSLEY G, *see also* Verwilghen J
 Kingsley GH *see* Choy EHS; Jobanputra P; Kirkham BW; Verwilghen J
 KINGSTON AE, HICKS CA, BILLINGHAM MEJ. Induction of an inhibitory splenic macrophage during progression of adjuvant arthritis in a susceptible rat strain, (A2) 115
 Kinase II activity in synovial fluid before and after joint exercise, (A2) 45
 KINNE R *see* Emmrich F
 KIPPS TJ *see* Carson DA
 KIRKHAM B, NAVARRO FJ, KERR LP, CORKILL MM, PANAYI GS. Characteristic patterns of cellular activation in chronic inflammation: immune-mediated activity and non-specific cellular infiltration distinguished by interleukin-1 beta distribution in arthritis, (S2) 84
 KIRKHAM B, THIEN F, AMLOT P, DENMAN M, PANAYI GS. Chimeric (human/mouse) CD7 monoclonal antibody treatment in rheumatoid arthritis, (S2) 88
 KIRKHAM BW, PITZALIS C, KINGSLEY GH, CHIKANZA IC, SABHARWAL S, BARBATTIS C, GRAHAME R, GIBSON T, AMLOT PL, PANAYI GS. Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody, 459
 KIRKHAM BW, *see also* Corkill MM
 KIRWAN JR. Outcome in rheumatoid arthritis—different perspectives, 233
 KIRWAN JR. Postgraduate training in rheumatology, (L) 65
 KIRWAN JR, SNOW SM. Which patients see a rheumatologist, 285
 KIRWAN JR, *see also* Dacre JE; McAlindon TE
 KITAS GD *see* Fart M
 KLARESKOG L. Antigen presentation in joints in the pathogenesis of arthritis, (S1) 53
 KLARESKOG L, *see also* Jobanputra P
 Knee
 computerized measurement of radiological changes in the rat knee, (A2) 127
 joint intra-articular pressure changes, effect of effusion volume and type on exercise induced, (A1) 38
 X-rays: should we take them lying down, (A1) 3
 Knee osteoarthritis
 and disability: is muscle strength more important than what we see on the X-ray, (A2) 71
 joint space loss using high definition macroradiography: comparison of weight bearing standing & tunnel views, (A2) 74
 keratan sulphate as a marker of progression, (A2) 118
 prevalence in the general population using different criteria: the Chingford Study, (A2) 72
 radiographic patterns in the community: the importance of the patello-femoral joint, (A2) 71
 radiological progression of OA: an 11 year follow-up study of the knee, (A2) 72
 KNEKT P *see* Kontinen Y
 KNIGHT S *see* MacLean L
 KNIGHT SM, GOWEN M. Bone cells from osteoporotic patients are able to respond normally to 1,25-dihydroxyvitamin D³, (A2) 54
 KNIGHT SM, RING F, SHENSTONE B, ROSS A, BHALLA AK. Femoral bone mineral density is increased in osteoarthritis of the hip, (A2) 73
 KONTOMERKOS TK *see* Papazoglou SN
 KONTINEN Y, HONKANEN V, SORSA T, SAARI H, HUKKANEN M, METSÄ-KETELÄ. Vitamin E in chronic arthritis. Role in non-enzymatic and enzymatic lipid peroxidation, (A2) 42
 KONTINEN Y, LINDY O, KEMPPINEN P, SAARI H, SORSA T. Collagenase reserves in synovial fluid neutrophils in RA, (A2) 128
 KONTINEN Y, SANTAVIRTA S, HELIÖVAARA M, KNEKT P, LUTHJE P, AROMAA A. Determinants of osteoporotic thoracic spine vertebral fractures, (A2) 55
 KONTINEN YT, HUKKANEN M, KEMPPINEN P, MALMSTROM M, ROSE S, ITESCU S, SORSA T, POLAK JM. Peptide-containing nerves in labial salivary glands in Sjögren's syndrome, (A1) 6
 KONTINEN YT, SANTAVIRTA S, ANTTI-POIKA I, NORDSTRÖM D, HUKKANEN M. Inflammation of the subacromial bursa in chronic shoulder pain, (A2) 42
 KONTINEN YT, *see also* Honkanen V; Hukkanen M
 KORN J *see* Vancheswaran R
 KRAFF F *see* Kalden J
 KRAUS A, GUERRA-BAUTISTA G, ESPINOZA G, BAROJAS E, QUIROZ-MERCADO H, SANCHEZ-ECHEVERRI G, ALARCON-SEGOVIA D. Defects of the retinal pigment epithelium in scleroderma, 112
 KRAUS DR *see* Poppelman WC
 KREIS H *see* Lebaill-Darné JL
 KROEMER G *see* Andreu JL
 KRUIZE AA, HENÉ RJ, BODEUTSCH C, DE WILDE PCM, VAN BUSTERVELD OP, FELTCAMP TEW, KATER L, BULSMA JWW. Long-term follow-up of Sjögren's syndrome and keratoconjunctivitis sicca, (A2) 25
 KRZESICKI RF *see* Aspar DG
 KUNTZ D *see* Lioté F
 KURAL AR *see* Hamuryudan V
 KYLE V, RODDY J, TIGHE H, WALDMANN H, HAZLEMAN BL. Humanized monoclonal antibody treatment in rheumatoid arthritis, (S2) 89
 LAAN RFJM, BUIJS WCAM, DRAAD MP, VERBEEK ALM, CORSTENS FHM, VAN DE PUTTE LBA, VAN RIEL PLCM. Bone mineral density in rheumatoid arthritis: influence of functional capacity and disease activity, (A2) 52
 Lack of
 concordance for rheumatoid factor positivity in a nationwide study of twins with rheumatoid arthritis, (A2) 58
 disease similarity in monozygotic twins with rheumatoid arthritis, (A2) 58
 influence of known environmental factors on the occurrence of scleroderma in males, (A2) 29
 tolerance induction by cationic antigens, (S2) 93
 LAFFEBER F, VANDER KRAAN PM, HUBER-BRUNING O, VANDEN BERG WB, BULSMA JWW. Osteoarthritic human cartilage is more sensitive to transforming growth factor β than normal cartilage, (A2) 144
 LAFYATIS R *see* Wilder RL
 LALOR PA, REVELL PA. Does deposition of debris from TiAlV alloy lead to prosthetic joint failure, (A2) 116
 LAMBERT CM, WHITE M. Short term outcome of musculoskeletal complaints in instrumental musicians, (A2) 81
 LAMERS CBHW *see* Janssen M
 LANCHBURY J, JAEGER E, HALL M, SANSOM D, WORDSWORTH P, PANAYI G.

- Primary selection for particular DR4 subtypes accounts for the HLA-DQw7 association with Felty's syndrome, (A2) 56
- LANCHBURY J, *see also* Verwilghen J
- LANCHBURY JSS. Genetics of rheumatoid arthritis, (L) 319
- LANCHBURY JSS, PANAYI GS. Genetics of RA: the HLA shared epitope hypothesis and its implications, (S2) 6
- LANCHBURY JSS, *see also* Boki K; Wordsworth BP
- LANDEWÉ RBM, MILTENBURG AMM, BREEDVELD FC, DAHA MR, DIJKMANS BAC. Production of interferon-gamma and interleukin-2 by activated T-cell clones is synergistically inhibited by cyclosporine and chloroquine, (A2) 109
- LAPPIN TRJ *see* Boyd HK
- LARÉDO JD *see* Lebaill-Darné JL
- Large inhibitor of metalloproteinase consists of TIMP-2 bound to 72000 Mr-progelatinase, (A2) 128
- Laryngeal and ear involvement in rheumatoid arthritis in North India, 65
- Laser scanning confocal microscopy and its application to the study of neuromuscular junctions and muscle spindles, (A2) 43
- LASSERE MN *see* Jones JG
- LATCHMAN D *see* Longhurst C
- LATCHMAN DS *see* Huntriss JD
- Late onset ankylosing spondylitis—a distinct disorder, (L) 69
- LATORRE P *see* Escudero D
- LAU C. Rheumatoid arthritis, fish oil or snake oil, (L) 72
- LAU CS, BRIDGES AB, MUIR A, MORLEY KD, BELCH JFF. Further evidence of a polymorphonuclear cell activation in patients with Raynaud's phenomenon, (A2) 115
- LAU CS, McCLAREN M, BELCH JFF. Factor VIII von Willebrand factor antigen levels correlate with symptoms severity in patients with Raynaud's phenomenon, 433
- LAU CS, McCLAREN M, HANSLIP J, MORLEY KD, BELCH JFF. Abnormal fibrinolytic response in patients with rheumatoid arthritis complicated by vasculitis, (A2) 34
- LAU CS, McMAHON H, MORLEY KD, BELCH JFF. Effects of Maxepa on non-steroidal anti-inflammatory drug usage in patients with mild rheumatoid arthritis, (A2) 137
- LAURENT MR, BUCHANAN WW, BELLAMY N. Methods of assessment used in ankylosing spondylitis clinical trials: a review, 326
- LAURENT MR, *see also* Pile KD
- LAVALLE C. Role of prolactin in autoimmune and autoimmunity, (L) 476
- LAVERDER JP *see* Hawkins PN
- LAW M *see* Hart DJ
- LAWRANCE RA, BROOKES SM, FOX J, CHARLES PJ, VENABLES PJW, MAINI RN. Antibodies to phospholipids in chronic fatigue syndrome: implications for a viral aetiology, (A2) 11
- LAWRENCE R *see* Wells AU
- LAWS D *see* Luqmani RA
- LAWTON C *see* Hill H
- LAYWOOD AA. Fibromyalgia, (L) 235
- LEAK AM, COOPER J. Validation of a new questionnaire devised to measure neck pain and disability, (A1) 2
- LEAKER B, MCGREGOR A, GRIFFITHS M, SNAITH M, NEILD GH, ISENBERG D. Insidious loss of renal function in patients with anticardiolipin antibodies and absence of overt nephritis, 422
- LEBAILL-DARNÉ JL, ZINGRAFF J, LARÉDO JD, BENOIT J, KREIS H, BARDIN T. Dialysis arthropathy and kidney transplantation, (A2) 89
- LEDINGHAM J, DOHERTY S, DOHERTY M. Primary fibromyalgia syndrome—an outcome study, (A2) 80
- LEDINGHAM J, JONES AC, REGAN M, DOHERTY M. Minimal rheumatological screening history and examination, (A1) 1
- LEDINGHAM J, *see also* Jones AC
- LEE MK *see* Teh LS
- LEEDHAM-GREEN M *see* Hart DJ
- LEIBOLD W *see* Ziesenis A
- LENA JL. *Pneumocystis carinii* pneumonia causing hypertrophic osteoarthropathy, (L) 476
- Letter from America, 368
- Leucocyte integrin and CR1 expression in rheumatoid arthritis, (A1) 13
- LEUTWILER A *see* Mackenzie AR
- Levels of α -tocopherol in rheumatoid serum and synovial fluid, (A2) 41
- LEVINE S *see* Davison AN
- LEWIN I *see* Davis MJ
- LEWIS RJ. Radionuclide angiography, (L) 477
- Li E *see* Seglias J
- LIAUTAUD J *see* Wendling D
- LIENARD A *see* Racadot E
- LIFE PF *see* Gaston JSH; Hassell AB
- LIGHTMAN SL *see* Harbuz MS; Rees RG
- LILLIE C *see* Dowling EJ
- LIMA J, FONOLLOSA V, CHACON P, FERNÁNDEZ-CORTIJO J, CASTRO A, MARSAL S, VILARDELL M, SIMÉON CP. Plasma lipid peroxides: are they a mechanism of vascular lesion in systemic sclerosis, (A2) 38
- Limited association of generalized osteoarthritis with alleles at the type II collagen locus: COL2A1, 272
- Limited forms of Wegener's granulomatosis presenting as polymyalgia rheumatica, 382
- Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive associations with HLA-DR4, DR1 and DRw10, 178
- LINDSEY NJ, HENDERSON FI, DAWSON R, MALIA R, GREAVES M, HUGHES P. Effect of immunoglobulin G from patients with systemic lupus erythematosus and the antiphospholipid syndrome on the release of von Willebrand factor antigen from human umbilical vein endothelium, (A2) 19
- LINDY O *see* Kontinen Y
- Link between vascular damage and fibrosis in degenerative disease of the spine, (A2) 49
- Link protein, rapid processing of an N-terminal fragment by human monocytes, (A2) 132
- LIOTÉ F, PAOLOZZI L, KUNTZ D. Inhibition of human endothelial cell proliferation by tiopronine, (A2) 107
- Lipocortin-1 in rheumatoid leukocytes, defective corticosteroid induction, (A2) 116
- LITTLEJOHN GO *see* Reilly PA
- LITTLEWOOD A *see* Stuart RA
- LIU S *see* Tanner SB
- LLENA J *see* Peris P
- LOYD J *see* David J
- LOBUGLIO AF *see* Jonker M
- Local injection treatment of tennis elbow—hydrocortisone, triamcinolone and lignocaine compared, 39
- Localisation of neutral endopeptidase to the human synovium, (A2) 121
- LOCKWOOD CM *see* Chan TM; Rifkin IR
- Locomotor problems, junior doctors' awareness, (A2) 1
- LOIZOU S, COFINER C, WALPORT MJ. IgA anticardiolipin antibodies are usually present in conjunction with the IgG and/or IgM isotypes, (A2) 20
- LOIZOU S, *see also* Beynon HLC; Harmer JJ
- Long-term follow-up of Iloprost infusion of patients with connective tissue disease using infra-red thermography, (A2) 76
- of Sjögren's syndrome and keratoconjunctivitis sicca, (A2) 25
- LONGHURST C, RAVIRAJAN C, WINSKA-WILOCH H, KALSI J, LATCHMAN D, ISENBERG D. VH gene usage in human/human hybridoma derived monoclonal antibodies from SLE patients, (A2) 15
- Longitudinal changes in serum cytidine deaminase in rheumatoid arthritis correlate with clinical assessments of joint inflammation, (A1) 33
- LOPEZ LARREA C *see* Torre Alonso JC
- LOPEZ-SOTO C *see* Font J; Khamashta MA
- Loss of functional activity of synovial fluid α -1-antitrypsin in rheumatoid arthritis correlates with disease activity as measured by serum C-reactive protein, (A2) 130
- LOVELL C *see* Stuart RA
- LOVERIDGE JA, WORDSWORTH P, GOUGH A, EMERY P, BELL JI. T-cell receptor V β repertoire in the joints of patients with early rheumatoid arthritis, (A1) 14
- Low back pain, 208
- indications for use of a lumbar corset, (CC) 62
- Low molecular weight metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage *in vitro*, (A2) 144
- Low prevalence of rheumatoid arthritis in a rural Nigerian population, (A2) 1
- Low-dose methotrexate in adult Still's disease, (A2) 101
- LOWE J *see* Hopkinson N
- LOWE JS *see* Pallis M
- LUCHETTI MM *see* Corvetta A
- LUFT S *see* Jedryka-Goral A
- Lumbar bone mineral density in rheumatoid arthritis: normal values in ambulant, non-steroid treated patients, (A2) 53
- LUNARDI C, MARGUERIE C, BOWNESS P, WALPORT MJ, SO AK. Reduction in Ty6 cell numbers and alteration in subset distribution in systemic lupus erythematosus, (A2) 13
- LUNARDI C, MARGUERIE C, WALPORT MJ, SO AK. Ty6 cells and their subsets in blood and synovial fluid in rheumatoid arthritis, (A2) 13
- LUNARDI C, *see also* Marguerie C
- LUNEC J *see* Blount S; Dowling EJ
- LUPOLI S. Lyme disease and localized scleroderma—no evidence for a common aetiology, (L) 154
- Lupus anticoagulant and acquired hypothyroidism: response to steroid therapy, 308
- crisis, severe, with agranulocytosis and anuric renal failure due to a mesangial lesion (WHO IIB)—successful treatment with cyclophosphamide pulse followed by plasmapheresis, (L) 312
- sera bind to a tissue-specific variant of the Sm antigen, (A2) 133
- LUQMANI R *see* Gado K; Rouseau E

- LUQMARI RA, DEUTSCH J, LAWS D, MISSON G, EMERY P, MURRAY PI, BACON PA. Ocular involvement in non-renal Wegener's granulomatosis, (A2) 26
- LUQMARI RA, GORDON M, GREAVES I, ADU D, MICHAEL J, EMERY P, BACON PA. Relationship between classical and microscopic polyarthritis, (A2) 88
- LUQMARI RA, SHEERAN TP, WINKLES J, RICHARDSON K, ROBINSON M, EMERY P. Cytokines and the acute phase response in rheumatoid arthritis, (A2) 6
- LUQMARI RA. *see also* Gado K
- LUTHJE P *see* Kontinen Y
- LYDYARD PM *see* Erkeller-Yuksel FM; Sinclair HD
- Lyme disease, 228
joint manifestations in Spain, (L) 71
and localized scleroderma—no evidence for a common aetiology, (L) 154
- LYNCH JA *see* Buckland-Wright JC
- LYNCH M *see* Phelan M
- Lytic bone lesions and polyarthritis associated with acne fulminans, 387
- MCALINDON T *see* Dieppe P
- MCALINDON TE, KIRWAN JR, COOPER C, DIEPPE PA. Knee osteoarthritis and disability: is muscle strength more important than what we see on the X-ray, (A2) 71
- MCALINDON TE, SNOW S, COOPER S, DIEPPE PA. Radiographic patterns of knee osteoarthritis in the community: the importance of the patello-femoral joint, (A2) 71
- MACALPINE L *see* Bowness P
- McCANN J *see* Jones JG
- MC CARTHY DA, TAYLOR AJ, BERNHAGEN J, PARRY JD, HAMBLIN AS. Leucocyte integrin and CR1 expression in rheumatoid arthritis, (A1) 13
- MC CARTHY DA. *see also* Farrell AJ
- McCLAREN M *see* Lau CS
- McCLELLAN D *see* Thompson PW
- McCLOSKEY EV *see* Spector TD
- McCONKEY B *see* Situnayake RD
- McCULLOUGH C *see* David J
- MACDIARMAID-GORDON AR, BEAMAN M, VENNING MC, ACKRILL P. Management of vasculitis without steroids, (A2) 88
- McDONAGH J, GRAY J, DEIGHTON CM, SYKES H, WALKER DJ. Failure to isolate *Proteus* in the urine of rheumatoid arthritis patients more frequently than controls, (A2) 3
- MACFARLANE DG *see* Buckland-Wright JC
- McGILL NW, DIEPPE PA. Effect of biological crystals and human serum on the rate of formation of crystals of monosodium urate monohydrate *in vitro*, 107
- McGOWAN I *see* Fewins HE
- McGREGOR A *see* Leaker B
- MACGREGOR AJ, CARTHY D, MAGEED R, OLLIER WER, SILMAN AJ. Lack of concordance for rheumatoid factor positivity in a nationwide study of twins with rheumatoid arthritis, (A2) 58
- MACGREGOR AJ, HOLLIGAN S, FOX H, SILMAN AJ. Lack of disease similarity in monozygotic twins with rheumatoid arthritis, (A2) 58
- McKEARN JP *see* Iyengar S
- McKEE P *see* D'Cruz DP
- McKENNA F. Assessment of disability in male and female rheumatoid patients, (L) 477
- MACKENZIE AR, BOLLINGER P, COOPER PH, DEL POZO E, ELFORD P, GRAEBER M, GUBLER H-U, LEUTWILER A, PAYNE T, RUCH W, SCHNYDER J, WUETHRICH H-J. Pharmacological effects of a new anti-arthritis agent IX 207-887, (S2) 75
- MACKWORTH-YOUNG CG *see* Harmer IJ
- McLAREN M *see* Lau CS
- MACLEAN L, IQBALL S, KNIGHT S, WOO P, KEAT A, HUGHES R. HLA-B27 subtypes in the spondarthropathies, (A2) 33
- McMAHON H *see* Lau CS
- McMAHON MJ, HOLLIS S, SANDERS PA, GRENNAN DM. Articular disease severity in rheumatoid subjects with and without Felty's syndrome, 217
- MACRO M. Effect of intrathecal dexamethasone injection on plasma cortisol level, (L) 238
- McWHIRTER A, IVARSSON M, RUBIN K, BLACK CM. Regulation of collagen synthesis and contraction of collagen gels is impaired in scleroderma fibroblasts, (A2) 145
- MADDISON P *see* Hall J; Hay EM
- MADDISON PJ *see* Herrero-Beaumont G; Stuart RA; Tooke AF; Whyte J; Woolf AD
- MADHOK R *see* Brzeski M; Murphy EA
- MAGEED R *see* MacGregor AJ
- Magnetic resonance imaging
in the assessment of rheumatoid arthritis—a comparison with plain film radiographs, 101
of the carpal tunnel before and after treatment for carpal tunnel syndrome, (A2) 61
in the evaluation of acromegaly, (A1) 37
in pigmented villonodular synovitis, (A1) 36
of the rat knee, (A2) 64
study of dialysis shoulder, (A2) 87
- MAHAJNA N *see* Barak V
- MAINI RN *see* Andrew EM; Brennan FM; Brookes SM; Brown CMS; Chu CQ; Deleuran B; Lawrance RA; Venables PJW
- MAKOWSKI RS, ATKINS RM. Treatment of fixed flexion deformities of the knee in rheumatoid arthritis using the flowtron inflatable splint, (A1) 27
- MALCOLM AJ *see* Kelly CA
- MALCUS JOHNSON P *see* Eberhardt K
- MALDYKOWA H *see* Jedryka-Goral A
- MALIA R *see* Lindsey NJ
- Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives, 471
- MALLYA R *see* Fewins HE
- MALMSTROM M *see* Kontinen YT
- MALYAK M *see* Arend WP
- Management of vasculitis without steroids, (A2) 88
- MANCEBO ARAGONES L *see* Alonso-Ruiz A
- MANDER M *see* Goodacre JA
- MANERO H *see* Salinas M
- MANIVASAGAR M *see* Teh LS
- MAPP PI, WALSH DA, CRUWYS SC, KIDD BL, BLAKE DR. Localisation of neutral endopeptidase to the human synovium, (A2) 121
- MAPP PI. *see also* Cruwys SC; Dowling EJ; Walsh DA
- Mapping of cartilage stiffness in the apophyseal joint, (A2) 70
- MARCHESONI A *see* Helliwell P; Sakkas LI
- MARCOS MAR *see* Andreu JL
- Marfan syndrome, study of joints and skin, (A2) 82
- MARGUERIE C, LUNARDI C, SO AK. Selectivity of T-cell receptor variable region gene usage by rheumatoid arthritis synovial T-cells, (A2) 59
- MARGUERIE C. *see also* Beynon HLC; Lunardi C
- MARKOVITZ D *see* Danieli MG
- MARBUS H, HOPKINSON N. Migraine in systemic lupus erythematosus and its relationship with antibodies to phospholipids, (A1) 22
- MARRERO JM *see* Collins DA
- MARSAL S *see* Lima J
- MARSH FP *see* Wilkie ME
- MARSHALL DAS, HUNTER JA, CAPELL HA. Metronidazole as a possible disease-modifying agent in the treatment of rheumatoid arthritis: a double-blind placebo controlled study, (A2) 101
- MARSHALL DAS, MURPHY E, COBBE SM, STURROCK RD. Subclinical valvular and myocardial disease in ankylosing spondylitis: a Doppler echocardiographic study, (A2) 60
- MARTIN H, DEAN MF. Rapid processing of an N-terminal fragment of link protein by human monocytes, (A2) 132
- MARTINEZ DE OSABA MJ *see* Peris P
- MARTINEZ-A C *see* Andreu JL
- MASON J *see* Beynon HLC
- MASON PJ *see* Turner N
- MASON RM *see* Worrall JG
- Mast cell-nerve inter-relationship in systemic sclerosis skin, (A2) 46
- MATA R *see* Muniain MA
- MATEO E *see* Salinas M
- MATSON M *see* Da Silva JAP
- MATSOUKA CI *see* Papazoglou SN
- MATTEY D *see* Wilkinson SM
- MATTEY DL, NIXON N, STRANGE RC. Identification and localisation of antioxidant enzymes in synovium and synovial fibroblasts, (A2) 39
- MATTEY DL. *see also* Close DR
- MATTHEWS S *see* Creamer P
- Maxepa effects on non-steroidal anti-inflammatory drug usage in patients with mild rheumatoid arthritis, (A2) 137
- MAYMO J *see* Woolf AD
- MAZURE G *see* Brown KA
- MEAGER A *see* Holt I
- Measurement of
collagenase by enzyme assay, (A2) 129
growth hormone in children with juvenile chronic arthritis and growth retardation on alternate day corticosteroid therapy, (A2) 75
synovial capillary perfusion pressure using video-arthroscopy—a new technique: implications for hypoxic reperfusion injury, (A1) 39
- Mechanisms of joint sparing in a hemiplegic patient presenting with unilateral psoriatic arthritis, (A2) 52
- Medical students, rheumatology curriculum, 123
- MEENAN RF. Rheumatology manpower—the US perspective, (E) 81
- MEHDIZADEH S *see* Pitsillides AA

- MEHTA R *see* David J
 MEIJERS T *see* Swann BP
 MERINO J *see* Ramos A
 MERRY P, SHATTLES W, SCOTT T. Transient erosion of the ulnar styloid process, 473
 MERRY P, SMITH E, STEVENS C, WINYARD P, BLAKE DR. Synovial fluid polymorphs and the oxygen paradox, (A2) 49
 MERRY P. *see also* Williams RB
 Metabolism of bradykinin, kallidin and HOE 140 in synovial fluid, (A2) 45
 Metacarpal bone mass following 18 months of slow-acting antirheumatic drugs for rheumatoid arthritis, 91
 Metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage *in vitro*, (A2) 144
 Metalloproteinase inhibitors—crystal gazing for a future therapy, (E) 242
 Metalloproteinases and tissue damage, (S1) 25
 Methods of assessment used in ankylosing spondylitis clinical trials: a review, 326
 Methotrexate
 accelerated nodulosis during low dose therapy for rheumatoid arthritis, (A2) 2
 in adult Still's disease, (A2) 101
 and azathioprine influence on the radiologic progression in rheumatoid arthritis, (A2) 2
 effect of food on the pharmacokinetics in the treatment of rheumatoid arthritis, (A2) 37
 effects on clinical and immunological parameters in refractory rheumatoid arthritis: a prospective study, (L) 73
 effects on glycosaminoglycan production of cultured fibroblasts from scleroderma patients and healthy controls: preliminary results, (A2) 133
 5-Methylcytosine content of DNA in blood and synovial mononuclear cells from patients affected by rheumatic disease, (S2) 98
 Methylprednisolone pulse therapy, arrhythmia after, (L) 392
 Metronidazole as a possible disease-modifying agent in the treatment of rheumatoid arthritis: a double-blind placebo controlled study, (A2) 101
 METSÄ-KETELÄ T *see* Kontinen Y
 MEYERS OL *see* Kalla AA
 MHC class II
 binding peptides use in immunotherapy, (S2) 14
 molecules, peptide interactions, (S2) 10
 variants in SLE, (A2) 33
 Mianserin as a cause of arthritis, (L) 74
 MICHAEL J *see* Luqmani RA
 MICK SJ *see* Iyengar S
 Microscopic polyarteritis, purification of proteinase 3 and its reactivity with sera from patients, (A2) 83
 MIDDLEMISS A *see* Bowness P
 MIGLIARESI S *see* Valentini G
 Migraine in systemic lupus erythematosus and its relationship with antibodies to phospholipids, (A1) 22
 MILTENBURG AMM, VAN LAAR JM, DE KUIPER R, DAHA MR, BREEDVELD FC. Interleukin-6 activity in paired samples of synovial fluid. correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation, 186
 MILTENBURG AMM. *see also* Landewé RBM; van Laar JM. Minimal rheumatological screening history and examination, (A1) 1
 MINUCCI PB *see* Valentini G
 Misoprostol
 immune modifying effects, (S2) 71
 influence on non-steroidal anti-inflammatory drug-influenced intestinal damage and disease activity in rheumatoid arthritis, (A2) 91
 and non-steroidal anti-inflammatory drug-associated gastro-duodenal damage, (A2) 5
 reno-protective effect in co-administration with indomethacin, (A2) 90
 MISRA H *see* Doherty M
 MISSON G *see* Luqmani RA
 MITCHISON NA. Genes beneficial to autoimmune disease, (S1) 38
 MITCHISON NA. Immunology of tolerance and autoimmunity, (S2) 1
 Mixed connective tissue disease, pneumatois intestinalis and pneumoperitoneum complicating, 146
 Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA idiotype, (S2) 93
 Molecular analysis of Ehlers-Danlos syndrome type II, (E) 163
 Molecular definition of the Ro(SSA) particles: a frequent target of autoimmunity in systemic lupus erythematosus and Sjögren's syndrome, (S1) 58
 Molecular markers of processes in cartilage in joint disease, (S1) 21
 MOLLER E *see* Abedi-Valgerdi M
 MOLLER G *see* Abedi-Valgerdi M
 MOLONEY RO *see* Pile KD
 MOLONY J *see* O'Neill TW
 MONEGAL A *see* Peris P
 Monoclonal antibodies, genetically engineered, (S2) 36
 Monoclonal antibody treatment
 of rheumatoid arthritis, (S2) 33
 in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody, 459
 Monocyte/macrophage increased numbers in rheumatoid synovial membrane predict a worse radiological outcome, (A1) 8
 Monosodium urate monohydrate crystals, effect of biological crystals and human serum on the rate of formation *in vitro*, 107
 MOORE AR, IWAMURA H, SCOTT DL, WILLOUGHBY DA. Neutrophil-induced cartilage damage is mediated by enzymes and not reactive oxygen species, (A2) 131
 MOORE AR. *see also* Edwards JCW
 MOORE EA, FRY ME, HUTTON CW, JACOBY RK, ELLIS RE, VENNART W. Features of early OA identified with MRI at two resolutions, (A1) 36
 MOORE EA, RAWSON MH, HUTTON CW, JACOBY RK, ELLIS RE, VENNART W. Preliminary experience using MRI in the evaluation of actomegaly, (A1) 37
 MORAND EF, JEFFERISS CM, GOULDING NJ. Defective corticosteroid induction of lipocortin-I in rheumatoid leukocytes, (A2) 116
 MORE J *see* Ejim OS
 MOREL FOURRIER B *see* Wendling D
 MORENO I *see* Andreu JL
 MORGAN K *see* Majeer AH; Worthington J
 MORLEY BJ *see* Botto M
 MORLEY KD *see* Lau CS
 MORRIS CJ *see* Blann AD; Winrow VR
 MOSCO G *see* Hukkanen M
 MOUTSOPOULOS H *see* Boki K
 MRAZEK I *see* Hunt K
 MRI scanning can detect cerebral abnormalities in lupus patients without clinical neurological disease, (A2) 61
 MUIR A *see* Lau CS
 MUIR K *see* Hopkinson N
 MULHERIN D *see* Callaghan M
 MULLY GP *see* Naylor JR
 MUNIAIN MA, RODRÍGUEZ MD, ROMERO A, MATA R, VARGAS C, NARANJO A. Circadian variations in the superoxide production, enzyme release and neutrophil aggregation in patients with rheumatoid arthritis and controls, 138
 MUÑOZ S, CUESTA M, ALVAREZ R, BALS A, FONTAN G, GUÓN J. Diagnostic value of antiperinuclear factor, (A2) 112
 MUÑOZ-GÓMEZ J *see* Peris P
 MURPHY E *see* Marshall DAS
 MURPHY EA. ANTIBODIES to *Proteus* in rheumatoid arthritis, (L) 390
 MURPHY EA, FOX JG, GALBRAITH I, MADHOK R, CAPELL HA, BOULTON-JONES JM. Spectrum of disease associated with a positive ANCA, (A1) 16
 MURPHY G, DOCHERTY AJP, HEMBRY RM, REYNOLDS JJ. Metalloproteinases and tissue damage, (S1) 25
 MURPHY G. *see also* Winyard PG
 MURPHY JC *see* Joshi AB
 MURRAY PI *see* Luqmani RA
 MURRAY-LESLIE C. Driving for the disabled by arthritis, 54
 Musicians, instrumental, short term outcome of musculoskeletal complaints, (A2) 81
 MUXLOW NJ, JAMES MF, HEALD G, SHORTER JH, HARPER GP. Computerized measurement of radiological changes in the rat knee, (A2) 127
 Mycobacterium vaccae immunisation as immunomodulatory therapy in rheumatoid arthritis: preliminary results of an open study, (A2) 9
 Mycophenolic acid and derivative RS-61443, immunosuppressive and long-acting anti-inflammatory activity, (S2) 57
 MYERS MJ *see* Jones AKP
 MYLES AB *see* Bowness P
 NARANJO A *see* Muniaín MA
 Natural history of shoulder problems in primary care, (A2) 78
 Natural killer cell cytotoxicity
 and alpha interferon levels in early synovitis and rheumatoid arthritis, (A2) 108
 inhibition in rheumatoid arthritis by the non-immune complex IgA-alpha-1-antitrypsin, (A2) 107
 Natural killer cells, changes in frequency in SLE patients with disease activity and renal involvement, (A2) 16
 NAUGHTON D, WHELAN M, GROOTVELD M, PARKES H, BLAKE DR. Anaerobic metabolism: elucidation of its role in rheumatoid and osteoarthritis by high field nuclear magnetic resonance imaging spectroscopy: evidence for hypoxic metabolism in rheumatoid arthritis, (A1) 32
 NAVARRO FJ *see* Kirkham B

- NAYAK U *see* Sheeran T
 NAYLOR G *see* Bowen JG
 NAYLOR JR, MULLEY GP. Surgical collars: a survey of their prescription and use, 282
 NAZHAT NB, FARRELL AJ, BLAKE DR. ESR spectroscopy of RA synovial fluid using the spin trap DBNBS demonstrates a reactive oxygen species which progressively increases after exercise, (A2) 132
 NAZHAT NB, *see also* Singh D
 NEILD GH *see* Leaker B
 NELSON RS *see* Hawkins PN
 Neuroendocrine-immune interactions in the pathogenesis of rheumatoid arthritis: therapeutic implications, (S2) 96
 Neuropeptides and inflammatory cells in synovium: possible involvement of free radicals in neuropeptide degradation, (A1) 5
 Neurosensory adverse effects after combined phenylbutazone and misoprostol, (L) 392
 Neutrophil-induced cartilage damage is mediated by enzymes and not reactive oxygen species, (A2) 131
 NIETFIELD JJ, BULSMA JWJ, DEN OTTER W, HUBER-BRUNING O. Role for IL-6 in the interaction of IL-1 and human articular cartilage, (A2) 125
 NIETFIELD JJ, ROHOLL PJM, DEN OTTER W, BULSMA JWJ. Detection of IL-6-receptors in cultured explants of human articular cartilage, (A2) 125
 NIETFIELD JJ, *see also* Wilbrink B
 Nineteen ninety-two and all that, (L) 76
 NIXON N *see* Close DR; Matthey DL; Taylor HG
 No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac, 56
 NOLAN J *see* Waller HA
 Non-fibrositic lumbar cutaneous nodules: prevalence and clinical significance, 376
 Non-infective verrucous endocarditis in a patient with primary antiphospholipid syndrome, 305
 Non-steroidal anti-inflammatory drug-associated gastro-duodenal damage and misoprostol, (A2) 5
 Non-steroidal anti-inflammatory drugs, *Helicobacter pylori* status does not modify the acute gastric toxicity, (A2) 138
 NORDSTRÖM D *see* Kontinen YT
 NORFOLK D *see* Kendall R
 NORFOLK DR *see* Kendall R
 North Humberside osteoporosis screening project—preliminary observations, (A1) 5
 NORTHFIELD TC *see* Collins DA
 Nuclear membrane terminal N-acetyl glucosamine in normal and rheumatoid synovium, (A1) 9
 NUKI G *see* Smith G
- Occurrence and significance of hand deformities in early rheumatoid arthritis, 211
 Ocular involvement in non-renal Wegener's granulomatosis, (A2) 26
 OEGAMA TR, BRADFORD DS. Inter-relationship of facet joint disease osteoarthritis and degenerative disc disease, (S1) 16
 Oestrogen, the prevention of bone loss and osteoporosis, 276
 OFFNER H *see* Vandenberg AA
 OGILVIE D *see* Priestley L
 OGILVIE DJ *see* Wordsworth BP
 O'HARE P *see* Hall J
 OKON E *see* Barak V
 Oligosaccharides, just the icing on the protein or are they of functional relevance, 196
 OLIVÉ A *see* Escudero D
 OLIVE A. Ferritin and adult Still's disease, (L) 158
 OLIVER DO *see* Hawkins PN
 OLIVERA DL *see* Badger AM
 OLLIER W *see* Hillaby MC; Kay R; Sidebottom D; Worthington J
 OLLIER WER *see* Holligan S; MacGregor AJ
 OLSEN I *see* Beauchamp JR; Vancheswaran R
 O'MAHONEY S *see* Callaghan M
 O'NEILL T, GROSCH C, EUSTACE S, BRESNIHAN B. Sciatica caused by isolated non-Hodgkin's lymphoma of the spinal epidural space: a report in two cases, 385
 O'NEILL TW, KING G, GRAHAM IM, MOLONY J, BRESNIHAN B. Cardiac abnormalities in ankylosing spondylitis. Early detection of aortic incompetence with Doppler echocardiography, (A2) 60
 OOSTERVELD FGJ *see* Jacobs JWJ
 Opinion of patients with rheumatoid arthritis about their functional capacity, (A2) 97
 Oral tolerance and collagen arthritis, (S2) 40
 Orderly arrangement of urate crystals in synovial fluid tissue fragments, (A2) 119
 ORME M *see* Phelan M
 OSMAN S *see* Jones AKP
- ØSTENSEN M. Mianserin as a cause of arthritis, (L) 74
 ØSTENSSON A, GEBOREK P. Septic arthritis as a non-surgical complication in rheumatoid arthritis: relation to disease severity and therapy, 35
 Osteoarthritic human cartilage is more sensitive to transforming growth factor beta than normal cartilage, (A2) 144
 Osteoarthritis
 anaerobic metabolism: elucidation of its role in rheumatoid and osteo-arthritis by high field nuclear magnetic resonance imaging spectroscopy: evidence for hypoxic metabolism in rheumatoid arthritis, (A1) 32
 animal models: insights provided by the cruciate-deficient dog, (S1) 5
 and athletes—is there any relationship, (L) 67, (L) 68
 bone mass in primary generalised, (A2) 54
 chondrocyte responses in cartilage and in experimental osteoarthritis, (S1) 32
 clinical and research perspective, (S1) 1
 cytochrome oxidase activity of guinea pig cartilage and its relationship to the onset, (A2) 126
 does the weather affect the patient, (L) 477
 features of early OA identified with MRI at two resolutions, (A1) 36
 joint, intra-articular steroid injections for treatment, (CC) 199
 limited association of generalized disease with alleles at the type II collagen locus: COL2A1, 272
 looking for directions, 232
 nodal generalised, increased frequency of IgG rheumatoid factor—further support for an auto-immune aetiology, (A2) 70
 relationship with osteoporosis in the general population: the Chingford Study, (A2) 55
 symmetry and compartmental involvement of established osteoarthritis of the knee joint, (A2) 65
 Osteoarthritis of the hip
 femoral bone mineral density is increased in, (A2) 73
 in men and physical activity, (A2) 73
 Osteoarthritis of the knee
 and disability: is muscle strength more important than what we see on the X-ray, (A2) 71
 evaluation of a method for clinically assessing, (A1) 3
 joint space loss using high definition macroradiography: comparison of weight bearing standing & tunnel views, (A2) 74
 keratan sulphate as a marker of progression, (A2) 118
 prevalence in the general population using different criteria: the Chingford Study, (A2) 72
 radiographic patterns in the community: the importance of the patello-femoral joint, (A2) 71
 radiological progression of OA: an 11 year follow-up study of the knee, (A2) 72
 Osteoarthropathy, hypertrophic, *Pneumocystis carinii* pneumonia causing, (L) 476
 Osteoporosis, 135
 in ankylosing spondylitis, 160
 and ankylosing spondylitis, (L) 318
 bone cells are able to respond normally to 1,25-dihydroxyvitamin D₃, (A2) 54
 clinical profile of acute vertebral compression fractures, 418
 coordinating a service to the community, (A1) 4
 cost-benefit analysis of three different recruitment techniques in a regional screening study: report of a pilot study, (A2) 93
 exercise in prevention, (E) 2, (L) 313
 North Humberside osteoporosis screening project—preliminary observations, (A1) 5
 oestrogen and the prevention of bone loss, 276
 post menopausal, compliance with hormonal replacement therapy after screening, (A2) 94
 post menopausal screening, (A2) 92
 relationship with osteoarthritis in the general population: the Chingford Study, (A2) 55
 in rheumatoid arthritis—the clinical viewpoint, (E) 82
 in rheumatoid arthritis—the laboratory perspective, (E) 84
 urinary excretion of deoxypyridinoline as a marker of bone resorption in an animal model, (A1) 35
 Osteoporotic fracture of the sacrum, (A2) 92
 Osteoporotic thoracic spine vertebral fracture determinants, (A2) 55
 O'SULLIVAN MM *see* Hillaby MC
- Outcome
 assessment in clinical trials of ankylosing spondylitis, (E) 321
 of parenteral gold therapy by RA patients: a comparison between two periods using life-table analysis, 407
 in rheumatoid arthritis—different perspectives, 233
 Overexpression of a common DNA antibody idiotype BEG-2β in the families of patients with rheumatoid arthritis but not SLE, (A2) 14
 Overinterpreting data on biochemical markers, a new epidemic in rheumatology, (L) 237

- Oxygen radical-mediated oxidative damage to lactate in rheumatoid synovial fluid, (A2) 40
- P blood group phenotype anti-*Proteus* antibody titres and rheumatoid arthritis, (A2) 3
- PAGE THOMAS DP *see* Vecchio PC
- Paget's disease
bone scintigraphy following intravenous pamidronate, (A2) 63
effect of a single infusion of pamidronate, (A2) 95
- PAICE E *see* Smith CR
- Pain scores, analogue, (L) 390
- PAK KY *see* Jonker M
- PAL B *see* Kelly CA
- PALFERMAN TG. Challenge of osteoporosis: coordinating a service to the community, (A1) 4
- PALLARÉS L *see* Font J
- PALLIS M, HOPKINSON ND, LOWE JS, POWELL RJ. Electron microscopic study of muscle capillary wall thickening in SLE and MCTD, (A2) 22
- PALLIS M, ROBSON DK, HASKARD DO, POWELL RJ. Distribution of cell adhesion molecules in peripheral muscle from patients with SLE, (A2) 23
- PANAYI G *see* Gough A; Lanchbury J
- PANAYI GS *see* Boki K; Chikanza IC; Choy EHS; Corkill MM; Dasgupta B; Farahat MNMR; Jobanputra P; Kirkham B; Kirkham BW; Lanchbury JSS; Sakkas LI; Verwilghen J
- PANDOLFINO YA *see* Brookes SM
- PAOLOZZI L *see* Lioté F
- PAPAGEORGIOU AC, RIGBY AS. Low back pain, 208
- PAPAGEORGIOU AC, *see also* Croft PR
- PAPADOPOULOS SE *see* Eggemeijer F
- PAPAZOGLU SN, ILIOPOULOS AG, ATHANASIOU PL, MATSOUKA CI, CHILAS GI, KONTOMERKOS TK. Use of high dose intravenous immunoglobulin in Behçet's syndrome, (S2) 91
- PARÉ C *see* Font J
- PARÉ C *see* Khamashta MA
- PARÉS A *see* Peris P
- PARKES H *see* Naughton D
- PARRY JD *see* McCarthy DA
- Partial biochemical characterization of new cytokine activity (Ig2b inducing factor) from synovial fluid of patients with rheumatoid arthritis, (S2) 86
- PARTRIDGE T *see* Beauchamp JR
- PASCUAL E. Orderly arrangement of urate crystals in synovial fluid tissue fragments, (A2) 119
- PASCUAL E, GINER V, ARÓSTEGUI A, RUIZ MT, PICÓ A. Higher incidence of carpal tunnel syndrome in oophorectomized women, 60
- PASCUAL E, *see also* Carto A; Ruiz MT; Salinas M
- PATEL U, SKINGLE S, CAMPBELL GA, CRISP AJ, BOYLE IT. Clinical profile of acute vertebral compression fractures in osteoporosis, 418
- Patients with ankylosing spondylitis show individual patterns of variation in disease activity, 336
- PATRICK M *see* Hamilton E; Jones AC; Priestley L
- PAUL PK. Detection of cartilage degradation with sodium NMR, (L) 318
- PAUWELS EKJ *see* Boers M; Eggemeijer F
- PAYNE T *see* Mackenzie AR
- PEEBLES ACI *see* Halsey JP
- PEEL NFA, BAX DE, EASTELL R. Evaluation of hand bone mineral measurement by dual-energy X-ray absorptiometry in rheumatoid arthritis, (A2) 62
- PEEL NFA, EASTELL R, RUSSELL RGG. Osteoporosis in rheumatoid arthritis—the laboratory perspective, (E) 84
- PEEMOELLER H *see* Bellamy N
- PEGLEY FS *see* Thompson PW
- PELL P *see* Sheldon P
- PEÑA AS *see* Janssen M
- Penylbutazone combination with misoprostol, neurosensory adverse effects, (L) 392
- PEPPELMAN WC, AGARWAL AK, KRAUS DR, EISENBEIS JR CH. Cervical spine surgery in rheumatoid arthritis: improvement of neurological deficit following cervical spine fusion, (A2) 96
- Peptide interactions with MHC class II molecules, (S2) 10
- Peptide-containing nerves in labial salivary glands in Sjögren's syndrome, (A1) 6
- PEPYS MB *see* Hawkins PN
- PÉREZ RUIZ F *see* Alonso-Ruiz A
- Pericardial tamponade and limited cutaneous systemic sclerosis, (L) 159
- PERIS P, LLENA J, GUAÑABENS N, HERRANZ R, PONS F, MONEGAL A, BRANCÓS MA, MUÑOZ-GÓMEZ J. Osteoporotic fracture of the sacrum, (A2) 92
- PERIS P, PARÉS A, GUAÑABENS N, PONS F, MARTÍNEZ DE OSABA MJ, HERNÁNDEZ ME, CABALLERÍA J, RODÉS J, MUÑOZ-GÓMEZ J. Effect of abstinence on bone mass in chronic alcoholism, (A2) 94
- PERITT D *see* Barak V
- PERRETT D *see* Axon JMC; Herbert KE; Herbert LL; Jacobs RA
- PERRY GJ, GREGSON N, CHAN TM, CAMERON JS, FRAMPTON G. Western blot analysis of membrane epitopes recognised by anti-endothelial cell antibodies in SLE, (A2) 85
- PERRY GJ, *see also* Chan TM
- PERRY JD *see* Brown KA; Davies GR; Farrell AJ
- PERRY LA *see* Da Silva JAP; Hall GM
- PERSCHITTE K *see* Vancheeswaran R
- PETERMANN M *see* Zienis A
- PETERS A *see* Racadot E
- PETERS AM *see* Davies KA
- PETERS M *see* Helliwell P
- Pharmacological effects of a new antiarthritic agent IX 207-887, (S2) 75
- Pharmacology of Rapamycin: a new immunosuppressive agent, (S2) 62
- PHELAN M, BUCKNALL R, EDWARDS S. Effect of sulphasalazine on reactive oxidant generation by neutrophils, (A2) 41
- PHELAN M, CAMPBELL A, BYRNE J, LYNCH M. Profile of the rheumatology nurse specialist in the United Kingdom, (A2) 105
- PHELAN M, ORME M, WILLIAMS E, THOMPSON RN. Effect of food on the pharmacokinetics of methotrexate in the treatment of rheumatoid arthritis, (A2) 37
- Phenotypic transformation of synovial cells in culture, (A2) 123
- Phthalylsulphathiazole in rheumatoid arthritis, (A1) 20
- Physical activity and osteoarthritis of the hip in men, (A2) 73
- PIAZZA I, GIUNTA G. Lytic bone lesions and polyarthritis associated with acne fulminans, 387
- PICÓ A *see* Pascual E
- PIELA T *see* Vancheeswaran R
- PILE KD, LAURENT MR, SALMOND CE, BEST MJ, PYLE EA, MOLONEY RO. Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements, 29
- PILE KD, WORDSWORTH BP, BELL JI. Class II heterozygote status contributes to RA susceptibility, (A2) 57
- PILLING D *see* Hassell AB
- PIRNER K *see* Bröker BM
- PITSILLIDES AA, ARCHER CW, WORRALL JG, BAYLISS MT, EDWARDS JCW. Uridine diphosphoglucose dehydrogenase activity and hyaluronan localisation at the site of joint cavitation in the embryo, (A2) 48
- PITSILLIDES AA, MEHDIZADEH S, WORRALL JG, WILKINSON LS, EDWARDS JCW. Demonstration of diphosphoglucose dehydrogenase activity in normal and rheumatoid synovial lining cells, (A1) 6
- PITSILLIDES AA, WILKINSON LS, WORRALL JG, BAYLISS MT, EDWARDS JCW. Assessment by microdensitometry of regional distribution of hyaluronan in normal and inflamed synovium, (A2) 123
- PITSILLIDES AA, WILKINSON LS, WORRALL JG, BAYLISS MT, EDWARDS JCW. Hyaluronan concentration in normal and rheumatoid synovium assessed by ELISA, (A2) 122
- PITSILLIDES AA, *see also* Wilkinson LS
- PTZALIS C *see* Kirkham BW
- Plasma levels of interleukin-1-alpha in rheumatoid arthritis, 295
- Plasma lipid peroxides: are they a mechanism of vascular lesion in systemic sclerosis, (A2) 38
- Plasmapheresis in the treatment of recalcitrant undifferentiated connective tissue disease, a case report, (S2) 92
- PLATER-ZYBERK C *see* Andrew EM; Williams RO
- PLUMPTON TA *see* Andrews HJ
- Pneumatosis intestinalis and pneumoperitoneum complicating mixed connective tissue disease, 146
- Pneumocystis carinii* pneumonia causing hypertrophic osteoarthropathy, (L) 476
- POLAK JM *see* Hukkanen M; Kontinen YT
- Polyarteritis, relationship between classical and microscopic, (A2) 88
- Polyarthritis, and lytic bone lesions associated with acne fulminans, 387
- Polychondritis, relapsing, treatment with chimaeric monoclonal antibodies, (A2) 10
- Polymorphonuclear cell activation in patients with Raynaud's phenomenon, (A2) 115
- Polymyalgia rheumatica
death from unsuspected diverticular disease in patients taking corticosteroids, (L) 159
- ESR, CRP, IL1 β and IL6 in, (A1) 24
- policy for weaning patients from corticosteroids, (CC) 34
- prevalence of hypothyroidism in patients, 349
- treatment: lower initial dose, (L) 393
- Pomponio G *see* Corveta A
- PONS F *see* Peris P
- POPE FM. Molecular analysis of Ehlers-Danlos syndrome type II, (E) 163
- PORTALES P *see* Wendling D
- PORTER DR, HUNTER JA, CAPELL HA. Double blind controlled trial of the addition of hydroxychloroquine or placebo to patients with a suboptimal response after 6 months of IM gold, (A2) 138
- PORTER DR, *see also* Capell HA

- Post menopausal screening for osteoporosis, (A2) 92
 Postgraduate training in rheumatology, (L) 65
 POSTON R *see* Farahat MNMR
 Potential role of B-lymphocytes in the pathogenesis of rheumatoid arthritis, (S1) 47
 POTOCNIK A *see* Bröker BM
 POUNTAIN G. Prevalence of rheumatoid arthritis in the Sultanate of Oman, 24
 POUNTAIN G, HAZLEMAN BL, CAWSTON TE. ESR, CRP, IL1 β and IL6 in polymyalgia rheumatica and giant cell arteritis, (A1) 24
 POUNTAIN G, *see also* Bhambhani MB
 POWELL R *see* Hopkinson N
 POWELL RJ *see* Pallis M
 Predictors of the long-term outcome of early synovitis: a 5-year follow-up study, 251
 Prednisolone
 effects on fibrinolytic activity and disease activity in rheumatoid arthritis, (A2) 35
 has a paradoxical effect on haemoglobin and erythropoietin concentrations in anaemic rheumatoid patients, (A2) 77
 Preferential activation of memory T cells by synovial antigen presenting cells in inflammatory arthritis, (A2) 8
 Preferential production of interleukin-8 in rheumatoid arthritis relationship to rheumatoid factors in vivo and inhibition by gold sodium thiomalate and methotrexate in vitro, (S2) 85
 Preliminary experience using MRI in the evaluation of acromegaly, (A1) 37
 Preliminary study of magnetic resonance relaxation times (T_1 and T_2) in inflammatory and degenerative synovial fluids, 464
 PRESTON SJ *see* Buchanan HM
 Prevalence of
 autonomic neuropathy in SLE, (A1) 22
 diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester City, (A1) 21
 gammadelta T cells and usage of TCR-V gene families in autoimmune disease, (S2) 97
 hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis, 349
 knee osteoarthritis in the general population using different criteria: the Chingford Study, (A2) 72
 rheumatoid arthritis in the Sultanate of Oman, 24
 PRICE LJ *see* Swann BP
 PRICE R, SINCLAIR H, HEINRICH I, GIBSON T. Local injection treatment of tennis elbow—hydrocortisone, triamcinolone and lignocaine compared, 39
 PRIESTLEY L, FERGUSSON C, OGILVIE D, WORDSWORTH P, SMITH R, PATRICK M, DOHERTY M, SYKES B. Limited association of generalized osteoarthritis with alleles at the type II collagen locus: COL2A1, 272
 Primary fibromyalgia
 and the irritable bowel syndrome: different expressions of a common pathogenetic process, 220
 syndrome—an outcome study, (A2) 80
 Primary Raynaud's phenomenon in early childhood, 223
 Primary selection for particular DR4 subtypes accounts for the HLA-DQw7 association with Fely's syndrome, (A2) 56
 Primary sequence and an amino acid sequence polymorphism of the Goodpasture antigen, (A2) 82
 Primary Sjögren's syndrome in north east England—a longitudinal study, 437
 PRINSEN CFM *see* de Vries N
 Prior score availability: observations using the WOMAC Osteoarthritis Index, (L) 150
 PRITCHARD MH *see* Camilleri JP
 Production of interferon-gamma and interleukin-2 by activated T-cell clones is synergistically inhibited by cyclosporine and chloroquine, (A2) 109
 Profile of the rheumatology nurse specialist in the United Kingdom, (A2) 105
 Prognosis of systemic sclerosis associated with fibrosing alveolitis: a comparison with lone cryptogenic fibrosing alveolitis, (A1) 24
 Prolactin
 as neuroimmune peptide, 203
 role in autoimmune and autoimmunity, (L) 476
 Prosthetic joint failure, deposition of debris from TiAlV alloy leading to, (A2) 116
Proteus, failure to isolate in the urine of rheumatoid arthritis patients more frequently than controls, (A2) 3
 Provision of medical and community services to people with severe arthritis: an audit, 356
 Psoriasis
 association with HLA-Cw6 detected by polymerase chain reaction, (A1) 10
 immunohistochemical markers for arthritis, (A2) 10
 re-evaluation of the osteoarticular manifestations, 339
 Psoriatic arthritis
 analysis of the immunohistological features of the synovial membrane and comparison with rheumatoid arthritis, (A1) 8
 association with HLA-Cw6 detected by polymerase chain reaction, (A1) 10
 a clinical, immunological and radiological study of 180 patients, 245
 immunohistochemical features of the synovial membrane compared to rheumatoid arthritis, (A2) 67
 mechanisms of joint sparing in a hemiplegic patient, (A2) 52
 rheumatoid-like, sex differences in, (A1) 28
 Psoriatic spondylitis presenting as chronic torticollis, (L) 478
 PUGH CW *see* Hawkins PN
 PULLAR T. Combination therapy in rheumatoid arthritis, (L) 311
 PULLAR T. Interpretation of trials—the other side, (L) 237
 PULLAR T, *see also* Gough SCL; Kay E; Kendall R
 Pulmonary function tests in rheumatoid arthritis: a double blind study of azathioprine and methotrexate, (A2) 99
 PUN YLW, RUSSELL DM, TAGGART GJ, BARRACLOUGH DRE. Pneumato-sis intestinalis and pneumoperitoneum complicating mixed connective tissue disease, 146
 PURDIE DW *see* Doherty SM
 Purification of proteinase 3 and its reactivity with sera from patients with Wegener's granulomatosis and microscopic polyarteritis, (A2) 83
 PUSEY CD *see* Beynon HLC; de'Oliveira J; Gaskin G; Turner N
 PYERITZ R *see* Grahame R
 PYLE C *see* Foster HE
 PYLE EA *see* Pile KD
 Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon, 190
 Quantitation of
 granulocyte migration with rheumatoid arthritis in response to intra-articular steroid injection using pure 111 In-labelled granulocytes, (A1) 26
 HLA class I in ankylosing spondylitis, (A1) 10
 Quantitative NMR-microscopy of the progression of antigen-induced arthritis in the rabbit knee, (A1) 35
 Questionnaire, validation of new, devised to measure neck pain and disability, (A1) 2
 QUIROZ-MERCADO H *see* Kraus A
 RACADOT E, WIJENES J, WENDLING D, GIRARD A, LIENARD A, PETERS A. Immunological follow up of 13 patients with rheumatoid arthritis treated by anti-T CD4+ monoclonal antibodies, (S2) 88
 RACADOT E, *see also* Wendling D
 Radiographic patterns of knee osteoarthritis in the community: the importance of the patello-femoral joint, (A2) 71
 Radiological progression of OA: an 11 year follow-up study of the knee, (A2) 72
 Radionuclide angiography, (L) 477
 RAINSFORD KD. Uncoupling the toxicological morass in the development of new antirheumatic drugs—is there any hope, (E) 161
 Raised levels of von Willebrand factor antigen in ankylosing spondylitis, (A2) 36
 RALSTON AJ *see* Hay EM
 RAMOS A, DE LA HERA M, ALONSO JL, MERINO J. B cell chimerism reduction as a major mechanism for the self-limitation of the lupus-like syndrome developed in mice neonatally tolerized to alloantigens, (A2) 12
 RAMPTON DS *see* Davies GR; Wilkie ME
 RANZA R *see* Sakkas LI
 Rapamycin pharmacology: a new immunosuppressive agent, (S2) 62
 Rapid processing of an N-terminal fragment of link protein by human monocytes, (A2) 132
 Rapidly progressive aortic valve incompetence in a patient with rheumatoid arthritis, 379
 RASKER JJ. Rheumatology manpower in the 1990s, in the Netherlands, (L) 234
 RASKER JJ, *see also* Jacobs JWG
 RAVIRAJAN C, WATTS R, YOUNOU P, ISENBURG D. Overexpression of a common DNA antibody idotype BEG-2 β in the families of patients with rheumatoid arthritis but not SLE, (A2) 14
 RAVIRAJAN C, *see also* Longhurst C
 RAWSON MH *see* Moore EA
 Raynaud's phenomenon
 comparison of three methods for clinical assessment, (A2) 28
 factor VIII von Willebrand factor antigen levels correlate with symptoms severity in patients, 433
 further evidence of a polymorphonuclear cell activation, (A2) 115
 primary, in early childhood, 223
 pyroelectric vidicon thermography and cold challenge quantify the severity, 190

- successful treatment with limaprost, an oral prostaglandin E₁ analogue, (L) 317
- Re-evaluation of the osteoarticular manifestations of psoriasis, 339
- Reactive arthritis
- absence of a class I MHC-restricted pathogen-specific T cell response in the synovial fluid, (A2) 67
 - after episode of salmonella enteritis, associated sterile urethritis, (CC) 140
- Receptor expression in synovial fluid neutrophils, (A1) 14
- Reclassifying adult rheumatoid arthritis, (L) 152
- Recovery of anterior spinal artery syndrome in a patient with systemic lupus erythematosus and antiphospholipid antibodies, (L) 314
- REDMOND U see Foley-Nolan D
- Reduction
- or elimination of rheumatoid arthritis by an IL-1 inhibitor, (S2) 84
 - in Tyb cell numbers and alteration in subset distribution in systemic lupus erythematosus, (A2) 13
- REED C see Clauw DJ
- REES AJ see Beynon HLC; de'Oliveira J; Gaskin G; Turner N
- REES RG, BISWAS S, BREWERTON DA, LIGHTMAN SL. Elevated neuropeptide levels in patients with algodystrophy, (A2) 64
- REES RG, see also Harbuz MS; Hukkanen M
- REGAN M see Jones AC; Ledingham J
- Regenerative joint disease, (E) 322
- REGINELLI R see Danieli MG
- Regulation of collagen synthesis and contraction of collagen gels is impaired in scleroderma fibroblasts, (A2) 145
- REICHLIN M. Molecular definition of the Ro(SSA) particles: a frequent target of autoimmunity in systemic lupus erythematosus and Sjögren's syndrome, (S1) 58
- REID DM see Garton MJ
- REILLY PA, LITTLEJOHN GO. Diurnal variation in the symptoms and signs of the fibrositis/fibromyalgia syndrome, (A2) 96
- Relationship
- of ANCA specificity and concentration to disease activity in patients with systemic vasculitis, (A2) 84
 - between classical and microscopic polyarthritis, (A2) 88
 - between osteoarthritis and osteoporosis in the general population: the Chingford Study, (A2) 55
 - between range of movement of joints and disability, (A1) 4
 - between rheumatological diseases of man, pet dogs and their viruses, (L) 393
 - of CD44 to hyaluronan in rheumatoid nodule, (A1) 12
 - of clinical and laboratory measurements to radiological change in ankylosing spondylitis, 330
 - of fibrinolytic activity to disease activity in rheumatoid arthritis, (A1) 25
- REMMERS EF see Wilder RL
- Renal microaneurysms in rheumatoid arthritis, (L) 235
- Renal tubular dysfunction in rheumatic diseases, 115
- Report of Senior Registrar's UK Travelling Fellowship London, 22-26 October 1990, 405
- Resistance to collagen-induced arthritis in rhesus monkeys: MHC antigens, CD8+ cells and IL2 determine T cell low responsiveness, (S2) 99
- RESSE M see Valentini G
- Results of long-term follow-up of the toxic oil syndrome, (A2) 29
- REVELL PA see Lalor PA
- Reversal of peripheral blood T cell anergy to bacterial antigens on recovery from acute reactive arthritis, (A1) 15
- REY B see Gerber NJ
- REYES PA see Khamashta MA
- REYNOLDS D see Hassell AB
- REYNOLDS JJ see Murphy G
- Rheumatic disease
- are retroviruses involved in the aetiology, (S1) 63
 - immune response to autoantigens and viruses in, (S1) 70
- Rheumatoid arthritis
- synovial microvasculature, increased expression of endothelial cell adhesion molecules *in vitro*, (A1) 13
- Rheumatoid arthritis
- abnormal fibrinolytic response in patients complicated by vasculitis, (A2) 34
 - accelerated nodulosis during low dose methotrexate therapy, (A2) 2
 - anaerobic metabolism: elucidation of its role in rheumatoid and osteo-arthritis by high field nuclear magnetic resonance imaging spectroscopy: evidence for hypoxic metabolism in rheumatoid arthritis, (A1) 32
 - analysis of cysteine/sulphate metabolism confirms defective sulphoxidation, (A2) 113
 - anti-Proteus antibodies in: a longitudinal and clinical study, (A1) 17
 - antibodies to HSP65 in twin pairs, (A2) 69
 - antibodies to *Proteus*, (L) 390
 - assessing activity with radiolabelled leucocytes, (A1) 25
 - associated pulmonary disease, high definition computed tomography, 214
 - association of a T-cell receptor β -chain variable region restriction fragment length polymorphism with outcome, (A2) 31
 - auranofin rashes, (A1) 20
 - before the 1870s, (A2) 65
 - benefit in social and physical function produced by early treatment, (A2) 99
 - bicentric open study of treatment with monoclonal CD4 antibody, clinical and immunological results, (S2) 87
 - bilateral iliopsoas bursitis in, (L) 68
 - bone mineral content in patients: relationship to low-dose steroid therapy, 86
 - bone mineral density: influence of functional capacity and disease activity, (A2) 52
 - C4 null alleles as a marker of drug toxicity to D-penicillamine and gold, (A2) 32
 - can genetic factors predict erosions, (A2) 31
 - cervical spine surgery: improvement of neurological deficit following cervical spine fusion, (A2) 96
 - changes in serum interleukin-6 following intramuscular gold treatment, (S2) 99
 - characterization of anti endothelial cell antibodies in systemic lupus erythematosus and rheumatoid arthritis complicated by vasculitis, (A2) 134
 - chimaeric (human/mouse) CD7 monoclonal antibody treatment, (S2) 88
 - circadian variations in the superoxide production, enzyme release and neutrophil aggregation in patients and controls, 138
 - class II heterozygote status contributes to RA susceptibility, (A2) 57
 - collagenase reserves in synovial fluid neutrophils, (A2) 128
 - combination therapy, (L) 311
 - combined studies of second line therapy from a single centre: an analysis of 1344 patients, (A2) 100
 - comparison of the efficacy of hydrotherapy and seated immersion, (A2) 76
 - cytokine expression, (S1) 76
 - cytokine network in, (S2) 44
 - cytokines and the acute phase response, (A2) 6
 - development and use of a patient knowledge questionnaire, 45
 - disease course and outcome, (A2) 98
 - DNA analysis of HLA class II polymorphisms in Greek patients, (S2) 97
 - does gold therapy reduce non-steroidal peptic damage, (A2) 139
 - effect of food on the pharmacokinetics of methotrexate, (A2) 37
 - effect of prednisolone on fibrinolytic activity and disease activity, (A2) 35
 - effects of Maxepa on non-steroidal anti-inflammatory drug usage, (A2) 137
 - epitopes within the CB-11 peptide of type II collagen recognised by sera, (A2) 112
 - erythrocyte glutathione reductase activity and riboflavin status, (A2) 39
 - ESR spectroscopy of synovial fluid using the spin trap DBNBS demonstrates a reactive oxygen species which progressively increases after exercise, (A2) 132
 - evaluation of hand bone mineral measurement by dual-energy X-ray absorptiometry, (A2) 62
 - evening primrose oil in patients and side-effects of non-steroidal anti-inflammatory drugs, 370
 - examination of the cause of low testosterone levels in male rheumatoid patients, (A2) 36
 - examination of synovial vascular endothelium, (A1) 7
 - extracellular lipocortin-1 binding to leucocyte membranes is decreased in, (A2) 51
 - failure to isolate *Proteus* in the urine of patients more frequently than controls, (A2) 3
 - female patients have an older age of menarche than their non-RA sisters, (A2) 32
 - fish oil or snake oil, 72
 - genetics, (L) 319, (L) 476
 - genetics: the HLA shared epitope hypothesis and its implications, (S2) 6
 - glycoprotein 60 on peripheral blood lymphocytes, (A2) 109
 - gold treatment decreases synovial expression of the endothelial leucocyte adhesion receptor ELAM-1, (S2) 81
 - gold treatment diminishes synovial membrane cytokine expression, (A2) 6
 - and hairy cell leukaemia, (L) 391
 - HLA class II antigens in susceptibility to rheumatoid arthritis, (L) 151
 - HLA class II association, (A1) 11
 - HLA haplotype sharing in sibships, (A2) 59

- how important are responses to mycobacterial HSP65, (A2) 68
 humanized monoclonal antibody treatment, (S2) 89
 Ig CH and D14S1 variants in—linkage and association studies, 167
 immune response to mycobacterial heat shock protein 65 kD, (S2) 94
 immunisation of patients with mycobacterium vaccae: an open study of a novel therapeutic approach, (S2) 95
 immunopathogenesis, (S2) 3
 immunotherapy with antibodies neutralizing aberrant interferon- β , (S2) 86
 importance of diet, 125, (L) 315
 increased metacarpal bone mass following 18 months of slow-acting antirheumatic drugs, 91
 increased release of bone sialoprotein into synovial fluid reflects tissue destruction, (A2) 48
 influence of methotrexate and azathioprine on the radiologic progression, (A2) 2
 influence of misoprostol on non-steroidal anti-inflammatory drug-influenced intestinal damage and disease activity, (A2) 91
 influence of steroidhormones on proliferation of peripheral blood mononuclear cells, (A2) 108
 inhibition of natural killer cell cytotoxicity by the non-immune complex IgA-alpha-1-antitrypsin, (A2) 107
 lack of concordance for rheumatoid factor positivity in a nationwide study of twins, (A2) 58
 lack of disease similarity in monozygotic twins, (A2) 58
 laryngeal and ear involvement in, in North India, (L) 65
 leucocyte integrin and CR1 expression, (A1) 13
 limited heterogeneity of the HLA class II contribution to susceptibility is suggested by positive associations with HLA-DR4, DR1 and DRw10, 178
 longitudinal changes in serum cytidine deaminase correlate with clinical assessments of joint inflammation, (A1) 33
 loss of functional activity of synovial fluid α -1-antitrypsin correlates with disease activity as measured by serum C-reactive protein, (A2) 130
 low prevalence in a rural Nigerian population, (A2) 1
 lumbar bone mineral density: normal values in ambulant, non-steroid treated patients, (A2) 53
 magnetic resonance imaging in assessment—a comparison with plain film radiographs, 101
 methotrexate effects on clinical and immunological parameters in refractory disease: a prospective study, (L) 73
 metronidazole as a possible disease-modifying agent in the treatment: a double-blind placebo controlled study, (A2) 101
 monoclonal antibody treatment, (S2) 33
 monoclonal antibody treatment: the clinical and immunological effects of a CD7 monoclonal antibody, 459
 Mycobacterium vaccae immunisation as immunomodulatory therapy: preliminary results of an open study, (A2) 9
 natural killer cell cytotoxicity and alpha interferon levels, (A2) 108
 neuroendocrine-immune interactions in the pathogenesis: therapeutic implications, (S2) 96
 occurrence and significance of hand deformities, 211
 opinion of patients about their functional capacity, (A2) 97
 osteoporosis in—the clinical viewpoint, (E) 82
 osteoporosis in—the laboratory perspective, (E) 84
 outcome—different perspectives, 233
 overexpression of a common DNA antibody idotype BEG-2 β in the families of patients with rheumatoid arthritis but not SLE, (A2) 14
 P blood group phenotype anti-*Proteus* antibody titres, (A2) 3
 partial biochemical characterization of new cytokine activity (Ig2b inducing factor) from synovial fluid of patients with rheumatoid arthritis, (S2) 86
 patients on intramuscular gold have a decreased prevalence of *Helicobacter pylori* infections, (A2) 139
 phthalylsulphathiazole in, (A1) 20
 plasma levels of interleukin-1-alpha, 295
 post menopausal, sex/hormone levels and relationship with bone density, (A2) 93
 postmenopausal, bone density of the hip and spine and the effect of low dose steroids, (A2) 53
 potential role of B-lymphocytes in the pathogenesis, (S1) 47
 prednisolone has a paradoxical effect on haemoglobin and erythropoietin concentrations in anaemic patients, (A2) 77
 preferential production of interleukin-8, relationship to rheumatoid factors in vivo and inhibition by gold sodium thiomalate and methotrexate in vitro, (S2) 85
 prevalence in the Sultanate of Oman, 24
 pulmonary function tests: a double blind study of azathioprine and methotrexate, (A2) 99
 quantitation of granulocyte migration in response to intra-articular steroid injection using pure ¹¹¹In-labelled granulocytes, (A1) 26
 rapidly progressive aortic valve incompetence in a patient, 379
 reclassifying adult, (L) 152, (L) 153
 reduction or elimination by an IL-1 inhibitor, (S2) 84
 relationship of fibrinolytic activity to disease activity, (A1) 25
 renal microaneurysms, (L) 235
 in same-sexed sibships with and without evidence of thyroid abnormalities, (A1) 11
 selectivity of T-cell receptor variable region gene usage by rheumatoid arthritis synovial T-cells, (A2) 59
 septic arthritis as a non-surgical complication: relation to disease severity and therapy, 35
 serological evidence of infection with *Helicobacter pylori* may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug treatment, 16
 serum angiotensin converting enzyme activity is lower in patients than age and sex matched controls, (A2) 117
 serum erythropoietin response to anaemia, (A1) 26
 serum keratan sulphate and disease activity, (A1) 34
 serum zinc and copper, (A2) 117
 should disease-modifying agents be used in mild disease, 451
 soluble CD23 expression, (A2) 110
 suprascapular nerve block with marcain alone effectively controls chronic shoulder pain, (A2) 77
 susceptibility in southern Chinese is linked to HLA-DR4 and DRB third hypervariable region sequence, (A2) 57
 synovial fluid α -1-antitrypsin is inactivated by exercise, (A2) 50
 synovial membrane, co-localisation of tumour necrosis factor α and its receptor, (A2) 7
 synovial tissue, immunolocalisation of GM-CSF, (A2) 7
 T cell vaccination, (S2) 28
 T-cell receptor V β repertoire in the joints of patients, (A1) 14
 T $\gamma\delta$ cells and their subsets in blood and synovial fluid, (A2) 13
 transferrin C subtypes in patients, 21
 treatment by murine antidiotype monoclonal antibodies to a syn- genetic anti-HLA class II monoclonal antibody, (S2) 90
 treatment of fixed flexion deformities of the knee using the flowtron inflatable splint, (A1) 27
 unspecific accumulation of anti-CD4 antibodies and negative signalling but not modulation of the CD4-molecule may contribute to the efficacy of anti-CD4 treatment, (S2) 100
 use of the air cast ankle support brace for subtalar joint instability. Analysis using a gait and balance laboratory, (A1) 27
 utility of the 1987 revised ARA criteria in early synovitis, (L) 319
 Rheumatoid disease, immunogenetic heterogeneity in, as illustrated by different MHC associations (DQ, Dw and C4) in articular and extra-articular subsets, 5
 Rheumatoid diseases, 474
 Rheumatoid factor production and circulating CD5+ B lymphocytes during bacterial infections, (A2) 5
 Rheumatoid monocytes exhibit abnormal adherence characteristics to cultures of cytokine-treated and untreated vascular endothelium, (A2) 106
 Rheumatoid mononuclear cell binding to high endothelial cells of mucosal origin, (A2) 106
 Rheumatoid synovial fluid mononuclear cells, 65kD heat-shock protein can activate to inhibit cartilage proteoglycan synthesis, (A2) 8
 Rheumatoid synovial neutrophils, single cell imaging reveals abnormal intracellular calcium signals, 443
 Rheumatoid synovocyte proliferation and fibronectin secretion, (A2) 120
 Rheumatological diseases of man, relationship with pet dogs and their viruses, (L) 393
 Rheumatological journals, study designs and statistical methods: an international comparison, 352
 Rheumatological screening history and examination, (A1) 1
 Rheumatologists, patient referrals, 285
 Rheumatology
 clinics, audit of new patient referrals, (A2) 104
 curriculum for medical students, 123
 nurse specialist in the United Kingdom, (A2) 105
 practice, European audit, (A2) 103
 referrals to a district general hospital, (A2) 104
 services, contracting for, 200
 Rheumatology manpower in the 1990s, 119
 in Canada, (L) 234
 in the Netherlands, (L) 234
 Rheumatology manpower
 —the US perspective, (E) 81
 in Australia, (L) 316
 RICCIATTI AM see Danielli MG; Gabrielli A
 RICE PJ see Gough SCL
 RICHARDSON K see Gado K; Luqmani RA
 RICHARDSON S see Hawkins PN

- RIDDERSTAD A *see* Abedi-Valgerdi M
 RIESTRA NORIEGA JL *see* Torre Alonso JC
 RIETHMULLER G *see* Jonker M
 RIFKIN IR, FUJIMOTO T, LOCKWOOD CM. Anti-neutrophil cytoplasm antibodies (ANCA) stimulate neutrophils by activating protein kinase C, (A2) 84
 RIGBY AS. Ankylosing spondylitis, 50
 RIGBY AS. HLA haplotype sharing in rheumatoid arthritis sibships, (A2) 59
 RIGBY AS, SILMAN AJ. Outcome assessment in clinical trials of ankylosing spondylitis, (E) 321
 RIGBY AS, *see also* Croft PR; Papageorgiou AC
 RILEY G, CHARD M, CAWSTON TE, HAZLEMAN BL. Rotator cuff tendinitis: changes in matrix composition associated with tendon pathology, (A1) 34
 RILEY GP, HARRALL RL, CAWSTON TE, CHARD MD, HAZLEMAN BL. Changes in glycosaminoglycan composition of adult human supraspinatus tendon, (A2) 79
 RING F *see* Knight SM
 Risk, acceptable, what do patients and rheumatologists regard as an acceptable risk in the treatment of rheumatic disease, (L) 318
 RIVERA F *see* Carro A
 ROBERTS B *see* Sivakumaran M
 ROBERTS DF *see* Deighton CM
 ROBINSON JJ *see* Watson F
 ROBINSON M *see* Gado K; Luqmani RA
 ROBSON DK *see* Pallis M
 RODDY J *see* Kyle V
 RODÉS J *see* Peris P
 RODRÍGUEZ MD *see* Muniain MA
 RODRÍGUEZ PEREZ A *see* Torre Alonso JC
 ROFFE C, CAHILL MR, SAMANTA A, BRICKNELL S, DURRANT STS. Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism, 301
 ROGERS S *see* Veale D
 ROHOLL PJM *see* Nietfeld JJ
 Role
 for IL-6 in the interaction of IL-1 and human articular cartilage, (A2) 125
 of prolactin in autoimmune and autoimmunity, (L) 476
 of TNF α , in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage, 265
 Rolfe I, Doyle DV, Denton A, Spector TD, Segal A, Corless W, Closkey EV. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis, (A2) 56
 ROMAGNOLI P *see* Verwilghen J
 ROMÁN J *see* Carro A
 ROMANO TJ. Efficacy of plasmapheresis in the treatment of recalcitrant undifferentiated connective tissue disease, a case report, (S2) 92
 ROMERO A *see* Khamashta MA; Muniain MA
 ROOK G *see* Worrall JG
 ROOK GAW *see* Sinclair HD; Thompson SJ
 ROSAS J *see* Carro A; Salinas M
 ROSE S *see* Kontinen YT
 ROSENBERG WCM *see* Wordsworth BP
 ROSS A *see* Knight SM
 ROSS CN *see* Beynon HLC
 ROSSMANN C *see* Bröker BM
 ROSSOUW D *see* David J
 Rotator cuff tendinitis
 changes in matrix composition associated with tendon pathology, (A1) 34
 thermographic imaging, (A2) 79
 ROTH JH *see* Bellamy N
 ROUND J *see* Worrall JG
 ROUSSEAU E, GORDON J, SYKES C, FARR M, LUQMANI R, SHEERAN T, BACON PA, EMERY P. Soluble CD23 expression in patients with rheumatoid arthritis, (A2) 110
 ROUTIER R *see* Botto M
 ROWE IF *see* Hughes RA
 ROY S *see* Samanta A
 RUBIN K *see* McWhirter A
 RUBINSTEIN HM. Osteoporosis in ankylosing spondylitis, (L) 160
 RUCH W *see* Mackenzie AR
 RUIZ MT, ALVAREZ-DARDET C, VELA P, PASCUAL E. Study designs and statistical methods in rheumatological journals: an international comparison, 352
 RUIZ MT, *see also* Pascual E
 RUSSELL DM *see* Pun YLW
 RUSSELL IT *see* Garton MJ
 RUSSELL RGG *see* Peel NFA
 RUSSELL RI *see* Taha AS
 RYAN JJ *see* Gaskin G
 RYAN M *see* Foley-Nolan D
 RYAN PJ, FOGELMAN I. Post menopausal screening for osteoporosis, (A2) 92
 RYAN PJ, GIBSON T, FOGELMAN I. Bone scintigraphy following intravenous pamidronate for Paget's disease, (A2) 63
 RYAN PJ, HARRISON R, FOGELMAN I. Compliance with hormonal replacement therapy after screening for post menopausal osteoporosis, (A2) 94
 RYDGREN L *see* Eberhardt K
 SAARI H *see* Hukkanen M; Kontinen Y; Kontinen Y
 SABHARWAL S *see* Kirkham BW
 SAKKAS LI, MARCHESONI A, KERR L-A, RANZA R, COLOMBO B, WELSH KI, PANAYI GS. Immunoglobulin heavy chain gene polymorphisms in Italian patients with psoriasis and psoriatic arthritis, 449
 SAKKAS LI, VAUGHAN RW, PANAYI GS, WELSH KI. Association of psoriatic arthritis and psoriasis with HLA-Cw6 detected by polymerase chain reaction, (A1) 10
 SALINAS M, MATEO E, ROSAS J, IVORRA J, MANERO H, PASCUAL E. Comparison of manual and automated cell counts in synovial fluid. Storage has little influence in the result of the cell counts, (A2) 130
 SALMON M *see* Emery P
 SALMOND CE *see* Pile KD
 SAMANTA A, ROY S, SYMMONS DPM, FEEHALLY J. Prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester City, (A1) 21
 SAMANTA A, *see also* Roffe C
 SANCHEZ-ECHEVERRI G *see* Kraus A
 SANDERS P *see* Clarkson RWE
 SANDERS PA. Haemarthrosis associated with thrombolytic therapy, (L) 236
 SANDERS PA, HAY EM. Report of Senior Registrar's UK Travelling Fellowship London, 22-26 October 1990, 405
 SANDERS PA, *see also* Hillarby MC; McMahon MJ; Sidebottom D
 SANDILANDS GP *see* Davidson JE
 SANO H *see* Wilder RL
 SANSOM D *see* Lanchbury J
 SANTAVIRTA S *see* Kontinen Y; Kontinen YT
 SANY J *see* Wendling D
 SAREMBOCK BD *see* Hift RJ
 SAXNE T, HEINEGÅRD D. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis, (A2) 48
 SAXNE T, *see also* Heinegård D
 SCANE TMN *see* Hicklin JA
 SCHNYDER J *see* Mackenzie AR
 SCHUURS AHWM *see* Verheul HAM
 Sciatica
 and back pain cause may be a venous matter too, (L) 70
 caused by isolated non-Hodgkin's lymphoma of the spinal epidural space: a report in two cases, 385
 Scleroderma, 365
 in childhood, (A2) 75
 defects of the retinal pigment epithelium, 112
 effects of methotrexate on glycosaminoglycan production of cultured fibroblasts from scleroderma patients and healthy controls: preliminary results, (A2) 133
 histopathological assessment of factor XIIIa and HLADR positive cells in skin biopsies, (A2) 46
 lack of influence of known environmental factors on the occurrence in males, (A2) 29
 Lyme disease and—no evidence for a common aetiology, (L) 154
 regulation of collagen synthesis and contraction of collagen gels is impaired in fibroblasts, (A2) 145
 Southern blot analysis of HLA-DP polymorphisms, (A1) 9
 SCOTT DGI. Antinuclear cytoplasmic antibody (ANCA) in pursuing cause of vasculitis, (CC) 254
 SCOTT DGI, *see also* Blann AD
 SCOTT DL. Inflammatory arthritis, with pitting oedema of ankles, indications for venography, (CC) 355
 SCOTT DL, BARDHAN KD, BJARNASSON I, GRIFFIN WM, FENN GC, SHIELD MJ. Misoprostol and non-steroidal anti-inflammatory drug-associated gastro-duodenal damage, (A2) 5
 SCOTT DL, BOURKE B, HASLOCK I, BAILLIE K. Contracting for rheumatology services, 200
 SCOTT DL, *see also* Axon JMC; Colville-Nash PR; Da Silva JAP; Dacre JE; Herbert KE; Herbert LL; Jacobs RA; Moore AR; Spector TD; Storey GO; Waller HA; Woodward L
 SCOTT T *see* Merry P
 SEBASTIANI GD. Anticardiolipin antibodies: their relationship with HLA-DR antigens in systemic lupus erythematosus, (L) 156
 SEGAL A *see* Rolfe I
 SEGERBERG M *see* Honkanen V; Hukkanen M
 SEGILAS J, LI E, WONG R, SO AK. Susceptibility to rheumatoid arthritis in

- southern Chinese is linked to HLA-DR4 and DRB third hypervariable region sequence, (A2) 57
- Segregation analysis of the structural genes of the major fibrillar collagens provides further evidence of molecular heterogeneity in type II Ehlers-Danlos syndrome, 173
- SEHGAL SN *see* Chang JY
- SEITZ M, DEWALD B, GERBER N, BAGGIOLINI M. Preferential production of interleukin-8 in rheumatoid arthritis relationship to rheumatoid factors in vivo and inhibition by gold sodium thiomalate and methotrexate in vitro, (S2) 85
- Selective suppression of IgM antibody production protects type II collagen-immunized rats to arthritis, (S2) 92
- Selectivity of T-cell receptor variable region gene usage by rheumatoid arthritis synovial T-cells, (A2) 59
- Senior Registrar's UK Travelling Fellowship London, 22-26 October 1990, 405
- Septic arthritis as a non-surgical complication in rheumatoid arthritis: relation to disease severity and therapy, 35
- Septic bone, joint and muscle lesions associated with human immunodeficiency virus infection, (A1) 38
- Serological evidence of infection with *Helicobacter pylori* may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis, 16
- Serum
- angiotensin converting enzyme activity is lower in rheumatoid arthritis patients than age and sex matched controls, (A2) 117
 - erythropoietin response to anaemia in rheumatoid arthritis, (A1) 26
 - keratan sulphate and disease activity in rheumatoid arthritis, (A1) 34
 - levels of hyaluronic acid correlate with disease activity during adjuvant arthritis, (A2) 143
 - zinc and copper in rheumatoid arthritis, (A2) 117
- SETHI D *see* Hawkins PN
- SETTIN A *see* Hafez M
- Severe lupus crisis with agranulocytosis and anuric renal failure due to a mesangial lesion (WHO IIB)—successful treatment with cyclophosphamide pulse followed by plasmapheresis, (L) 312
- Severe thrombocytopenia associated with auranofin: evidence for immunological mechanism with peripheral destruction in the spleen, (L) 75
- Sex
- hormone levels in post menopausal rheumatoid arthritis and relationship with bone density, (A2) 93
 - ratio in spondylarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset, (A1) 28
 - steroids effects on cartilage damage, (A1) 37
- Sex differences
- in cartilage damage using an *in vivo* model, (A2) 127
 - in rheumatoid-like psoriatic arthritis, (A1) 28
- SHADFORTH MF *see* Davis MJ
- SHANSON D *see* Hughes RA
- SHARIF M *see* Sinclair HD; Worrall JG
- SHARP CA *see* Butler RC
- SHARROCK C *see* Hunt K
- SHATTLES W *see* Merry P
- SHATTLES WG *see* Brookes SM
- SHAWE DJ, GUMPEL JM, BADDERLY H. Magnetic resonance imaging in pigmented villonodular synovitis, (A1) 36
- SHEASHAA A *see* Hafez M
- SHEEHAN NJ *see* Amos RS
- SHEERAN T, NAYAK U, CLARKE R, ISSACS B, JUBB R, EMERY P. Use of the air cast ankle support brace for subtalar joint instability in patients with rheumatoid arthritis. Analysis using a gait and balance laboratory, (A1) 27
- SHEERAN T, *see also* Gado K; Rousseau E
- SHEERAN TP *see* Blann AD; Luqmani RA
- SHELDON P, PELL P. Effect of sulphasalazine on in vivo antibody response to orally administered antigen—evidence for an effect on the mucosal immune system, (A2) 4
- SHELDON P, *see also* Kadioglu A
- SHENSTONE B *see* Herrero-Beaumont G; Knight SM
- SHIELD MJ *see* Scott DL
- SHOENFELD Y, BLANK M, BEN-BASSAT M. Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA idiotype, (S2) 93
- Short term outcome of musculoskeletal complaints in instrumental musicians, (A2) 81
- SHORTER J *see* James MF
- SHORTER JH *see* Muxlow NJ
- SHOTLIFF K *see* Bowness P
- Should disease-modifying agents be used in mild rheumatoid arthritis, 451
- Shoulder
- pain, chronic, inflammation of the subacromial bursa, (A2) 42
 - problems, natural history of in primary care, (A2) 78
- Sialoprotein, bone, increased release into synovial fluid reflects tissue destruction in rheumatoid arthritis, (A2) 48
- SIDEBOTTOM D, GRENNAN DM, GREEN JR, SANDERS PA, OLLIER W, DE LANGE G. Ig CH and D14S1 variants in rheumatoid arthritis—linkage and association studies, 167
- SILLS J *see* Symmons DPM
- SILMAN A, JONES S, COGGER D. Lack of influence of known environmental factors on the occurrence of scleroderma in males, (A2) 29
- SILMAN A, *see also* Brennan P; Worthington J
- SILMAN AJ *see* Holligan S; MacGregor AJ; Rigby AS; Williams GH
- SILVA S *see* Jones AKP
- SILVERMAN GJ *see* Carson DA
- SIMÉON CP *see* Lima J
- SINCLAIR H *see* Price R
- SINCLAIR HD, ERKELLER-YUKSEL F, SHARIF M, ROOK GAW, LYDYARD PM, ISENBERG DA, STANFORD JL. Mycobacterium vaccae immunisation as immunomodulatory therapy in rheumatoid arthritis: preliminary results of an open study, (A2) 9
- SINCLAIR HD, SHARIF M, ROOK GAW, ISENBERG DA, STANFORD JL. Immunisation of rheumatoid arthritis patients with mycobacterium vaccae: an open study of a novel therapeutic approach, (S2) 95
- SINGARAYER C, VANCHEESWARAN R, KHOKHER MA. Effects of anti-inflammatory drugs on human osteoblast metabolism, (A2) 47
- SINGH D, NAZHAT NB, FREEMAN MAR, BLAKE DR. In-vitro assessment of hypoxic-reperfusion injury in inflamed and non-inflamed synovial tissue using electric spin resonance, (A2) 40
- SINGH YN. Methotrexate effects on clinical and immunological parameters in refractory rheumatoid arthritis: a prospective study, (L) 73
- Single cell imaging reveals abnormal intracellular calcium signals within rheumatoid synovial neutrophils, 443
- SITUNAYAKE RD, THURNHAM DI, DAVIS M, DAVIS J, MCCONKEY B. Erythrocyte glutathione reductase activity and riboflavin status in rheumatoid arthritis, (A2) 39
- SIVAKUMARAN M, SNOWDEN N, ROBERTS B, SWINSON DR, BHAVNANI M, STEWART A. Heterogeneity of T cell receptor gene rearrangement in patients with granular lymphocyte proliferation, neutropenia and polyarthropathy, (A1) 15
- Sjögren's syndrome
- autoantibodies and thyroid disease in a family study, (A1) 17
 - correlation of serum IgG1 with biopsy findings, (A1) 18
 - cranial MRI, (A2) 25
 - ELISA of anti-La but not anti-Ro correlates with total serum IgG1 and degree of salivary gland infiltration, (A2) 24
 - influence on Vβ6.7 T cell receptor gene expression, (A2) 136
 - long-term follow-up, (A2) 25
 - molecular definition of the Ro(SSA) particles: a frequent target of autoimmunity, (S1) 58
 - peptide-containing nerves in labial salivary glands, (A1) 6
 - primary, in north east England—a longitudinal study, 437
 - von Willebrand factor antigen in, (A2) 23
- SK&F 105685
- induction of non-specific suppressor cells and myeloregulatory effects of an anti-arthritis azaspirane, (S2) 82
 - a novel suppressor cell-inducing compound, effects in the adjuvant arthritic rat, (S2) 66
 - a novel suppressor cell-inducing compound, effects on disease parameters in the adjuvant arthritis rat, (S2) 82
- SKEVINGTON S *see* Hall J
- SKINGLE S *see* Patel U
- SKINGLE SJ *see* Bhambhani MB
- SKURKOVICH B *see* Skurkovich S
- SKURKOVICH S, SKURKOVICH B. Immunotherapy of acute rheumatoid arthritis with antibodies neutralizing aberrant interferon-alpha, (S2) 86
- SLINGERLAND W *see* Jonker M
- SMEATHERS J *see* Swanepoel M
- SMITH AG *see* Wilkinson SM
- SMITH CF *see* Arend WP
- SMITH CR, HERON CW, BOWMAN S, PAICE E, WHITE AG. Magnetic resonance imaging of the carpal tunnel before and after treatment for carpal tunnel syndrome, (A2) 61
- SMITH E *see* Merry P
- SMITH G, JAMES V, BLACKWELL CC, WEIR DM, NUKI G. Ankylosing spondylitis and secretor status—a reappraisal, (A2) 4
- SMITH JL *see* Howell CJ
- SMITH MA *see* Hordon LD
- SMITH PR *see* Kalla AA
- SMITH R *see* Priestley L
- SNATH M *see* Hay EM; Leaker B
- SNATH ML. Systemic lupus erythematosus, renal involvement with proteinuria and active urinary sediment, (CC) 281
- Snake oil in rheumatoid arthritis cure, (L) 72

- SNOW S *see* McAlindon TE
 SNOW SM *see* Kirwan JR
 SNOWDEN N *see* Sivakumaran M
 So AK *see* Botto M; Lunardi C; Marguerie C; Seglias J
 So AKL *see* Harner IJ
 Socioeconomic influences on the occurrence of common musculoskeletal problems, (A2) 102
 SOKHI RS *see* Bradley H
 Soluble CD23 expression in patients with rheumatoid arthritis, (A2) 110
 SORSA T *see* Hukkanen M; Kontinen Y; Kontinen YT
 Southern blot analysis of HLA-DP polymorphisms in scleroderma patients, (A1) 9
 SOUTHWOOD TR *see* Symmons DPM
 SPECTOR TD, DACRE JE, HARRIS PA, HUSKISSON EC. Radiological progression of OA: an 11 year follow-up study of the knee, (A2) 72
 SPECTOR TD, DACRE JE, WOODWARD L, HARRIS PA, SCOTT DL, HUSKISSON EC. Keratan sulphate as a marker of progression of knee OA, (A2) 118
 SPECTOR TD, McCLOSKEY EV, KANIS JA, DOYLE DV. Epidemiology of vertebral fractures in the general population: the Chingford Study, (A2) 91
 SPECTOR TD, *see also* Da Silva JAP; Hall GM; Hart DJ; Rolfe I; Woodward L
 Spectrum of disease associated with a positive ANCA, (A1) 16
 SPEIGHT P *see* Blanco F
 Spinal trabecular bone density by lateral dual energy X-ray absorptiometry in ankylosing spondylitis, (A1) 29
 Splenic localisation of immune complexes is complement dependent, (A2) 136
 Spondarthropathies, HLA-B27 subtypes in, (A2) 33
 Spondylarthropathies, sex ratio in and its relationship to phenotypic expression, mode of inheritance and age at onset, (A1) 28
 SPRINGALL DR *see* Hukkanen M
 STACK JP *see* Foley-Nolan D
 STAINES NA. Oral tolerance and collagen arthritis, (S2) 40
 STAITE ND *see* Aspar DG
 STANFORD J *see* Thompson SJ
 STANFORD JL *see* Sinclair HD
 STANWORTH DR *see* Close DR; Davis MJ
 STEDEFORD J *see* Wordsworth BP
 STEINMETZ M, UEMATSU Y. Heterogeneity of T cell repertoires in human autoimmune disease, (S2) 24
 STEINSSON K *see* Davies KA
 STEPHENS CO, HALL MA, BRIGGS DC, WELSH KI, BLACK CM. Southern blot analysis of HLA-DP polymorphisms in scleroderma patients, (A1) 9
 STEPHENS CO, *see also* Whyte J
 Steroid hormones influence on proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis, (A2) 108
 Steroids in early rheumatoid disease: no long term impact when given with sulphasalazine, (A2) 140
 STEVENS C *see* Merry P
 STEVENS CR *see* Abbot SE
 STEWART A *see* Sivakumaran M
 STEWART OJ *see* Symmons DPM
 STEWART SP *see* Hordon LD
 Still's disease, adult, and ferritin, (L) 158
 STOCKS MR *see* Venables PJW
 STOREY GO, SCOTT DL. Rheumatoid arthritis before the 1870s, (A2) 65
 STRANGE RC *see* Mathey DL
 STRAUSS K *see* Erkeller-Yuksel FM
 65kDa Stress protein induces synovial inflammation in rats, (A2) 69
 STROM H *see* Abedi-Valgerdi M
 Stromelysin, human α_1 antitrypsin is cleaved and inactivated by, (A1) 30
 STUART RA, DAVIES J, LOVELL C. Auranofin rashes in rheumatoid arthritis, (A1) 20
 STUART RA, LITTLEWOOD A, MADDISON PJ, HALL ND. Elevated serum IL6 levels associated with active disease in systemic connective tissue disorders, (A2) 135
 STUART RA, *see also* Tooke AF
 Study
 designs and statistical methods in rheumatological journals: an international comparison, 352
 of human recombinant manganese superoxide dismutase in experimental inflammation, (A2) 142
 of joints and skin in the Marfan syndrome, (A2) 82
 STURROCK RD *see* Marshall DAS; Taha AS
 Subclinical valvular and myocardial disease in ankylosing spondylitis: a Doppler echocardiographic study, (A2) 60
 Subcutaneous air pouch lacks a specialised cell population found in synovial lining, (A2) 121
 Substance P—a specific vascular receptor in rat synovium, (A2) 44
 Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E₁ analogue, 317
 SULLIVAN J *see* Creamer P
 Sulphasalazine
 effect on reactive oxidant generation by neutrophils, (A2) 41
 effect on in vivo antibody response to orally administered antigen—evidence for an effect on the mucosal immune system, (A2) 4
 immunodeficiencies associated with therapy in inflammatory arthritis, 413
 Suprascapular nerve block with marcan alone effectively controls chronic shoulder pain in patients with rheumatoid arthritis, (A2) 77
 Surgical collars: a survey of their prescription and use, 282
 Susceptibility to
 rheumatoid arthritis in southern Chinese is linked to HLA-DR4 and DRB third hypervariable region sequence, (A2) 57
 and severity of rheumatoid arthritis in multicase families, 181
 SWANEPOEL M, SMEATHERS J, ADAMS L, WRIGHT V. Mapping of cartilage stiffness in the apophyseal joint, (A2) 70
 SWANN A *see* Heywood BR
 SWANN BP, MEIJERS T, PRICE LJ. Cytochrome oxidase activity of guinea pig cartilage and its relationship to the onset of osteoarthritis, (A2) 126
 SWEETMAN BJ. Analogue pain scores, (L) 390
 SWEZEY RL. Non-fibrotic lumbar cutaneous nodules: prevalence and clinical significance, 376
 SWIFT BA *see* Badger AM
 SWINDEN DC, BARDSLEY M, DEIGHTON CM, GRIFFITHS ID. Health assessment questionnaire and the Nottingham health profile in chronic inflammatory arthritis, (A2) 105
 SWINSON DR *see* Sivakumaran M
 SYKES B *see* Priestley L
 SYKES BC *see* Wordsworth BP
 SYKES C *see* Rousseau E
 SYKES H *see* McDonagh J
 SYKES HR. Severe thrombocytopenia associated with auranofin: evidence for immunological mechanism with peripheral destruction in the spleen, (L) 75
 SYKES HR, DEIGHTON CM, WALKER DJ. Female rheumatoid arthritis patients have an older age of menarche than their non-RA sisters, (A2) 32
 Symmetry and compartmental involvement of established osteoarthritis of the knee joint, (A2) 65
 SYMMONS DPM. Systemic lupus erythematosus, 288
 SYMMONS DPM, FINN JD, KAY A. EULAR study of immunosuppressive drugs: mortality and malignancy experience of the first 461 patients to complete 10 years follow-up, (A2) 141
 SYMMONS DPM, JONES S, HOTHERSALL TE. Rheumatology manpower in the 1990s, 119
 SYMMONS DPM, STEWART OJ, SILLS J, SOUTHWOOD TR, WOO P. British Paediatric Rheumatology Group national diagnostic index: development and implementation, (A2) 103
 SYMMONS DPM, *see also* Hay E; Hay EM; Samanta A
 SYMONS JA *see* Eastgate JA
 Synergy between low concentrations of cytokines and acute agonists causes increased endothelial permeability, (A2) 51
 Synovial capillary perfusion pressure measurement using video-arthroscopy—a new technique: implications for hypoxic reperfusion injury, (A1) 39
 Synovial fluid
 α_1 -antitrypsin is inactivated by exercise in rheumatoid arthritis, (A2) 50
 cell counts, comparison of manual and automated. Storage has little influence in the result of the cell counts, (A2) 130
 enzymes are cytotoxic to endothelial cells and fibroblasts, (A1) 30
 inflammatory and degenerative, preliminary study of magnetic resonance relaxation times (T_1 and T_2), 464
 leucocytes and ATP catabolism, (A2) 131
 mineral deposits, chemical, structural and morphological analyses, (A2) 129
 neutrophils, receptor expression in, (A1) 14
 normal human, inorganic pyrophosphate, nucleoside triphosphate pyrophosphatase, and cartilage fragments, 260
 polymorphs and the oxygen paradox, (A2) 49
 rheumatoid, oxygen radical-mediated oxidative damage to lactate, (A2) 40
 and serum levels of the complex immunoglobulin A alpha-1-antitrypsin in inflammatory and non-inflammatory arthritis, (A2) 114
 Synovial surface fibroblastic cell functional differentiation, (A2) 120
 Synovial tissue, demonstration of initial lymphatics in, (A1) 7
 Synovial vascular endothelium in untreated and advanced rheumatoid arthritis, (A1) 7
 Synovitis
 early, predictors of the long-term outcome: a 5-year follow-up study, 251

- natural killer cell cytotoxicity and alpha interferon levels, (A2) 108
 pigmented villonodular, magnetic resonance imaging in, (A1) 36
 Synovium, normal and rheumatoid, nuclear membrane terminal N-acetyl glucosamine in, (A1) 9
 Systemic connective tissue disorders, elevated serum IL6 levels associated with active disease, (A2) 135
 Systemic lupus erythematosus, 288
 absence of microalbuminuria in patients without renal disease, (A2) 90
 adult respiratory distress syndrome: an unrecognized premortem event, 346
 analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases, (A2) 134
 anticardiolipin antibodies: their relationship with HLA-DR antigens, (L) 156
 antiendothelial cell antibodies in patients with SLE and urticarial vasculitis, (A2) 19
 antiribosomal P protein antibodies in different populations of patients, (A2) 18
 antiribosomal P protein antibodies and neuropsychiatric disease in, (A2) 18
 aplastic anaemia in: a cellular immune mechanism, 301
 associated pulmonary hypertension, delayed diagnosis, (L) 391
 BILAG index is a valid instrument for measuring clinical disease activity, (A2) 16
 binding of anti-DNA antibodies to ROS-DNA in spouses and relatives of patients, (A2) 15
 changes in frequency of natural killer cells in patients with disease activity and renal involvement, (A2) 16
 characterization of anti endothelial cell antibodies in systemic lupus erythematosus and rheumatoid arthritis complicated by vasculitis, (A2) 134
 distribution of cell adhesion molecules in peripheral muscle from patients, (A2) 23
 does plasma exchange have any role in treatment, (CC) 335
 effect of immunoglobulin G from patients with systemic lupus erythematosus and the antiphospholipid syndrome on the release of von Willebrand factor antigen from human umbilical vein endothelium, (A2) 19
 electron microscopic study of muscle capillary wall thickening in SLE and MCTD, (A2) 22
 geographical distribution of SLE/MCTD in Nottingham, (A2) 17
 8-hydroxydeoxyguanosine: a marker of oxygen radical damage to DNA
 in systemic lupus erythematosus, (A2) 50
 incidence and prevalence in Nottingham, UK 1989-1990, (A2) 17
 intravenous pulsed cyclophosphamide as a treatment for bone marrow hypocellularity, (A2) 140
 MHC class II variants in, (A2) 33
 migraine in and its relationship with antibodies to phospholipids, (A1) 22
 modulation of induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA idiotype, (S2) 93
 molecular definition of the Ro(SSA) particles: a frequent target of autoimmunity, (S1) 58
 MRI scanning can detect cerebral abnormalities in lupus patients without clinical neurological disease, (A2) 61
 prevalence of autonomic neuropathy, (A1) 22
 prevalence of diagnosed in whites and Indian Asian immigrants in Leicester City, (A1) 21
 recovery of anterior spinal artery syndrome in a patient with antiphospholipid antibodies, (L) 314
 reduction in T γ cell numbers and alteration in subset distribution, (A2) 13
 renal involvement with proteinuria and active urinary sediment, (CC) 281
 treatment of murine with the novel immunomodulator BTS 63 155, (A2) 12
 VH gene usage in human/human hybridoma derived monoclonal antibodies, (A2) 15
 Western blot analysis of membrane epitopes recognised by anti-endothelial cell antibodies, (A2) 85
 Systemic rheumatic diseases, immunoglobulin gene expression in, (S1) 43
 Systemic sclerosis
 analysis of fibroblast cell surface markers, (A2) 119
 bronchoalveolar lavage cell profiles and high resolution computed tomography: a correlation, (A2) 28
 enhanced 99mTcDTPA clearance correlates with extent of lung involvement on high resolution computed tomography and is a predictor of decline in gas transfer, (A1) 23
 evidence of complete activation in both limited and progressive, (A2) 27
 high resolution computed tomography assessment of disease activity in fibrosing alveolitis: a histological correlation, (A2) 27
 immunohistochemical localization of TGF β in the skin of patients, (S2) 85
 mast cell-nerve inter-relationship in skin, (A2) 46
 pericardial tamponade and, (L) 159
 plasma lipid peroxides: are they a mechanism of vascular lesion, (A2) 38
 prognosis of associated with fibrosing alveolitis: a comparison with lone cryptogenic fibrosing alveolitis, (A1) 24
 use of anti-thymocyte globulin in treatment, (A1) 21, (S2) 91
 Systemic vasculitis
 ANCA specificity, (A2) 83
 clinical importance of anti-endothelial cell antibody (AECA), (A2) 86
 relationship of ANCA specificity and concentration to disease activity, (A2) 84
 T cell
 receptor gene rearrangement heterogeneity in patients with granular lymphocyte proliferation, neutropenia and polyarthropathy, (A1) 15
 receptor peptide immunization, (S2) 20
 receptor V β repertoire in the joints of patients with early rheumatoid arthritis, (A1) 14
 repertoire heterogeneity in human autoimmune disease, (S2) 24
 vaccination in rheumatoid arthritis, (S2) 28
 T HART BA, BAKKER NPM. Selective suppression of IgM antibody production protects type II collagen-immunized rats to arthritis, (S2) 92
 TABORRO R *see* Gabrielli A
 TAGGART GJ *see* Pun YLW
 TAHA AS, CAPELL H, STURROCK RD, RUSSELL RI. Does gold therapy reduce non-steroidal peptic damage in rheumatoid arthritis, (A2) 139
 TAM S *see* Jonker M
 TANNER SB, TIMMS A, WILLIAMS JD, VANCHEESWARAN R, LIU S, BLACK CM. Use of anti-thymocyte globulin in the treatment of systemic sclerosis, (A1) 21, (S2) 91
 TANNER SB, *see also* Darton K
 TAYLOR AJ *see* McCarthy DA
 TAYLOR HG. Hairy cell leukaemia and rheumatoid arthritis, (L) 391
 TAYLOR HG. Utility of the 1987 revised ARA criteria for rheumatoid arthritis in early synovitis, (L) 319
 TAYLOR HG, NIXON N, DAWES PT. Natural killer cell cytotoxicity and alpha interferon levels in early synovitis and rheumatoid arthritis, (A2) 108
 TAYLOR HG, WARDLE T, BESWICK EJ, DAWES PT. Relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis, 330
 TAYLOR HG, *see also* Close DR; Zukovskis K
 TEH LS, HAY EM, AMOS N, BLACK D, HUDDY A, CREED F, HOLT PJL, WILLIAMS BD. Antiribosomal P protein antibodies and neuropsychiatric disease in patients with systemic lupus erythematosus, (A2) 18
 TEH LS, LEE MK, WONG F, MANIVASAGAR M, CHARLES PJ, HAY EM, ISENBERG DA. Antiribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus, (A2) 18
 TELFORD G *see* Bowen JG
 TENNANT A *see* Badley EM; Chamberlain MA
 Tennis elbow, local injection treatment—hydrocortisone, triamcinolone and lignocaine compared, 39
 TEPPA A-M *see* Julkunen H
 TERENGHI G *see* Hukkanen M
 TESIO L. Cause of back pain and sciatica may be a venous matter too, (L) 70
 T γ cell number reduction and alteration in subset distribution in systemic lupus erythematosus, (A2) 13
 T γ cells and their subsets in blood and synovial fluid in rheumatoid arthritis, (A2) 13
 T'HART LA *see* Bakker NPM
 Therapeutic trials, interpretation, (L) 66
 Thermographic imaging of frozen shoulder and totator cuff tendinitis, (A2) 79
 THIEN F *see* Kirkham B
 Thompson articular score evaluation, (A2) 97
 THOMPSON PW, EDWARDS AC, DE SILVA L. Spinal trabecular bone density by lateral dual energy X-ray absorptiometry in ankylosing spondylitis, (A1) 29
 THOMPSON PW, McLELLAN D, PEGLEY FS, JAMES IT. Longitudinal changes in serum cytidine deaminase in rheumatoid arthritis correlate with clinical assessments of joint inflammation, (A1) 33
 THOMPSON PW, PEGLEY FS. Comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients, 298

- THOMPSON PW. *see also* Alam C
 THOMPSON RN *see* Phelan M
 THOMPSON RT *see* Bellamy N
 THOMPSON SJ, ROOK GAW, VAN DER ZEE R, STANFORD J, ELSON CJ. Use of bacterial antigens and stress proteins in the modulation of pristane induced arthritis, (S2) 95
 THOMSON W *see* Holligan S; Kay R
 THURNHAM DI *see* Situnayake RD
 TIGHE H *see* Kyle V
 TIMMS A *see* Tanner SB
 Tiopronine inhibition of human endothelial cell proliferation, (A2) 107
 TIRRI G *see* Valentini G
 TIRRI R *see* Valentini G
 TNF α role in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage, 265
 α -Tocopherol levels in rheumatoid serum and synovial fluid, (A2) 41
 Tolerance
 induction lack by cationic antigens, (S2) 93
 therapy as a plausible possibility, (S1) 75
 TONKS S *see* Gaston JSH
 TOOKE AF, STUART RA, MADDISON PJ. Prevalence of autonomic neuropathy in SLE, (A1) 22
 TORGERSON D *see* Garton MJ
 TORRE ALONSO JC, RODRIGUEZ PEREZ A, ARRIBAS CASTRILLO JM, BAL-LINA GARCIA J, RIESTRA NORIEGA JL, LOPEZ LARREA C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients, 245
 TOSSWILL J *see* Bonness P
 Total hip arthroplasty in ankylosing spondylitis, (A1) 29
 Toxic oil syndrome, long-term follow-up, (A2) 29
 Transferrin C subtypes in patients with rheumatoid arthritis, 21
 Transforming growth factor β , osteoarthritic human cartilage is more sensitive to than normal cartilage, (A2) 144
 Transient erosion of the ulnar styloid process, 473
 TREACY G *see* Jonker M
 Treatment of
 fixed flexion deformities of the knee in rheumatoid arthritis using the flowtron inflatable splint, (A1) 27
 murine SLE with the novel immunomodulator BTS 63 155, (A2) 12
 polymyalgia rheumatica: lower initial dose, (L) 393
 relapsing polychondritis with chimaeric monoclonal antibodies, (A2) 10
 rheumatoid arthritis by murine antiidiotypic monoclonal antibodies to a syngeneic anti-HLA class II monoclonal antibody, (S2) 90
 TREVES AJ *see* Barak V
 TRIMMINGS N *see* Williams RB
 TRIPATHI P *see* D'Cruz DP
 TROUGHTON PR *see* Hordon LD
 TSUKAMOTO H. Successful treatment of Raynaud's phenomenon with lim-aprost, an oral prostaglandin E₁ analogue, 317
 TUCKER SC, FARR M, BACON PA. Benefit in social and physical function produced by early treatment of rheumatoid arthritis, (A2) 99
 Tumour necrosis factor α and its receptor co-localisation in rheumatoid arthritis synovial membrane, (A2) 7
 TUNN E *see* Emery P
 TUNN EJ *see* Farr M
 TURNBALL N *see* Hopkinson N
 TURNER AN *see* Gaskin G
 TURNER N, MASON PJ, BROWN R, REES AJ, PUSEY CD. Primary sequence and an amino acid sequence polymorphism of the Goodpasture antigen, (A2) 82
 TURNER RA *see* James MF
 UEMATSU Y *see* Steinmetz M
 Ulnar styloid process, transient erosion, 473
 Uncoupling the toxicological morass in the development of new antirheumatic drugs—is there any hope, (E) 161
 Unresolved questions in clinical T cell vaccination, (S2) 17
 Unspecific accumulation of anti-CD4 antibodies and negative signalling but not modulation of the CD4-molecule may contribute to the efficacy of anti-CD4 treatment in rheumatoid arthritis, (S2) 100
 Urate crystals, orderly arrangement in synovial fluid tissue fragments, (A2) 119
 Uridine diphosphoglucose dehydrogenase activity and hyaluronan localisation at the site of joint cavitation in the embryo, (A2) 48
 Urinary C3D/neopterin ratio in assessment of connective tissue diseases—a measure of humoral/cellular immunity, (A2) 110
 Urinary excretion of deoxyypyridinoline as a marker of bone resorption in an animal model of inflammation associated osteoporosis, (A1) 35
 Use of
 the air cast ankle support brace for subtalar joint instability in patients with rheumatoid arthritis. Analysis using a gait and balance laboratory, (A1) 27
 anti-thymocyte globulin in the treatment of systemic sclerosis, (A1) 21, (S2) 91
 bacterial antigens and stress proteins in the modulation of pristane induced arthritis, (S2) 95
 class II MHC binding peptides in immunotherapy, (S2) 14
 cyclosporin A in the eosinophilia myalgia syndrome, (A2) 30
 high dose intravenous immunoglobulin in Behçet's syndrome, (S2) 91
 infra-red thermography in a Rheumatology Unit, (L) 71, (L) 72
 nasal calcitonin in the treatment of post-traumatic algodystrophy, 291
 Utility of the 1987 revised ARA criteria for rheumatoid arthritis in early synovitis, (L) 319
 VALDIMARSSON H *see* Davies KA
 VALENTINI G, IMPROTA RDG, RESSE M, MIGLIARESI S, MINUCCI PB, TIRRI R, FARZATI B, TIRRI G. Antinuclear antibodies in first degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes, 429
 Validation of a new questionnaire devised to measure neck pain and disability, (A1) 2
 VALKEMA R *see* Eggemeijer F
 VAN BUSTERVELD OP *see* Kruize AA
 VAN BRUMMELEN P *see* Boers M
 VAN DE PUTTE LB *see* Jeurissen ME
 VAN DE PUTTE LBA *see* de Vries N; Kerstens PJSM; Laan RFJM; van den Hoogen FHJ
 VAN DEN BERG WB *see* Jacobs HJM; van den Hoogen FHJ
 VAN DEN BRINK HR, VAN DER VEEN MJ, CORNELIS C, VAN DER HEIDE A, BUSLMA JWJ. Evaluation of the Thompson articular score, (A2) 97
 VAN DEN BRINK HR, VAN WIJCK MJG, BUSLMA JWJ. Influence of steroid-hormones on proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis, (A2) 108
 VAN DEN BROEK AEM *see* Jacobs HJM
 VAN DEN HOEK AEM *see* Jacobs HJM
 VAN DEN HOOGEN FHJ, BOERBOOMS ATM, VAN DER KRAAN PM, VAN DEN BERG WB, VAN LIER HJJ, VAN DE PUTTE LBA. Effects of methotrexate on glycosaminoglycan production of cultured fibroblasts from scleroderma patients and healthy controls: preliminary results, (A2) 133
 VAN DER HEIDE A *see* van den Brink HR
 VAN DER KRAAN PM *see* van den Hoogen FHJ
 VAN DER VEEN MJ *see* van den Brink HR
 VAN DER VOORT EAM *see* van der Zee JM
 VAN DER ZEE JM, HEURKENS AHM, VAN DER VOORT EAM, DAHA MR, BREEDVELD FC. Characterization of anti endothelial cell antibodies in systemic lupus erythematosus and rheumatoid arthritis complicated by vasculitis, (A2) 134
 VAN DER ZEE R *see* Thompson SJ
 VAN DUYN W *see* Janssen M
 VAN ERCK MGM *see* Bakker NPM
 VAN LAAR JM, MILTENBURG AMM, VERDOMK MJ, DAHA MR, DE VRIES RRP, BREEDVELD FC. T cell vaccination in rheumatoid arthritis, (S2) 28
 VAN LAAR JM, *see also* Miltenburg AMM
 VAN LIER HJJ *see* van den Hoogen FHJ
 VAN RIEL PCLM *see* de Vries N
 VAN RIEL PLCM *see* Laan RFJM
 VAN ROY JLAM *see* Wilbrink B
 VAN 'T HOF MA *see* de Vries N
 VAN WIJCK MJG *see* van den Brink HR
 VANCHEESWARAN R, BLACK C, PERSICHTTE K, CHU S, HIGLEY HR. Histopathological assessment of factor XIIIa and HLADR positive cells in scleroderma skin biopsies, (A2) 46
 VANCHEESWARAN R, OLSEN I, ABRAHAM DJ, KORN J, PIELA T, BLACK C. Analysis of fibroblast cell surface markers in systemic sclerosis, (A2) 119
 VANCHEESWARAN R, *see also* Singarayer C; Tanner SB
 VANDEN BERG WB *see* Lafeber F
 VANDENBARK AA, CHOU YK, HASHIM G, OFFNER H. Immunization with T cell receptor peptides, (S2) 20
 VANDENBROUCKE JP *see* Janssen M
 VANDER KRAAN PM *see* Lafeber F
 VANEDEN W *see* Wilbrink B
 VANROY JLAM *see* Wilbrink B
 VARGAS C *see* Muniain MA
 VARGAS J *see* Khamashta MA
 Variation in dose and monitoring schedules for disease modifying antirheumatic drugs amongst UK and Irish rheumatologists, (A1) 19
 Vasculitis
 activated, cytotoxic non-T lymphocytes, (A1) 16
 antiendothelial cell antibodies in patients with SLE and urticarial vasculitis, (A2) 19

- antineutrophil cytoplasmic antibodies (ANCA): their role in diagnosis and pathogenesis, 229
- antinuclear cytoplasmic antibody (ANCA) in pursuing cause, (CC) 254
- C3D estimation in patients: evidence for in vivo complement activation and correlation with disease activity, (A1) 18
- management without steroids, (A2) 88
- sera stimulate von Willebrand factor secretion by endothelial cells in culture. This activity correlates with AECA but not ANCA, (A2) 85
- small vessel, anticardiolipin antibodies in, (A2) 20
- small vessel, extrinsic pathway inhibitor levels, (A2) 35
- VAUGHAN RW *see* Boki K; Sakkas LI
- VEALE D, FARRELL M, FITZGERALD O. Mechanisms of joint sparing in a hemiplegic patient presenting with unilateral psoriatic arthritis, (A2) 52
- VEALE D, KAVANAGH G, FIELDING JF, FITZGERALD O. Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process, 220
- VEALE D, ROGERS S, BARNES L, FITZGERALD O. Immunohistochemical markers for arthritis in psoriasis, (A2) 10
- VEALE D, ROGERS S, BARNES L, YANNI G, BRESNIHAN B, FITZGERALD O. Analysis of the immunohistological features of the synovial membrane in psoriatic arthritis and comparison with rheumatoid arthritis, (A1) 8
- VEALE D, ROGERS S, BARNES L, YANNI G, BRESNIHAN B, FITZGERALD O. Immunohistochemical features of the synovial membrane in psoriatic arthritis compared to rheumatoid arthritis, (A2) 67
- VECCHIO PC, ADEBAJO AO, CHARD MD, PAGE THOMAS DP, HAZLEMAN BL. Thermographic imaging of frozen shoulder and totator cuff tendinitis, (A2) 79
- VELA P *see* Carro A; Ruiz MT
- VENABLES PJW, WILLIAMS DG, HORSFALL AC, WILLIAMS RO, STOCKS MR, MAINI RN. Immune response to autoantigens and viruses in rheumatic disease, (S1) 70
- VENABLES PJW, *see also* Brookes SM; Lawrance RA
- VENN G *see* Hardingham TE
- VENNART W *see* Moore EA
- VENNING MC *see* MacDiarmid-Gordon AR
- Venostasis, subclinical vasculitis and von Willebrand factor antigen, 373
- VERBEEK ALM *see* Laan RFJM
- VERDONK MJ *see* van Laar JM
- VERHEUL HAM, VERVELD M, DECKERS G, SCHUURS AHWM. Further evidence that endocrine properties of androgen-derived steroids are not correlated with favourable effects on lupus and sialoadenitis in NZB/W mice, (S2) 96
- Vertebral fractures in the general population: the Chingford Study, (A2) 91
- VERVELD M *see* Verheul HAM
- VERWILGHEN J, KINGSLEY GH, CHIECO-BIANCHI F, LANCHBURY J, PANAYI GS. Gold responsive T cells in patients with gold induced dermatitis: gold (III) rather than gold (I) induces lymphocyte proliferation, (A2) 66
- VERWILGHEN J, ROMAGNOLI P, LANCHBURY J, KINGSLEY G, PANAYI GS. Gold (III) but not gold (I) induces lymphocyte proliferation in patients with gold induced dermatitis, (S2) 81
- VH gene usage in human/human hybridoma derived monoclonal antibodies from SLE patients, (A2) 15
- VIANNA JL *see* Khamashta MA
- Video-arthroscopy in measurement of synovial capillary perfusion pressure—a new technique: implications for hypoxic reperfusion injury, (A1) 39
- VILARDELL M *see* Lima J
- VINER N *see* Hay EM
- VINER NJ, GASTON JSH, BACON PA. Preferential activation of memory T cells by synovial antigen presenting cells in inflammatory arthritis, (A2) 8
- VINER NJ, *see also* Hassell AB
- Visiting other departments, (E) 403
- Vitamin E in chronic arthritis. Role in non-enzymatic and enzymic lipid peroxidation, (A2) 42
- Vitronectin distribution in tissue biopsies of synovitis, (A2) 122
- Von Willebrand factor antigen
- raised levels in ankylosing spondylitis, (A2) 36
- in Sjögren's syndrome, (A2) 23
- and venostasis and subclinical vasculitis, 373
- WAINWRIGHT AC *see* Blann AD
- WALDMANN H, COBBOLD SP. Is tolerance therapy a plausible possibility, (S1) 75
- WALDMANN H, *see also* Isaacs JD; Kyle V
- WALKER D *see* Foster H
- WALKER DJ *see* Deighton CM; Foster HE; McDonagh J; Sykes HR
- WALKER PS. Joint replacement in the 1990s, (E) 401
- WALLER HA, BUTLER MG, NOLAN J, DOWD GSE, SCOTT DL. Distribution of vitronectin in tissue biopsies of synovitis, (A2) 122
- WALPORT MJ *see* Beynon HLC; Botto M; Bowness P; Davies KA; Harmer IJ; Loizou S; Lunardi C
- WALSH DA, MAPP PI, CRUWYS SC, KIDD BL, BLAKE DR. Angiotensin converting enzyme- and dipeptidyl peptidase IV-like immunoreactivity in human synovium, (A2) 124
- WALSH DA, *see also* Cruwys SC; Mapp PI
- WARD R *see* Fairburn K
- WARDLE T *see* Taylor HG
- WARING G *see* Emery P
- WARING R *see* Bradley H
- WARREN CJ *see* Howell CJ
- WARSY AS *see* El-Hazmi MA
- WATERTON JC, JOHNSTONE D, CHECKLEY D. Quantitative NMR-microscopy of the progression of antigen-induced arthritis in the rabbit knee, (A1) 35
- WATSI A *see* Kendall R
- WATSON BUCHANAN W *see* Buchanan HM
- WATSON F, ROBINSON JJ, BUCKNALL RC, EDWARDS SW. Receptor expression in synovial fluid neutrophils, (A1) 14
- WATSON HR *see* Darton K
- WATSON P *see* Carpenter TA
- WATTS R *see* Ravirajan C
- WATTS RA *see* Bhambhani MB
- WEBER JN *see* Bowness P
- Wegener's granulomatosis
- adherent properties of blood leucocytes, (A2) 87
- limited forms presenting as polymyalgia rheumatica, 382
- occurring in siblings, 144
- ocular involvement, (A2) 26
- purification of proteinase 3 and its reactivity with sera from patients, (A2) 83
- WEIR DM *see* Smith G
- WEIS MA *see* Eyre JJ
- WELLS AU, CULLINAN P, BLACK CM, DU BOIS RM. Prognosis of systemic sclerosis associated with fibrosing alveolitis: a comparison with lone cryptogenic fibrosing alveolitis, (A1) 24
- WELLS AU, HANSELL DM, HARRISON K, BLACK C, DU BOIS RM, CORRIN B. High resolution computed tomography assessment of disease activity in the fibrosing alveolitis of systemic sclerosis: a histological correlation, (A2) 27
- WELLS AU, HANSELL DM, HASLAM PL, CULLINAN P, BLACK CM, DU BOIS RM. Bronchoalveolar lavage cell profiles and high resolution computed tomography in systemic sclerosis: a correlation, (A2) 28
- WELLS AU, HANSELL DM, LAWRENCE R, BLACK CM, HARRISON NK, DU BOIS RM. Enhanced 99mTcDTPA clearance in systemic sclerosis correlates with extent of lung involvement on high resolution computed tomography and is a predictor of decline in gas transfer, (A1) 23
- WELLS T *see* Ejim OS
- WELSH G *see* Dacre JE
- WELSH KI *see* Sakkas LI; Stephens CO; Whyte J
- WENDLING D, DIDRY C, WIDENES J, RACADOT E, MOREL FOURRIER B, CLOT J, BROCHIER J, ANDARY M, PORTALES P, LIAUTARD J, COMBE B, SANY J. Bicentric open study of the treatment of rheumatoid arthritis with monoclonal CD4 antibody, clinical and immunological results, (S2) 87
- WENDLING D, *see also* Racadot E
- WESELOH G *see* Bröker BM
- WESTERMARK T *see* Honkanen V
- Western blot analysis of membrane epitopes recognised by anti-endothelial cell antibodies in SLE, (A2) 85
- What do patients and rheumatologists regard as an acceptable risk in the treatment of rheumatic disease, (L) 318
- WHELAN A *see* Callaghan M; Yanni G
- WHELAN M *see* Naughton D
- Which patients see a rheumatologist, 285
- Which rheumatic disorders have the greater impact on the population? Estimates of severity and prevalence from the Calderdale rheumatic disablement survey, (A2) 102
- WHITE AG *see* Smith CR
- WHITE M *see* Lambert CM
- WHITEHOUSE GH *see* Fewins HE
- Why early arthritis clinics, (E) 241
- WHYTE J, STEPHENS CO, HARVEY GR, BRIGGS DC, BLACK CM, MADDISON PJ, WELSH KI. Anti-centromere antibodies in multiple family members, (A2) 26
- WICKHAM C *see* Croft P
- WIDENES J *see* Racadot E; Wendling D
- WILBRINK B, NIETVELD JJ, DEN OTTER W, VAN ROY JLAM, BIJLSMA JWJ, HUBER-BRUNING O. Role of TNF α in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage, 265

- WILBRINK B, VANROY JLAM, HOLEWIJN M, DENOTTER W, BUIJLSMA JWJ, VANEDEN W. 65kD Heat-shock protein can activate rheumatoid synovial fluid mononuclear cells to inhibit cartilage proteoglycan synthesis, (A2) 8
- WILDER RL, REMMERS EF, SANO H, CASE JP, LAFYATIS R. Cytokine network in rheumatoid arthritis, (S2) 44
- WILKIE ME, DAVIES GR, MARSH FP, RAMPTON DS. Does misoprostol have a reno-protective effect in co-administration with indomethacin, (A2) 90
- WILKINSON L. Bilateral iliopsoas bursitis in rheumatoid arthritis, (L) 68
- WILKINSON LS, EDWARDS JCW. Demonstration of initial lymphatics in human synovial tissue, (A1) 7
- WILKINSON LS, PITSILLIDES AA, DODDS RA, EDWARDS JCW. Collins Grimley Sokoloff synovial giant cell: mononuclear phagocyte polykaryon, fibroblast polykaryon, osteoclast or all three, (A2) 44
- WILKINSON LS, PITSILLIDES AA, EDWARDS JCW. Functional differentiation of the synovial surface fibroblastic cell, (A2) 120
- WILKINSON LS, *see also* Edwards JCW; Pitsillides AA
- WILKINSON SM, SMITH AG, DAVIS MJ, MATTEY D, DAWES PT. Cutaneous gold toxicity, keeping patients on treatment, (A2) 100
- WILL R, ARMAS J. Clearance of intraarticular albumin in RA, AS and OA patients: what is the effect of IA corticosteroid, (A1) 33
- WILL R, ARMAS J. Intraarticular corticosteroids and cartilage: what is the effect, (A1) 32
- WILL R, *see also* Kennedy LG
- WILL RK. Use of infra-red thermography in a Rheumatology Unit, (L) 71
- WILLIAMS A *see* Woodward L
- WILLIAMS B *see* Hillarby MC
- WILLIAMS BD *see* Davies EV; Teh LS
- WILLIAMS DG *see* Andrew EM; Brown CMS; Huntriss JD; Venables PJW; Williams RO
- WILLIAMS E *see* Phelan M
- WILLIAMS GH, SILMAN AJ. Scleroderma, 365
- WILLIAMS GH, *see also* Croft PR
- WILLIAMS J *see* Fewins HE
- WILLIAMS JD *see* Tanner SB
- WILLIAMS R *see* Fairburn K
- WILLIAMS RB, CARR A, MERRY P, BLAKE DR, COX NL. Effect of effusion volume and type on exercise induced intra-articular pressure changes in human knee joints, (A1) 38
- WILLIAMS RB, CARR A, TRIMMINGS N, BLAKE DR, COX NL. Measurement of synovial capillary perfusion pressure using video-arthroscopy—a new technique: implications for hypoxic reperfusion injury, (A1) 39
- WILLIAMS RO, PLATER-ZYBERK C, WILLIAMS DG. Adoptive transfer of severe collagen-induced arthritis into immunodeficient mice, (A2) 114
- WILLIAMS RO, *see also* Venables PJW
- WILLOUGHBY DA *see* Colville-Nash PR; Da Silva JAP; Edwards JCW; Moore AR
- WILSON E *see* Jonker M
- WILSON J *see* Davidson JE
- WINEARLS CG *see* Hawkins PN
- WINFIELD J *see* Amos RS
- WINKLER T *see* Kalden J
- WINKLES J *see* Gado K; Luqmani RA
- WINROW VR, DABBAGH A, MORRIS CJ, COATES ARM, COLTON MJ, BLAKE DR. 65kDa Stress protein induces synovial inflammation in rats, (A2) 69
- WINSKA-WILOCH H *see* Longhurst C
- WINYARD P *see* Fairburn K; Merry P
- WINYARD PG, ZHANG Z, CHIDWICK K, MURPHY G, BRUCE D, CARRELL RW, BLAKE DR. Human α 1-antitrypsin is cleaved and inactivated by stromelysin, (A1) 30
- WINYARD PG, *see also* Chidwick K; Zhang Z
- WISNIESKI J *see* D'Cruz DP
- WITHAM F. Psoriatic spondylitis presenting as chronic torticollis, (L) 478
- WONG F *see* Teh LS
- WONG R *see* Seglias J
- WOO P *see* David J; Davies UM; MacLean L; Symmons DPM
- WOODS NC *see* Eastgate JA
- WOODS PE *see* Eyre JJ
- WOODWARD L, HALL G, BUTLER MG, SPECTOR TD, SCOTT DL. Serum keratan sulphate and disease activity in rheumatoid arthritis, (A1) 34
- WOODWARD L, SPECTOR TD, HAMMOND A, HALL GM, WILLIAMS A, DOYLE DV, SCOTT DL. Keratan sulphate and the acute phase response, (A2) 118
- WOODWARD L, *see also* Spector TD
- WOOLF AD. 1992 and all that, (L) 76
- WOOLF AD. Osteoporosis in rheumatoid arthritis—the clinical viewpoint, (E) 82
- WOOLF AD, HALL ND, GOULDING NJ, KANTHARIA B, MAYMO J, EVISON G, MADDISON PJ. Predictors of the long-term outcome of early synovitis: a 5-year follow-up study, 251
- WOOLF AJ *see* Grahame R
- WORDSWORTH BP *see* Pile KD
- WORDSWORTH BP. HLA Class II antigens in susceptibility to rheumatoid arthritis, (L) 151
- WORDSWORTH BP, OGILVIE DJ, SYKES BC. Segregation analysis of the structural genes of the major fibrillar collagens provides further evidence of molecular heterogeneity in type II Ehlers-Danlos syndrome, 173
- WORDSWORTH BP, STEDEFORD J, LANCHBURY JSS, ROSENBERG WCM, BELL JI. HLA class II association of rheumatoid arthritis, (A1) 11
- WORDSWORTH BP, STEDEFORD J, ROSENBERG WCM, BELL JI. Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive associations with HLA-DR4, DR1 and DRw10, 178
- WORDSWORTH P *see* Lanchbury J; Loveridge JA; Priestley L
- WORRALL JG, BAYLISS MT, CROSSMAN MV, MASON RM, EDWARDS JCW. Antibodies to CD44 and to a hyaluronan-binding protein from rat chondrosarcoma co-distribute in normal human tissues, (A1) 12
- WORRALL JG, BAYLISS MT, EDWARDS JCW. Relationship of CD44 to hyaluronan in rheumatoid nodule, (A1) 12
- WORRALL JG, BAYLISS MT, ISENBERG DA, ROUND J, EDWARDS JCW. Inflammatory muscle disease is associated with differential alteration in the distribution of chondroitin sulphate species, (A2) 22
- WORRALL JG, SHARIF M, ROOK G, EDWARDS JCW. Nuclear membrane terminal N-acetyl glucosamine in normal and rheumatoid synovium, (A1) 9
- WORRALL JG, *see also* Edwards JCW; Pitsillides AA
- WORSFOLD M *see* Butler RC
- WORTHINGTON J, MORGAN K. Epitopes within the CB-11 peptide of type II collagen recognised by sera from patients with rheumatoid arthritis, (A2) 112
- WORTHINGTON J, OLLIER W, SILMAN A. Antibodies to HSP65 in twin pairs with rheumatoid arthritis, (A2) 69
- WORTHINGTON J, *see also* Hay E; Majer AH
- WORTHY K *see* Bond AP
- WRAITH DC. Use of class II MHC binding peptides in immunotherapy, (S2) 14
- WRIGHT JK *see* Clark IM
- WRIGHT V. Aspects of ankylosing spondylitis, (E) 1
- WRIGHT V, *see also* Helliwell P; Helliwell PS; Hill H; Hill J; Hordon LD; Swanepoel M
- WU JJ *see* Eyre JJ
- WUETHRICH H-J *see* Mackenzie AR
- YANAI P *see* Barak V
- YANNI G, WHELAN A, FEIGHERY C, BRESNIHAN B. Greater monocyte/macrophage numbers in rheumatoid synovial membrane predict a worse radiological outcome, (A1) 8
- YANNI G, WHELAN A, FEIGHERY C, DUFF G, BRESNIHAN B. Cytokine levels in rheumatoid synovial fluid do not reflect levels in synovial membrane cultures, (A1) 31
- YANNI G, WHELAN A, FEIGHERY C, FITZGERALD O, BRESNIHAN B. Examination of synovial vascular endothelium in untreated and advanced rheumatoid arthritis, (A1) 7
- YANNI G, *see also* Farahat MNMR; Veale D
- YAZICI H *see* Hamuryudan V
- YEBRA M. Pericardial tamponade and limited cutaneous systemic sclerosis, (L) 159
- YOUINOU P *see* Ravirajan C
- YU GARIB F *see* Davtyan VG
- YUCEL AE, FREEMONT AJ, JAYSON MIV. Mast cell-nerve inter-relationship in systemic sclerosis skin, (A2) 46
- YURDAKUL S *see* Hamuryudan V
- ZEBOUNI L *see* Gough SCL
- ZERVAS J. Hairly-cell leukaemia-associated polyarthritis: a report of two cases, (L) 157
- ZHANG Z, FARRELL AJ, CHIDWICK K, WINYARD PG. Synovial fluid α 1-antitrypsin is inactivated by exercise in rheumatoid arthritis, (A2) 50
- ZHANG Z, *see also* Chidwick K; Winyard PG
- ZIESENIS A, PETERMANN M, FRANZ B, LEIBOLD W. Immunomodulating properties of a monoclonal antibody protecting rats from chronic erysipelas polyarthritis, (S2) 90
- ZINGRAFF J *see* Lebal-Darné JL
- ZOMA A *see* Hay EM
- ZUKOVSKIS K, TAYLOR HG, BESWICK EJ, DAWES PT, JONES P. Enthesitis as a measure of disease activity in ankylosing spondylitis, (A2) 81

